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Systemic lupus erythematosus (SLE) is a polygenic autoimmune disease characterized 
by the presence of antinuclear autoantibodies and immune complex formation. More 
than 30 genes are known to contribute to the pathogenesis of the disease. Among 
them, homozygous deficiency of early classical pathway components (C1q, C1r, C1s, 
or C4) exhibits causal association with SLE pathogenesis. Their importance in SLE 
pathogenesis is evident by the earlier onset of disease and loss of female 
predominance, implying a protective role for these complement components. C1q 
binds to apoptotic cells, which enhances apoptotic cell clearance through 
phagocytosis. This partially explains the protective role of C1q against SLE as 
efficient apoptotic cell clearance reduces exposure of intracellular autoantigens to B 
cells for autoantibody induction. However, the protective roles of C1r and C1s are 
unclear.  
 
In this study, we hypothesize that C1s, historically recognized as a complement-
specific serine protease for C2 and C4, may be recruited to apoptotic cells through 
C1q and cleave exposed intracellular autoantigens to prevent dendritic cell (DC) 
presentation and B cell activation. We observed that C1q binds progressively from the 
periphery to inner regions of the cell during ultraviolet (UV)-induced cell apoptosis. 
C1q binds to the nucleolus in UV-irradiated cells in 6 hours. Nucleolus is the core 
region of a cell and it contains numerous autoantigens. To study whether the binding 
of C1q to nucleolus causes C1s cleavage of autoantigens, we isolated the nucleolus 
from HeLa cell nuclear homogenate. By sucrose gradient centrifugation, C1q was 
xi 
found to co-sediment with nucleolus. By immunofluorescent (IF) microscopy, C1q 
was found to bind to isolated nucleolus.  
 
Incubation of C1 complex with isolated nucleolus caused cleavage of a number of 
nucleolar proteins. The cleavage by C1 complex was inhibited by C1 inhibitor. A 
major nucleolar protein nucleophosmin (NPM1/B23), which is also an autoantigen 
found in SLE patients, was cleaved by C1s into distinct fragments. The cleavage was 
dose dependent, and was inhibited by C1 inhibitor. Potential cleavage sites on B23, 
which were predicted by a publicly accessible tool PoPS using the computational C1s 
protease model, were evaluated by site directed mutagenesis. C1s was also found to 
cleave other nucleolar autoantigens such as nucleolin (NCL).  
 
The result is significant because it helps to explain why C1r/C1s deficiency causes 
SLE. Trimming of autoantigens or danger associated molecular patterns (DAMPs) 
that are exposed during cell apoptosis or necrosis by C1s could presumably eliminate 
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Chapter 1 Introduction  
 
1.1 IMMUNE SYSTEM OVERVIEW 
The immune system protects organisms from infection by layered defenses of 
increasing specificity. It can be classified into two branches, namely innate immune 
system and adaptive immune system, differing in the mechanism of recognition and 
effector responses (Dempsey et al., 2003; Medzhitov & Janeway, 2000).  Innate 
immune system is highly conserved from simplest animals, highlighting its 
importance in survival, while adaptive immunity only exists in higher animals (Parkin 
& Cohen, 2001).  
 
Innate immunity includes physical, chemical and microbiological barriers. It provides 
rapid host defense exploring genetic memory of a fixed number of germline-encoded 
receptors, called pattern recognition receptors (PRR) (Parkin & Cohen, 2001). The 
expression of PRR is not clonal, which means a certain type of effector cell has the 
expression of identical receptors (Medzhitov & Janeway, 2000).   
 
Due to the limited number of PRR-encoding genes, PRR recognizes only highly 
conserved structures presented in microbial pathogens, namely pathogen-associated 
molecular patterns (PAMP) (Medzhitov & Janeway, 2000). PAMPs are usually 
structures that are essential for the survival of pathogen, and are usually invariant 
among the same class of pathogens. Through this way, innate immunity provides 
rapid response to microbial invasion with certain specificity.  
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Compared to innate immunity, adaptive immunity is precise but takes longer to 
develop. In adaptive immune system, antigen is recognized by antigen-specific T cell 
or B cell, leading to cell priming, activation and differentiation, hence the effector 
response takes place (Parkin & Cohen, 2001). The antigen-specific receptor is 
generated by somatic rearrangement and splicing of the antigen-binding region in the 
receptors. This leads to the extremely diverse receptor repertoire with the number of T 
cell and B cell receptors predicted to be over 108 and 1010 each (Arstila et al., 1999; 
Parkin & Cohen, 2001; Pertea & Salzberg, 2010). However, an efficient adaptive 
immune response takes several days to develop due to clonal expansion in response to 
antigen recognition (Medzhitov & Janeway, 2000).  Generation of memory T and B 
cells during clonal expansion will accelerate the secondary immune response to 
repeated challenge of similar antigens (Vitetta et al., 1991).  
 
Innate immunity and adaptive immunity are not independent, but closely inter-
dependent on each other. Recent studies have also shown that certain immune cells 
exhibit features of both arms of the immune system (Lanier & Sun, 2009). The 
complexity and delicacy heightens the importance of regulation and interplay between 
the two branches of immune system.  
 
1.2 ADAPTIVE IMMUNITY  
Organization of adaptive immunity mainly consists of antigen presenting cells (APC), 
T and B lymphocytes (Litman et al., 2010). The remarkable features of adaptive 
immune system are specificity, diversity and memory (Litman et al., 2010). 
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It is estimated that B and T cells are capable of producing over 1015 and 1018 variable 
antigen receptor regions respectively. The recognition diversity of B cells is further 
enhanced through somatic hypermutation (Hardy & Hayakawa, 2001; LeBien & 
Tedder, 2008; Litman et al., 2010; Tonegawa, 1983).  
 
1.2.1. T cell and antigen recognition  
There are two ways in which antigens can be presented. Endogenous antigens (e.g., 
antigens from virus) can be complex with major histocompatibility complex (MHC) 
class I in ER and delivered to cell surface. Both endogenous and exogenous antigens 
can be presented by professional APC (dendritic cells, B cells and macrophages), 
internalized through phagocytosis or endocytosis and then complex with MHC class 
II molecules and presented to the cell surface (Parkin & Cohen, 2001).  
 
MHC class I can only be recognized by CD8+ cytotoxic T lymphocytes (CTLs). The 
infected host cell that present antigens with MHC I on the surface will then be 
removed CTL attack. In contrast, MHC class II can only be recognized by CD4+ 
helper T cells. CD4 activation will then lead to a series of cytokine production, which 
activates effector cells. The co-stimulatory receptors (e.g. CD80 and CD86) are also 
expressed on APCs together with MHC class II which ensures the specificity in 
antigen presentation and effector responses (Parkin & Cohen, 2001).  Some activated 
T cells remain in lymph nodes as memory cells (CD45RO+). Memory T cells can 
sustain in lymph nodes for over 10 years, and react quickly on similar antigen 
exposure (Parkin & Cohen, 2001; Vitetta et al., 1991).  
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1.2.2. B cells and antibody production 
B cells produce antibodies of difference forms and affinities to antigens. However, 
early in B cell activation, it acts as APC, which capture antigens through surface B-
cell receptors (BCRs) and present these antigens through MHC II to CD4+ T cells. 
Activated T cells in turn secrete B-cell growth factors, which facilitate B cell 
activation. Binding of CD40 on B cells by CD40 ligand (CD40L) on T cells leads to 
class switch of antibody from IgM to IgG, IgA or IgE which undergo hypermutation 
in the germinal center for increased affinity (LeBien & Tedder, 2008).  
 
1.2.3. Tolerance mechanism   
The large repertoire of B- and T- cell receptors initially also contain autoreactive 
receptors. There are several tolerance mechanisms in both early and late stage of B 
and T cell development that reduce the risk of autoimmune disease. First, binding of 
self-antigens with immature B and T lymphocytes leads to apoptosis and clonal 
deletion (MacDonald & Lees, 1990). In addition, B cells that bear autoreactive 
antigen receptors could undergo receptor editing to change antibody specificity. Anti-
idiotypic antibodies can bind to matching B cell receptors and suppress autoantibody 
production. T cell tolerance developed during development can  reduce autoantibody 
production in the periphery (Parkin & Cohen, 2001).  
 
Recent studies have shown that early complement element C4 plays a role in 
maintaining peripheral B-cell tolerance in a myeloid cell-dependent manner 
(Chatterjee et al., 2013). 
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1.3 INNATE IMMUNITY  
In contrast to adaptive immunity, innate immunity differs by the recognition receptors, 
focusing only on a limited number of highly conserved structures in microorganisms 
(Bianchi, 2007; Janeway, 1992; Parkin & Cohen, 2001). These structures are known 
as PAMP, and the receptors are known as PRR. PAMP has three common features. 
Firstly, they are strictly produced by the microorganism but not by the host. Secondly, 
they are essential to the survival of the microorganism. Thirdly, they are usually 
common constitutes shared by many microorganisms of the same class (Medzhitov & 
Janeway, 2000). The best-known PAMPs include bacterial DNA, double-stranded 
RNA, yeast mannans, lipopolysaccharide (LPS), glycan, glucans and lipoteichoic 
acids. PAMPs are able to trigger a rapid innate response because no clonal expansion 
is required in the receptor bearing cells for an efficient response to occur (Janeway, 
1992; Medzhitov & Janeway, 2000). Hence, PAMPs act as an alert for the innate 
immune system to respond to invading pathogens. Innate immune system has been 
traditionally considered to play an important role in containing the infection before 
adaptive immunity takes place.  
 
Innate immunity also deals with endogenous molecules that signal tissue and cell 
damages, known as alarmins (Bianchi, 2007). Alarmins rise from sterile injuries such 
as trauma, excessive heat, cold, chemical insults, radiation, withdraw of oxygen and 
drugs (Bianchi, 2007). Common alrmins include HMGB1, uric acid, heat shock 
proteins, nucleolin and neurotoxins (Bianchi, 2007; Christian et al., 2003; Oppenheim 
& Yang, 2005). Appropriate recognition and removal of alamins is crucial for the 
resolution of tissue damage. However, inappropriate recognition or exaggerated 
response leads to the development of autoimmunity, which further damages the tissue.  
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PRRs can be divided into three classes: secreted, endocytic and signaling (Medzhitov 
& Janeway, 2000). Secreted PRRs function as opsonins and sensitize microorganisms 
for complement system and phagocyte recognition. The best-characterized secreted 
PRR is mannan-binding lectin (MBL), which initiates the lectin pathway of 
complement system. Endocytic PRRs mediate the uptake or endocytosis of 
microorganisms after recognizing PAMPs on the microbial surface. The macrophage 
mannose receptor and scavenger receptor are examples of endocytic PRRs. Signaling 
PRRs are molecules that activate signaling pathways in innate immune cells and 
induce the production of cytokines, chemokines and surface co-stimulation molecules 
(Medzhitov & Janeway, 2000). Toll-like receptors (TLRs) are typical signaling PRRs.  
 
1.3.1. Pathways of complement system  
Complement, consisting of more than 35 plasma and host surface proteins, is part of 
the innate immune system (Mark J Walport, 2001a). It was first discovered in 1896 as 
a heat-labile serum component that “complements” antibodies in the killing of 
bacteria. Complement proteins amount to more than 3 grams per liter in plasma (Mark 
J Walport, 2001a). The benefits of complement derive from its controlled activation. 
Excessive complement activation or defective regulation can lead to inflammatory 
tissue damages. 
 
Complement can be activated through three pathways depending on the triggers: 
classical pathway, lectin pathway and alternative pathway (K. Reid, 1986) (Fig 1.1). 
The main function is to recognize endogenous and exogenous danger signals and 
dispose their sources. All three pathways converge in the formation of C3 convertase 
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and the activation of C3. This leads to the formation of membrane attack complexes 
(MAC) that disrupt the cell wall causing cell lysis. Complement activation also causes 
target opsonizaiton by C3b and C4b fragments and the generation of soluble C3a and 
C5a anaphylatoxins that attract macrophages and enhance phagocytosis (K. Reid, 
1986).  
 
Complement also plays an important role in bridging innate immunity and adaptive 
immunity (Mark J Walport, 2001b). First, classical complement system is activated 
through binding to antibody-antigen complex. Second, the threshold of B cell 
activation is lowered when antigen meets B cell in the presence of complement 
component. Third, IgG production is enhanced by a mechanism that is dependent on 
IgM and C1q. These facts collectively show that complement has an adjuvant effect 
on amplifying adaptive immune response evoked by lower amount of antigen (Mark J 
Walport, 2001b). 
 
1.3.1.1. Classical pathway  
C1q is the recognition unit of complement classical pathway (Table 1.1). It activates 
complement by strongly binding to IgM or IgG clusters, pentraxins (for example, C-
reactive protein; CRP), cellular structures from damaged cells, lipids, DNA and some 
gram negative bacteria (for example, Escherichia Coli) (Cooper, 1985; Tenner et al., 
1984). In blood circulation, C1q exists together with two serine proteases C1r and C1s 
forming C1 complex (C1qr2s2). Upon C1q binding to its ligand, a conformation 
change occurs in the C1 complex and the mechanical stress activates proenzyme C1r, 
which then cleaves and activates C1s (A. R. Duncan & Winter, 1988; R. C. Duncan et 
al., 2008).  
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Activated C1s initiates the subsequent proteolytic steps by cleaving C4 into C4a and 
C4b. Opsonin C4b deposit on the surface of pathogen and recruit C2, which is then 
cleaved by C1s leading to the generation of C3 convertase (C4bC2a). C3 convertase 
will cleave C3 into C3a and C3b, with the latter acting as a potent opsonin and 
participating in the generation of C5 convertase (C4bC2aC3b). C5 convertase cleaves 
C5 into C5a and C5b, which will recruit C6, C7, C8 and C9 forming the MAC leading 
to cell lysis. Anaphylatoxin C4a and C3a are generated in this process for the 
recruitment of inflammatory cells (K. Reid, 1986).  
 
Table 1.1 Activators of the classical complement pathway. (Apated from Cooer, 1985)  
Microorganisms 
x Bacteria (Escherichia coli, Salmonella and Klebsiella) 
x Mycoplasma (Mycoplasma pneumoniae) 
x Viruses (Sindbis, Newcastle disease, Epstein–Barr virus, 
human immunodeficiency virus (HIV)) 




x Antigen-antibody complex containing IgM or IgG 
x Lipid (ipid A, cardiolipin and enzymatically modified form of 
low-density lipoprotein) 
x Oligosaccharides and polysaccharide 
x Protein (C-reactive protein (CRP), long pentraxin PTX3, 
myelin, β-amyloid peptide, serum amyloid P component and 
prion protein) 
x Polyanions (heparin and DNA) 
 
 
1.3.1.2. Lectin pathway  
The lectin pathway differs from classical pathway in the recognition unit and 
initiation serine proteases. Mannose-binding lectin (MBL) and ficolins recognizing 
carbohydrate patterns are PRMss in lectin pathway (Lynch et al., 2004; Matsushita & 
Fujita, 1992). MBL-associated serine proteases (MASP-1 and MASP-2) share 
structural similarities with C1r and C1s (Gal et al., 2007; Gal et al., 2009). Lectin 
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pathway merges with classical pathway at the step of C3 convertase generation after 
MASP-2 cleavage of C2 and C4 (R. C. Duncan et al., 2008).  
 
 
Figure 1.1 Complement system. Complement can be activated through three pathways 
depending on the triggers: classical pathway, lectin pathway and alternative pathway. The 
classical pathway is initiated when the C1 complex binds to the constant regions of IgG or 
IgM in immune complexes, e.g. antibodies bound to the surface of pathogens or apoptotic 
cells, inducing cleavage of C2 and C4 by C1s and the formation of C3 convertase (C2aC4b). 
The lectin pathway is initiated after binding of mannose binding lectin (MBL) to mannose 
groups on pathogen surface, which activates MBL-associated serine protease 1 and 2 
(MASP1 and MASP2, structurally similar to C1s). MASPs then cleave C4 and C2 to form 
C2aC4b complexes. The alternative pathway is initiated when activated C3b covalently binds 
to surface proteins and carbohydrate molecules. It then recruits factor B, which is then 
cleaved by factor D to form the C3 convertase C3bBb. All three pathways converge in the 
formation of C3 convertase and the activation of C3. This leads to the formation of membrane 
attack complexes (MAC) that disrupt the cell wall causing cell lysis. Complement activation 
also causes target opsonizaiton by C3b and C4b fragments and the generation of soluble C3a 
and C5a anaphylatoxins that attract macrophages and enhance phagocytosis 
 
1.3.1.3. Alternative pathway  
In contrast to classical and lectin pathways, alternative pathway is activated in a 
distinct but dependent manner. Hydroxylation of C3 (C3H2O) exposes more binding 
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sites on C3. Factor B (fB) binds to hydrolyzed C3 and is then cleaved by factor D 
(fD), generating C3 convertase of alternative pathway (C3bBb). The C5 convertase 
equivalent homologue in alternative pathway is C3bBbC3b (K. Reid, 1986).  
 
1.3.2. Complement system deficiency and autoimmunity  
Given the important function of complement system, malfunction of complement is 
associated with a wide range of diseases including autoimmune, infectious, 
cardiovascular and neurological disease. Of interest here is the association of 
deficiency of early complement components and the development of autoimmune 
disease systemic lupus erythematosus (SLE).  
 
SLE is a systemic autoimmune disease characterized by circulating IgG 
autoantibodies targeting mainly on nuclear autoantigens. Deposition of immune 
complexes (ICs) consisting self-antigens and autoantibodies causes subsequent 
complement activation, crosslinking of Fc receptors, and systemic tissue injuries 
(Rahman & Isenberg, 2008; Ravetch & Bolland, 2001). SLE is a complex disease 
involving disorders in both adaptive and innate immune system. Studies have shown 
that disease failed to develop in the absence of B cells. More recent study has shown 
stimulation of TLRs on B cells promotes class-switch recombination and somatic 
hypermutation, leading to T-cell independent activation of autoreactive B cells 
(Leadbetter et al., 2002; Viglianti et al., 2003).  
 
Accumulation of complement components is found at site of lesion, indicating the 
participation of complement in the effector phase of autoimmune response. Hence, 
deficiency of C1q indicates the impairment in initiating classical pathway by ICs. 
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However, SLE occurs when immune system is hyperactive or dysregulated. In fact, 
the aetiology of SLE can be a mix of multiple genetic and environmental factors, yet a 
rare single gene deficiency of early complement components (C1q, C1r/s, C4) is 
strongly associated with the development of SLE (Lewis & Botto, 2006). Among C1q 
deficient individuals, the majority (93%) develops SLE. 57%, 75% and 10% of those 
with C1r/s, C4 and C2 deficiency respectively also develop SLE (Lewis & Botto, 
2006). Deficiency of late complement components or early lectin pathway 
components has not been found to cause SLE. This is intriguing because it logically 
leads to a paradox in understanding the role of complement in SLE. On one hand, 
complement can be pathogenic but on the other hand, it can be protective. These 
observations suggest that complement is involved in the pathogenesis of SLE in more 
than one way. Two main hypotheses have been developed to explain the association: 
complement deficiency leads to 1) impaired clearance of dying cells (M. Botto & 
Walport, 2002); 2) failure in maintaining peripheral tolerance (Carroll, 2004a; Lewis 
& Botto, 2006). These hypotheses are not mutually exclusive. Experimental and 
clinical evidences will be discussed in detail later.   
 
1.3.2.1. C1q deficiency and SLE 
C1q is a 460 kDa macromolecule produced uniquely by macrophages and dendritic 
cells. It is composed of 18 polypeptides (6 C1qA, 6 C1qB, and 6 C1qC) that form 6 
triple helices each consisting of one C1qA chain, one C1qB chain and one C1qC 
chain (Lu et al., 2008). The three chains are connected at N-terminus by covalent 
disulfide bonds (C1qA-C1qB and C1qC-C1qC bonds (Kishore & Reid, 2000; Lu et 
al., 2008). Two A-B heterodimers each forms a triple helix with a single C chain at N-
terminus collagenous domain (Lu et al., 2008; K. Reid & Porter, 1976). Further 
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interaction brings three ABC-CBA structures together to form the functional C1q 
molecule (Lu et al., 2008; K. Reid & Porter, 1976). In human, the three C1q genes 
(C1qA-C1qC-C1qB) are bundled on chromosome 1 within a region of approximately 
25 kb (Sellar et al., 1991). Their basal and stimulated expression is largely 
synchronized (Chen et al., 2011). 
 
Genetic C1q deficiency is rare. To date, only 71 cases of C1q-deficient patients have 
been documented (Stegert et al., 2015). As noted earlier, 93% of C1q deficient 
individuals develop SLE (Lewis & Botto, 2006). Homozygous deficiency of C1q 
genes almost always causes SLE (Lewis & Botto, 2006). It is now widely believed 
that the C1q has a protective role against SLE due to its role in the clearance of 
apoptotic cells (ACs).  
 
A hallmark of SLE is the development of autoantibodies against heterogeneous 
intracellular antigens, especially nuclear antigens. 90% of SLE patients from C1q 
deficient cohort are positive in anti-nuclear autoantibody (ANA) (Stegert et al., 2015). 
AC debris is believed to be the source of autoantigens driving the immune response. 
In 1990s, Rosen et al. found that autoantigens targeted in SLE are clustered on the 
surface of ACs (L. A. Casciola-Rosen et al., 1994; Rosen et al., 1995). For example, 
anti-phospholipid antibodies bound to apoptotic blebs, where phosphatidylserine was 
exposed due to externalization during cell apoptosis (L. Casciola-Rosen et al., 1996).  
Another supporting evidence is that intravenous injection of syngeneic apoptotic 
thymocytes into mice leads to the production of autoantibodies (Mevorach et al., 
1998). More recent studies have shown that non-autoimmune mice injected with ACs 
can develop lupus-like diseases (Bondanza et al., 2004; Georgiev et al., 2005).   
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Concatenating the results, a logical hypothesis would be that impaired clearance of 
ACs increases the chance of developing SLE. Backed up by the evidence that 
excessive amount of apoptotic bodies were observed in the kidney and blood 
circulation of C1q-deficient mice (Marina Botto et al., 1998), C1q has been shown to 
have a major role in promoting AC clearance in both C3-dependent and C3-
independent pathways. Delayed clearance of ACs will lead to cell debris being taken 
up by dendritic cells instead of macrophages and release of alarmins, which activate 
DCs (Albert et al., 1998; Inaba et al., 1998). DCs will then process and present the 
cellular materials as antigen, leading to subsequent activation of adaptive immunity. 
 
C1q also has a regulatory role on professional APCs (macrophages, DC and B cells) 
and other immune cells (Lu et al., 2008), which may further explain its protective role 
towards SLE. C1q-opsonized ACs modulates LPS-induced cytokine production in 
DCs (Baruah et al., 2006; Fraser et al., 2009; Nauta et al., 2004).  C1q ligation with 
LAIR-1 expressed on pDCs inhibits IFN-α secretion from pDCs (Son et al., 2012). 
C1q also modulates differentiation of DCs from monocyte precursors. Recent study 
shows that pericellular C1q induces tolerogenic DC (Teh et al., 2011). C1q has been 
shown to modulate functions of B and T cells (Nayak et al., 2010). In C1q knockout 
mice, negative selection of autoreactive B cells is less efficient, leading to reduced B 
cell tolerance (Ferry et al., 2007). T cell proliferation and activation is inhibited in the 
presence of C1q. Also, in C1q knockout mice, IFN-γ production is reduced in antigen 




1.3.2.2. C1r/s deficiency and SLE 
Deficiencies of C1r and C1s are the most rare among early complement components 
(C1q, C1r/s, C2, C3, C4) and the least studied. Since the first C1r/s deficiency case 
identified in 1968, there have been 22 cases reported worldwide in total, 14 of which 
were reviewed in one major review paper in 2001 by Pickering and Botto (Abe et al., 
2009b; Amano et al., 2008; Bienaime et al., 2010; Dragon-Durey et al., 2001b; M. C. 
Pickering et al., 2001; Pondman et al., 1969; Wu et al., 2011). All individuals are 
characterized by the absence of complement hemolytic activity (CH50), and a 
decreased level of C1r (0-12%) or C1s (0-50%). 16 (73%) of the 22 cases developed 
SLE (Amano et al., 2008; Kallel-Sellami et al., 2008).  
 
 
 Table 1.2 Clinical cases with complement C1r and/or C1s deficiency. (Adapted from Pickering and Botto 2001) 
Family Complement deficiency Mutation 
Age at conset, 
gender, race Clinical features Laboratory features Reference 





american black  




1) ANA (1/80), anti-dsDNA and anti-Sm 
positive, 
2) CH50 0,  
3) C3 and C4 increase,  
4) Renal biopsy IF: positive for IgG, IgA, IgM, 
C3 and C1q.   
 










Malar rash, polyarthritis, 
oral aphthous ulcers, digital 
pulp vasculitis, 
Hashimoto’s thyroiditis, 
nephritis and hepatitis 
Increase susceptibility to 
infections 
1) Anti-SSA, anti-SSB, anti-dsDNA, anti-
thyroid peroxidase antibodies positive, 
2) CH50 0,  
















including arthritis and 
proteinuria. Recurrent 
infections 
1) ANA and anti-Sm positive,  
2) CH50 0,  
3) C4 increase, 













including arthritis and 
photosensitivity 
1) ANA and anti-Sm positive,  
2) CH50 0,  









/Brazilian  Asymptomatic   
1) CH50 0,  








/Brazilian  Asymptomatic  
1) CH50 0,  




Table 1.2 continued  
Family Complement deficiency Mutation 
Age at conset, 












but no SLE manifestations. 
Died at age 7 due to fever 
of unknown origin and loss 
of consciousness.  





T376fsX407 11/male /Japanese  
Malar rash, chronic 
glomerulonephritis with 
proteinuria and haematuria. 
1) ANA 1/160 and anti-dsDNA positive, 
2) Anti-Sm and anti-RNP negative,  
3) CH50 0,  
4) C4 increase, 
5) Renal biopsy IF: positive for IgG and C3.   
 
(Inoue et al., 
1998; Suzuki 
et al., 1992) 






Recurrent fever of 
unknown origin, recurrent 
sacroiliac arthritis, 
hypersensitivity to multiple 
antibiotics 
1) ANA (1/640) but anti-dsDNA negative, 
2) CH50 0. 
 (Abe et al., 
2009a) 
6b C1s deficiency  C1r decrease 




/Japanese Recurrent infections 
1) ANA (1/40) but anti-dsDNA negative, 
2) CH50 0. 
 
 ANA, anti-nuclear antibody;  
CH50, 50% haemolytic complement activity of serum;  
SS-A, Sjögren's-syndrome-related antigen A; 
SS-B, Sjögren's-syndrome-related antigen B; 
anti-Sm, anti-Smith antibody;  




The deficiency is usually concomitant for C1r and C1s. A decreased level of C1r or 
C1s is usually associated with the deficiency of the other (Loos & Heinz, 1986). This 
is possibly due to the close proximity of the two genes on the short arm of 
chromosome 12 within 9.5 kb (Kusumoto et al., 1988). They are likely to be regulated 
similarly because C1r and C1s are encountered as a complex at 1:1 ratio (K. Reid, 
1986). C1 complex fails to assemble or be hemolytically active in the absence of any 
subcomponent (R. J. Pickering et al., 1970). In fact, among all reported cases, only 
one case is selective C1r deficiency. However, 9 cases of complete selective 
deficiency of C1s have been reported (Abe et al., 2009a; Amano et al., 2008; 
Bienaime et al., 2010; Dragon-Durey et al., 2001a; Endo et al., 1999; Inoue et al., 
1998; Suzuki et al., 1992). Selective complete deficiency of C1s usually closely 
correlates to the early onset of the disease and severe disease condition. So far, all the 
10 selective deficiency cases have been analyzed on a molecular level and the 
mutations have been identified (Table 1.2). Notably, only in one case, complete 
selective C1s deficiency does not affect serum C1r level (Bienaime et al., 2010; 
Dragon-Durey et al., 2001a). The mechanism of how C1r/s deficiency leads to the 
pathogenesis of SLE is still poorly studied. 
 
1.3.2.3. C4 deficiency and SLE 
C4 is present in human serum as two isotypes, C4A and C4B. The genetics of C4 is 
complex. C4A and C4B genes are located within the MHC region, and the number 
and size of C4 genes can be of high variations in individuals. The number of C4 gene 
modules can vary from one to four, resulting in a two to seven copies of genes in 
diploid genome. The size of C4 gene varies due to the presence or absence of 
retrovirus HERV-K (C4) (Dangel et al., 1994). The presence of retrovirus is 
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associated with a lower level of plasma C4 (Schneider et al., 2001; Yang et al., 2003). 
Complete C4 deficiency requires mutations on both C4A and C4B genes (Lokki et al., 
1999). The first case of complete C4 deficiency was reported in 1974 (Hauptmann et 
al., 1974). Until 2001, 24 cases of C4 deficiency had been reported and 18 (75%) of 
them develops SLE-like disease (M. C. Pickering et al., 2001).  They are often 
associated with early onset of disease and positive ANAs in the serum. Partial 
deficiency of C4 or acquired deficiency resulting from drug inactivation of C4 is more 
common, and is also an important factor for susceptibility towards SLE 
(Kristjansdottir et al., 2000; Speirs et al., 1989).  
 
C4 is known to be involved in the formation of C3 convertase (C4bC2a) in the 
complement classical pathway. Formation and deposition of C3b on the surface of 
microbials or apoptotic blebs will signal for phagocytosis. This indicates the 
important role of C4 in the clearance of ACs. Other than this, C4 is shown to be 
critical in maintaining B cell tolerance (Carroll, 2004a; Chatterjee et al., 2013). As 
described earlier, intravenous injection of ACs induces production of autoantibodies, 
indicating the loss of tolerance in circulating lymphocytes. Using transgenic models 
of crossing complement  (C4, C3, CR1 or CR2) deficient mice with double transgenic 
mice carrying genes expressing hen-egg lysozyme (HEL) specific immunoglobulin 
(Ig) and soluble HEL (sHEL), it was demonstrated that C4 or C4 receptor (CR1, CR2) 
deficiency led to loss of B cell anergy (Prodeus et al., 1998). Furthermore, C4 or CR1 
deficient mice in combination with lpr (lymphoproliferation) on C57BL/6×129 




In 1990s, Fearon and Locksley proposed that complement facilitates B cell response 
through complement receptors, bridging innate immunity and adaptive immunity 
(Dempsey et al., 1996; Dempsey & Fearon, 1996). Activated C4 covalently binds to 
an antigen to mark it as foreign, providing a ligand for CR1 in bone marrow and 
spleen stromal cells. Binding of C4b-coated self-antigen with immature B cells 
through CR1-CD81-CD19 co-receptor delivers a strong negative signal that promotes 
deletion of autoreactive B cells. Alternatively, uptake of C4b-self antigen complex by 
follicular dendritic cells (FDC) helps to concentrate and retain self-antigens for the 
enhanced antigen encounter with autoreactive B cells, which facilitates the removal of 
autoreactive B cells (Carroll, 2004b). In the absence of C4 or CR1, the encounter of 
self-antigen with autoreactive B cells is not sufficient to trigger negative selection, 
leading to defects in negative selection and loss of self-tolerance.  
 
Notably, B cell anergy is intact in the absence of C1q or classical complement 
pathway activation (Cutler et al., 2001). C1qa-/- IgHEL B cells are functionally anergic 
in the presence of soluble self-antigen. It is possibly due to the different genetic 
background of the C1q-deficient and C4-deficient mice. Another possible explanation 
is that C4 can be activated independent of C1q through lectin pathway.  
 
1.3.2.4. Other complement component deficiency and SLE  
C3 
Given the central role of C3 as a converging point of complement pathways and 
major route for complement activation mediated activities, it is surprising that C3 
deficiency only rarely leads to autoimmune diseases such as SLE (Lewis & Botto, 
2006).  Only 3 (13%) out of 23 reported C3 deficient cases are associated with lupus-
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like disease, but none of them are ANA positive (M. C. Pickering et al., 2001). This is 
consistent with the experiment where crossing C3 deficient mice with IgHEL / sHEL 
double transgenic mice, or lpr murine model did not lead to the loss of B cell anergy 
(Prodeus et al., 1998). Einav et al. has demonstrated that C3nullC4nulllpr mice is 
similar to C4nulllpr mice, but different from C3nulllpr mice, in disease severity (Einav 
et al., 2002). Together these results show that C3 has little effect in terms of 
protection towards SLE. This could be due to the protective effect (e.g., C3 is 
required for B cell tolerance) being negated by its role in mounting inflammatory 
response. Hence, in the absence of C3, disease susceptibility may be increased, but 
the ability to mount an immune response may also be impaired.  
 
C1 inhibitor  
C1 inhibitor (C1-Inh) is responsible for controlling spontaneous activation of C1 
complex. Patients with deficiency of C1-Inh usually suffer from hereditary 
angioedema (HAE) (Donaldson, 1989). C1-Inh deficiency can be caused by genetic 
mutations in C1-Inh gene, or acquired from increased catabolism of C1-Inh or 
autoantibodies against C1-Inh. It is usually associated with increased turnover and 
chronically low levels of C4 and C2 due to its failure in regulating C1r and C1s.  
HAE patients have higher risk of developing SLE, sharing common features including 
female predominance, skin lesions, photosensitivity and ANA (Koide et al., 2002; 
Lewis & Botto, 2006). This association reinforces that, in addition to inherited 
classical complement deficiency, acquired classical complement component 





Homozygous C2 deficiency is most common among deficiencies of all classical 
pathway components. The prevalence of homozygous C2 deficient individuals in 
Western Europe as indicated in population studies is around 1/20,000 (M. C. 
Pickering et al., 2001). Its association with SLE is relatively weak, with only ~10% of 
C2-deficient individuals developing SLE (M. C. Pickering et al., 2001). It is usually 
associated with a much milder disease with less common renal involvement and lower 
tiers of ANA and anti-DNA antibodies. Deficiency of C2 can be due to failure in 
synthesizing or secreting of the protein (Agnello, 1978; Hauptmann et al., 1982; 
Pariser et al., 1978; Raum et al., 1978).  
 
1.3.3. Serine protease C1s 
 
1.3.3.1. Serine protease family  
C1r, C1s, MASP-1, MASP-2 and MASP-3 are early complement proteases that are 
responsible for the activation of classical and lectin complement pathways in complex 
with pattern recognition molecules. Belonging to the same serine protease family, 
they share identical domain organization, similar overall structure but differ in 
substrate specificities and evolution phylogenetic markers (Gal et al., 2007). It is well 
recognized that C1r autoactivates and cleaves C1s. Activated C1s cleaves C4 and C2. 
Compared with C1r and C1s, MASPs exhibit more promiscuous substrate specificity. 
MASP-1 and MASP-2 have the ability to autoactivate. Activated MASP-1 cleaves C2 
and C3, while activated MASP-2 cleaves C2 and C4 (Gal et al., 2007; Rossi et al., 
2005). The enzymatic properties of MASP-3 are not very well characterized.  
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1.3.3.2. Structure of C1s 
C1s is a protease subunit of C1, and one of the early proteolytic elements in the 
complement pathways. It was first described as “C1 esterase” in the 1950s (Ratnoff & 
Lepow, 1957). The primary structure and enzymatic property was characterized 20 
years later (Campbell et al., 1988). Human C1s consists 673 residues sharing 40% 
similarities in amino acid residue sequence with that of C1r (Tosi et al., 1987). The 
genes encoding C1r and C1s are closely linked on the short arm of chromosome 12 
(Nguyen et al., 1988). It is likely that they were generated 600 millions years ago by a 
duplication of a ancenstral gene (Kusumoto et al., 1988). They are synthesized as 
single chain proenzymes consisting of 673 and 688 amino acids with molecular 
weight around 83 kDa and subsequently cleaved into a heavy chain and a light chain 
upon activation (K. Reid, 1986). The production of C1s is predominantly in 
hepatocytes in the liver, as well as other cells such as fibroblasts, macrophages, 
monocytes and cells of nervous system.  
 
Structurally, C1s, together with other complement proteases C1r and MASPs form a 
family of serine proteases (SPs) with identical domain organizations (Fig 1.2). They 
are modular proteases consisting of six domains including 5 non-catalytic domains at 
N-terminus and one catalytic domain at C-terminus (Gal et al., 2007). Starting from N 
terminus, C1s consists of a CUB domain (CUB1), an epidermal growth factor (EGF)-
like domain (K. B. Reid et al., 1986), another CUB domain (CUB2), a tandem repeat 
of complement control protein (CCP) domains  (CCP1, CCP2) (Bork & Beckmann, 
1993), and a chymotrypsin-like SP domain. The assembly of C1s-C1r-C1r-C1s 
tetramer as well as its interaction with C1q collagen-like arms in assemble of C1 
complex is known to involve Ca2+-dependent interactions between CUB1-EGF-CUB2 
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domains on C1r and C1s (T. F. Busby & Ingham, 1990; Gál & Závodszky, 1998; 
Gregory et al., 2003; Thielens et al., 1990). On the other hand, the enzymatic 
properties are mediated by C-terminal CCP1-CCP2-SP region, which shows all the 
catalytic properties of the full-length protease (Rossi et al., 1995). During C1 complex 
activation, C1s is activated through cleavage of Arg422-Ile423 bond in SP domain by 
autolytically activated C1r, leading to the generation of one heavy chain (56 kDa) and 
one light chain (27 kDa) held together by a disulfide bond (C. Gaboriaud et al., 2004). 
The structure of CCP2-SP region of recombinant C1s has been resolved using X-ray 
crystallography (Christine Gaboriaud et al., 2000).  
 
 
Figure 1.2 Domain organization of C1s. C1s consists of 6 independently folding domains 
from N terminus: CUB1 (residues 16 to 128)-EGF (residues 129 to 174)-CUB2 (residues 175 
to 289)-CCP1 (residues 290 to 355)-CCP2 (residues 358 to 422)-serine protease (residues 423 
to 688). The N-terminal CUB1-EGF-CUB2 domains are responsible for the Ca2+  dependent 
interaction in the formation of the C1s-C1r-C1r-C1s tetramer and the assembly of C1 
complex with C1q. The C-terminus CCP1-CCP2-SP domains provide the exosites and active 
sites for the proteolysis of C1s substrates. The disuphide bond connecting the two chains of 
activated C1s is shown by a black line. (Adapted from (Gal et al., 2007) 
 
1.3.3.3. C1s in the assembly of C1 complex  
In the blood, C1s is found in a complex with C1r and C1q, to yield the C1 complex. 
The characteristic of C1s is that it exerts its catalytic activities in the context of 
multimolecular C1 complex. The association with C1q and C1r is required for the 
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activation of C1s. It is also demonstrated that the enzymatic efficiency of C1s in C1 
complex is 7 fold higher than that of C1s alone using fluorescent quenched substrate 
assay on an 8 amino acid truncated peptide containing cleavage site from its natural 
substrate C4 (O'Brien et al., 2003).  
 
C1 is a large multicomponent complex (790 kDa) composed of a recognition unit C1q 
(460 kDa), serine proteases C1r (90 kDa) and C1s (83 kDa) in a 1:2:2 ratio (Kishore 
& Reid, 2000). C1q is made up of 18 polypeptides (6A, 6B, and 6C chains) that are 
similar in length and sequence. The N terminus regions are interconnected via 
disulfide bond between A-B and C-C chains (Kishore & Reid, 2000; Lu et al., 2008). 
This is followed by a collagen-like region that forms 6 heterotrimeric helix. Because 
of interruptions at repeated Gly-Xaa-Yaa motif, the collagen “stalk” diverges into 6 
arms each ending with a C-terminus globular head consisting one A, one B and one C 
module (Lu et al., 2008; K. B. Reid et al., 1986). C1r and C1s have similar overall 
structure with domains from N terminal in the order of CUB1-EGF-CUB2-CCP1-
CCP2-SP (Arlaud et al., 2001). They are both synthesized as single chain proenzyme 
first consisting 688 and 673 amino acids each, and are both activated by cleavage of 
an Arg-Ile bond located in SP domain, yielding two-chain activated proteases (Arlaud 
et al., 2001; Christine Gaboriaud et al., 2000).  
 
The C1s CUB1-EGF domain structure served as a major breakthrough in 
understanding the interaction between C1q-C1r-C1s (Gregory et al., 2003). In C1 
complex, C1r and C1s form a compact “∞-shaped” tetramer (C1s-C1r-C1r-C1s) under 
the scaffold of C1q, with C1r polypeptide at the innermost layer (Venkatraman Girija 
et al., 2013). The structure is formed from two heterodimers linked though a 
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connecting hydrophobic core (Venkatraman Girija et al., 2013). Crystallography of 
C1s tetramer reveals that the tetramer has an overall diameter of 120 Å, with a 
maximum separation of 190 Å at the two CUB2 domains of C1s polypeptide 
projected opposite each other (Venkatraman Girija et al., 2013). The CUB1 module of 
one monomer interacts with the EGF module of its counterpart in a head-to-tail 
pattern, enabling the contact of SP modules of C1r and C1s. Two of the six 
heterotrimeric collagenous stems of C1q each fits into the groove of a C1r-C1s 
heterodimer. C1q interacts with the C1s-C1r-C1r-C1s tetramer through two Ca2+-
binding sites on each C1r CUB1 and CUB2 and one binding site on each C1s CUB1 
module, yielding a total of six binding sites on the tetramer (Bally et al., 2009). On 
C1q, the Ca2+-binding sites fall on its LysA59, LysB61 and LysC58 (Bally et al., 
2009). The stability of C1 complex structure is highly dependent on calcium binding. 
Additional interaction includes hydrogen bonds between C1s and C1q collagenous 
stems (Venkatraman Girija et al., 2013). Together, the structural information on how 
C1q, C1r and C1s assemble the C1 complex provides important implications on the 
activation process.   
 
1.3.3.4. Activation of C1 complex  
Autoactivation of the C1r serves as the central event in C1 activation, which transmits 
a recognition event into an enzymatic signal. The recent studies on the 
crystallography of CCP1-CCP2-SP domains of both C1r and C1s and activated C1r 
dimer helped greatly in understanding the autoactivation of C1r and the subsequent 
activation of C1s (Budayova-Spano et al., 2002; Kardos et al., 2008).  
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C1r forms a head-to-tail dimer with the CCP1 domain of one monomer interacts with 
the SP domain of the other. The crystal structure of the dimer revealed the existence 
of a large opening (13 Å × 30 Å) between the two SP domains, separating the 
cleavage site of one monomer and the active site of the other is by a distance of 92 Å 
(Kardos et al., 2008). To allow the autoactivation to occur, a transient conformational 
change must occur to allow a physical contact between two SP domains, and this is 
achieved by the dissociation of the dimer (Kardos et al., 2008). In solution phase at 
physiological pH, dissociation and re-association of C1r dimers can occur and this 
allows an exchange of monomers between C1r dimers (Dobo et al., 1999; Lorincz et 
al., 2000). The binding of C1q globular heads to its ligands causes a change in the 
relative angle and position between the six stems shifting the equilibrium to the 
dissociation of the C1r dimer. After dissociation, the transient enzyme-substrate 
complex is formed between the two SP domains and is stabilized by the 
intermolecular CCP2-SP interaction. The autoactivation will then occur and the 
activated head-to-tail C1r dimer will be restored (Budayova-Spano et al., 2002).  
 
A single activated C1r unit in C1 is able to activate both C1s in the complex (Dobo et 
al., 1999). Activated C1r has its active site on SP domain facing outwards and 
accessible to C1s SP domain. The transient conformational change facilitating C1r 
activation of C1s requires the appropriate positioning of its Arg437-Ile438 bond 
within the active site of C1r. This is achieved by an inward shift of C1s SP domain, or 
an outward shift of C1r SP domain. C1r then activates C1s by cleaving at its Arg437-
Ile438 bond in the SP domain. The flexibility of the C1r/s CCP1-CCP2, CUB2-CCP1 
linkers, and C1r CCP2-SP linkers plays an important role in helping orienting the 
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enzyme and the substrate (Bally et al., 2005; Budayova-Spano et al., 2002; Harmat et 
al., 2004).  
 
1.3.3.5. Catalytic fragment of C1s 
The crystal structure of C1s catalytic domain consisting the CCP2 module (residues 
358 - 422) and SP module (residues 423 - 688) has been solved to 1.7 Å (Christine 
Gaboriaud et al., 2000).  
 
The core of C1s SP domain folds into two six-stranded β-barrels interlinked by 
several surface loops, three trans-segments, and one C-terminal α-helix (Christine 
Gaboriaud et al., 2000). The catalytic residues Ser632, His475 and Asp529 sit in the 
junction of both barrels. A putative sulfate ion of which the oxygen atoms form 
hydrogen bonds with the active residues is also found in the active site. The structures 
of CCP domains are less conserved as compare to SP domains. C1s CCP2 domain 
consists a hydrophobic core surrounded by six β-strands (B1 – B6) stabilized by 
disulfide bond bridges in a 1 – 3 and 2 – 4 pattern.  
 
The CCP2-SP domains assemble into a club-shaped formation, with the CCP2 
module tightly anchored on SP domain on the opposite side of the active site forming 
a very rigid interface arising from several non-covalent interactions. The CCP2 
domain is orientated perpendicular to the surface of SP domain. Activated C1s is 
positioned inside C1 complex and the outward movement towards its substrates could 
be achieved by the flexible hinge and enhanced by this rigid surface. This observation 
also accounts for the fact that CCP2 domain provides additional exosites (substrate-
binding regions) for its complement substrate C4 (Perry et al., 2013; Rossi et al., 
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1998). The accessory recognition sites in CCP module may contribute to the substrate 
specificity of C1s (Arlaud et al., 2002).  
 
1.3.3.6. Restricted substrate specificity of C1s 
Study of C1s active site and exosites allows the elucidation of its substrate specificity. 
It can be understood from the following methods: 1) three dimensional structural 
analysis of the active site and exosites; 2) analysis of known C1s substrates cleavage 
sequences; 3) randomized phage display library; and 4) synthetic substrate library 
(Gosalia et al., 2005; F. K. Kerr et al., 2005; O'Brien et al., 2003).   
 
The access to the substrate binding sites in the vicinity of the active site is severely 
restricted as compared to other serine proteases. The three catalytic residues (Ser632, 
His475 and Asp529) sit in a conformation that is identical to that of trypsin. Asp626 
lies at the bottom of the primary specific pocket (S1) and is characteristic of serine 
proteases demonstrating trypsin-like activities. The nomenclature of subsites in C1s 
active site is based on that established by Schechter and Berger (Fig 1.3) (Schechter & 
Berger, 1967). The unique structural features that C1s displays is the disordered 
conformation in loop 3 and E and the C-terminal segment caused by insertions in 
loops 3 and C and deletions in loop 1, 2 and A (Perona & Craik, 1997). The insertion 
of loop C positioned right above the active site restricted the access to S2. The 
restricted access is also partially attributable to the presence of bulky hydrophobic 
residues (Phe511, Tyr595, Trp640) in the vicinity of S2 – S4 subsites (Arlaud et al., 
2002). This explains the preference of C1s for hydrophobic P3 residue and small P4 
residue. Lys614 lies above the entrance to S1, preventing most amino acids from 
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entering except for Arg, the only one that seems to be able to overcome the steric 
hindrance. These features help to fine tune the substrate specificity of C1s.  
 
In addition to the structure of C1s active site, the exosites on CCP1, CCP2 and SP 
modules also help to determine its substrate specificity. This is demonstrated by 
enzyme kinetic studies of the interaction between C1s and C4 (Rossi et al., 1998). 
Both CCP domains (CCP1-CCP2) are required for efficient cleavage of C4 by C1s. 
Also, four charged residues (Lys575, Arg576, Arg581 and Lys583) form another 
exosite by interacting with sulfotyrosin residues on C4 α-chain (R. C. Duncan et al., 
2012). However, the cleavage of C2 by C1s does not require the presence of CCP 
domains, as the SP domain alone was able to cleave C2 as efficiently as the complete 
molecule (Rossi et al., 1998).   
 
 
Figure 1.3 Schechter and Berger nomenclature for protease specificity. P1-P1’ represents 
the cleavage site, and substrate residues are notated as P4-P4’ from the cleavage bond. 
Subsites at enzyme active site are notated as S4-S4’ in accordance with the substrate. 
(Schechter & Berger, 1967) 
 
The importance of the prime subsites of C1s has been studied by O’Brien and 
colleagues using fluorescent quenched substrate assay on a limited substrate library 
(O'Brien et al., 2003). Peptides were designed such that P1 – P4 residues were 
identical to that of C4 cleavage site with single substitution at each of P1’ – P4’. The 
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amino acid substitution was chosen to make changes to at least each of major classes 
of all amino acids. The study showed that P1’ is the most selective site for cleavage 
among P1’ – P4’.  A more complete study was done by Kerr and colleagues using a 
randomized phage display library (F. K. Kerr et al., 2005).  An Arg is fixed at P1 
because it is required for C1s cleavage. 93 different phage peptide sequences were 
analyzed. The frequency of occurrence of amino acids found at each of P4 – P4’ was 
analyzed and ranked. Both studies also demonstrated that C2 sequence has a 
significant better kcat/K0.5 value as compare to that of C4. The interaction between 
cleavage sequence of C4 and C1s is less optimal. This may also explain why enzyme-





Table 1.3 Summarization of C1s complement and no-complement substrates. 
C1s substrates Cleavage site Physiological functions References 
Complement C4  GLQR-ALEI 
C1s cleavage of C4 leads 




Complement C2 SLGR-KIQI 
C4b binding with C2 
facilitates the C1s 
cleavage and leads to the 






inhibitor  SVAR-TLLV 
C1-Inh acts as a 
pseudosubstrate of C1s, 
cleavage of which will 






C1s cleavage at Lys58 
aids in the deneration of 
des-Lys58- β2 
microglobulin, which 
plays a role in chronic 
inflammatory diseases.  
 
(Nissen et al., 
1990) 
MHC class I heavy 
chain  
C1s cleaves an area 
between the α2 and α3 
domains 
The cleavage generates a 
soluble fragment, or alters 
the exposure of α3, and 
prevents T cells from 




Type I and II collagen  
C1s cleaves type I 
collagen into several 
products, but cleaves 
type II collagen into 
distinct 2:1 in length 
fragments.   
Cls might participate in 
the metabolism in 
cartilage matrix. 
(Yamaguchi 
et al., 1990) 
Insulin-like growth 
factor binding protein-
5 (IGFBP5)  
C1s cleaves IGFBP-5 
into 22kDa fragment. 
Fibroblast secreted C1s 
cleavage of IGFBP5 leads 
to the release of insulin-
like growth factor I and 
regulates cellular growth 
and regeneration.  
 
(W. H. 
Busby, Jr. et 
al., 2000; 




related protein 6 
(LRP6) 
NVGR-ANGL 
C1s cleavage of Wnt co-
receptor LRP6 activates 
the Wnt signaling pathway 
and plays a role in aging. 
 





Based on these studies, a model was constructed for evaluating the substrate 
selectivity within the computer program Prediction of Protease Specificity (PoPS) 
(Boyd et al., 2005; F. K. Kerr et al., 2005). PoPS can be used to predict and rank the 
likely cleavage sites within a single substrate or within a whole proteome. Secondary 
or tertiary structure information can be accessed to exclude the unlikely sites. Known 
structural information can be extracted from Accessible Surface Area (ASA) database, 
which automatically prunes the Protein Data Bank (PDB). If no three-dimensional 
information is available, substrate will be aligned against SWISS-PORT database 
using PSI-BLAST and pass to PSIPRED for secondary structure prediction. The 
model worked well in predicting the known cleavage sites on C2, C4 and C1-Inh with 
consideration of secondary structure and exosites. The program was utilized to screen 
human genome for proteins that match the cleavage criteria of C1s and returned a 
large number of matches in comparison to the three physiological substrates (Boyd et 
al., 2005).  
 
Overall, the analysis showed that C1s protease activity may not be restricted to the 
interaction with the known substrates, but other potential substrates outside 
complement system may exist. The author’s approach was to use the location of the 
potential substrates as criteria to eliminate physiologically irrelevant candidate 
substrates. This meant intracellular proteins were disregarded. However, in the event 
of cell apoptosis, intracellular proteins can be exposed and C1q is known to be able to 
interact with ACs. Taking all together, it is highly possible that C1s has other 
physiological function and substrates yet to be discovered.  
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1.3.3.7. C1 inhibitor 
C1-inh is a key regulator of the complement classical system (Davis, 1988; Wuillemin 
et al., 1995). Human C1-Inh is a member of the serine protease inhibitor (serpin) 
family, which acts as a suicide substrate of serine and cysteine proteinase (Gettins, 
2002). C1-Inh targets include C1r and C1s (Arlaud et al., 1979; Sim et al., 1979), 
MASP-1 and -2 (Endo et al., 2002), coagulation factors (Pixley et al., 1985b; 
Wuillemin et al., 1995) and plasma kallikrein (Schapira et al., 1982). 
 
C1-Inh consists of three β-sheets and nine α-helices. Active C1-Inh has its reactive 
center loop (RCL) protruding from the core of the molecule, allowing it to engage the 
C1s protease. The speptidyl bond Arg444 - Thr445 on the RCL matches the substrate 
selectivity of C1s and is subsequently cleaved, resulting in a drastic conformational 
change of the serpin. This will distort the catalytic residues in C1s and traps the 
enzyme with the serpin (Huntington et al., 2000), leading to the formation of a highly 
stable complex (Pixley et al., 1985a; Sim et al., 1979). 
 
Recent studies show that C1-Inh is a multi-functional anti-inflammatory protein that 
not only plays a role in protease inhibition but also has other un-related functions such 
as binding to gram-negative bacteria and the endotoxins (Davis et al., 2007; Liu et al., 
2003).  
 
1.3.3.8. C1s in health and diseases 
The association of C1s deficiency and SLE has been discussed in section 1.3.2.2. 
Other than SLE, C1s also participates in many other diseases and physiological 
processes (Gal et al., 2002).  
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Unwanted or uncontrolled activation of C1s can lead to the inflammatory events in 
ischemia-reperfusion injury (Hill & Ward, 1971; Mollnes et al., 2002; Riedemann & 
Ward, 2003). It can also lead to the pathogenesis of neurodegenerative diseases of the 
central nervous system, such as Alzheimer’s (Tacnet-Delorme et al., 2001). 
 
Cleavage of IGFBP-5 by C1s may present a link between inflammation and cellular 
repair process (W. H. Busby, Jr. et al., 2000). C1s cleavage of MHC class I indicates 
its role in regulation of immune response (Eriksson & Nissen, 1990). Cleavage of 
type I and type II collagens by C1s leads to the hypothesis that C1s could be involved 
in the metabolism of cartilage matrix (Yamaguchi et al., 1990) (Table 1.3).  
 
1.4 APOPTOSIS  
 
1.4.1. Features of cell apoptosis 
The term “apoptosis” was first used to describe a form of programmed cell death on 
morphological basis by Kerr et al (J. F. Kerr et al., 1972). It distinguishes exclusive 
from necrosis, which is marked by the loss of membrane integrity and exposure of 
cellular materials, on the morphology of the cells and the formation of apoptotic 
bodies, as well as the wide range of biochemical changes. Apoptosis is essential in 
maintaining the homeostasis of tissue, failure of which will often result in defects 
such as neurodegenerative disorders, tumerigenesis and autoimmunity. 
 
Cells that undergo apoptosis are demolished from the inside of the cells to minimize 
the damage to the surrounding. The remaining debris is readily recognized by 
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phagocytes for recycling of materials. During the process, DNA condensation and 
fragmentation take place and all life-supporting systems such as transcription and 
translation are shut down. Cells become rounded, retracting themselves from 
neighboring cells, followed by a prolonged period of apoptotic body formation. The 
most notable features include activation of caspases, drastic condensation of nuclear 
chromatins and the cytoplasm, and the display of markers on the cell surface for 
phagocytosis (Hengartner, 2000; J. F. Kerr et al., 1972; Strasser et al., 2000).  
 
Caspases exist in healthy cells as inactive zymogens, but certain stimuli are able to 
trigger apoptosis by culminating caspase activation, albeit in difference routes 
(Creagh et al., 2003). All pathways eventually lead to the activation of major effector 
caspaeses, which carry out most of the proteolysis during cell apoptosis.  
 
During cell apoptosis, weakening of key cellular structures by activated caspases 
takes place. Cytoskeleton constituents are targeted, such as actin and actin associated 
proteins (Browne et al., 2000; Communal et al., 2002; Gerner et al., 2000; Martin et 
al., 1995; Thiede et al., 2005), tubulins and microtubule-associated proteins (Adrain 
et al., 2006; Canu et al., 1998; Lane et al., 2001), and intermediate filament including 
vimentin and nuclear lamins (Morishima, 1999; Orth et al., 1996). Proteolysis of 
cytoskeleton contributes to the rounding and shrinkage of cells, and may also 
contribute to the formation of membrane blebs. Moreover, caspase-dependent 
proteolysis of cell-matrix focal adhesion and cell-cell adhesion complexes facilitates 
removal of cell debris by phagocytes by means of detaching the cell from its 
surrounding milieu. For example, β- and γ- catenins are cleaved by caspase-3, 
abrogating their ability to bind to α-catenin for the linkage of cadherins to the actin 
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cytoskeleton and disrupting the cell-cell adhesion junctions (Bannerman et al., 1998; 
Brancolini et al., 1997).  
 
Nuclear morphological changes during apoptosis are striking, conceivably due to the 
fragmentation of DNA and proteolysis of nuclear proteins. Typical changes in cell 
nucleus include shrinkage of nucleus in size, the collapse of chromatin against the 
nuclear envelope, condensation and budding of chromatin. Nuclear lamina including 
lamin B1 (Dynlacht et al., 1996), lamin A and C (Takahashi et al., 1996), and other 
nuclear peripheral domain associated proteins such as lamin B receptor (LBR)  
(Duband-Goulet et al., 1998) are cleaved by caspases during apoptosis. This together 
with the proteolysis of actin cytoskeleton serves as the main force causing nuclear 
fragmentation. Nuclear matrix is also markedly affected during cell apoptosis. Many 
DNA binding proteins such as topoisomerase IIα (Casiano et al., 1996) are cleaved 
during apoptosis. While most cellular organelles are gradually compressed or 
dispersed, nucleolus is generally resistant to apoptosis and nucleolar components 
remain to be recognized for prolonged period. For example, the nucleolar granular 
component marker nucleophosmin (B23), nucleolin, and dense fibrillar component 
marker fibrillarin were found to redistribute to nucleoplasm in apoptotic K562 and 
HeLa cells (Chan & Chan, 1999; Martelli et al., 2000).  
 
The more subtle changes are the fragmentation of Golgi, ER and mitochondria (Frank 
et al., 2001; Lane et al., 2002). The fragmented Golgi and ER are subsequently 
packed into apoptotic bodies. Mitochondria are broken down into much smaller 
fragments and are dispersed throughout the cell.  
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Recent studies have manifested the diversity of apoptosis with respect to the necessity 
of caspase involvements. Some other alternative caspase-independent pathways have 
been identified, but serve the same purpose as the classical caspase-denpendent 
pathways in expediting the safe and non-inflammatory removal of unwanted cells 
(Leist & Jaattela, 2001).  
 
1.4.2. Immune system in the clearance of apoptotic cells  
The generation of binding sites on cell surface and the release of chemokines to the 
milieu mark the last act of the apoptotic cells and initiate the final removal of the 
dying cells by immune system.  
 
Apoptotic cells release chemoattractants to recruit phagocytes to the site of apoptotic 
cell death, which facilitates a timely removal of the apoptotic cells. By caspase-
dependent activation of iPLA2, membranous phosphatidylcholine was cleaved into 
lysophosphatidylcholine (LPC) and released from apoptotic cells as a chemoattractant 
(Lauber et al., 2003). LPC induces the migration of professional phagocytes to the 
site and facilitates the subsequent engulfment together with the eat-me signal 
displayed on cell surface (Lauber et al., 2003).  
 
Loss of lipid bilayer asymmetry happens at the initial phase at apoptosis and displays 
the eat-me signals on cell surface while the “don’t-eat me” signals are down regulated, 
internalized or shed (Elward & Gasque, 2003; Elward et al., 2005; Fadok, Bratton, 
Frasch, et al., 1998; Gardai et al., 2005; Oldenborg et al., 2000). One of the best-
defined “eat-me” signals is phospholipid phosphatidylserine (PS). The caspase-
dependent translocation of PS from inner plasma membrane to cell surface serves as a 
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signal for apoptotic cell recognition. Binding of PS to serum opsonins leads to the 
clearance of apoptotic cells by phagocytosis (Fadok, Bratton, Frasch, et al., 1998; 
Martin et al., 1995). Another example of phagocytic ligands is ER chaperone protein 
calreticulin. Calreticulin is externalized during cell apoptosis and its ligation with 
scavenger receptor CD91 triggers subsequent cell engulfment (Gardai et al., 2005; 
Ogden et al., 2001). Other receptors such as CR3, CR4, class A and B scavenger 
receptors, have also been shown to initiate macrophage phagocytosis of apoptotic 
cells opsonized by thrombonspondin and iC3b (Mevorach et al., 1998; Takizawa et 
al., 1996).  
 
Ingestion of apoptotic cells by macrophages is immunosuppressive. It induces the 
expression of immunosuppressive cytokines such as IL-10 and TGF-β1, and reduces 
the production of inflammatory cytokines such as TNF-α, IL-6 and IL-12 (Fadok, 
Bratton, Konowal, et al., 1998; Huynh et al., 2002; Kim et al., 2004; Voll et al., 
1997). Peptides derived from ACs may be cross-presented via the MHC calss I 
antigen-presenting pathway and prime for cytotoxic T cell response (Albert et al., 
1998; Bellone et al., 1997; Steinman et al., 2000).  
 
Defects in apoptotic cell uptake resulting from complement deficiency or 
overwhelming cell apoptosis can lead to the cell debris being taken up by DC instead 
of macrophages (Albert et al., 1998; Inaba et al., 1998). DC are potent APCs and their 
uptake of these apoptotic cells leads to increased exposure of self-antigens to the 
adaptive immune system, which may break the tolerance and cause autoreactive T 
cells and B cell activation. Once autoantibodies are generated, the binding of 
autoantibodies to autoantigens amplifies the immune response through B cell 
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receptors and plasmacytoid DC (pDC), and causes tissue damage by activating 
complement.  
 
1.4.3. C1q in the clearance of apoptotic cells 
It has been manifested that C1q enhances the clearance of ACs through C3-dependent 
or -independent opsonization followed by phagocytosis by macrophages to maintain 
self-tolerance. Clearance of intraperitoneally injected apoptotic Jurkat T cells was 
severely impaired in C1q deficient mice, indicating that the absence of C1q was 
significant for the defective uptake of ACs (Taylor et al., 2000). Immobilized C1q is 
able to engage CD93 and enhances Fc receptor and CR1 dependent phagocytosis 
(Bobak et al., 1988; Bobak et al., 1987; Nepomuceno et al., 1997). 
 
C1q binds to ACs via its ligands on surface blebs. Known C1q ligands on ACs 
include phosphatidylserine (Païdassi et al., 2008), DNA (Jiang et al., 1992; Païdassi et 
al., 2008), and cariticulin (Stuart et al., 1997). Direct opsonization of ACs by C1q 
involves binding of cariticulin (Ogden et al., 2001). It has been proposed that C1q 
recognizes ACs via its globular head and binds directly to calreticulin/CD91 on 
phagocyte membrane through collagenous tail. The ACs are then ingested via CD91 
mediated macropinocytosis (Ogden et al., 2001).  
 
C1q together with its other known ligands, such as C reactive protein (CRP) and IgM, 
also mediates the clearance of ACs through complement activation. CRP binds to 
ACs surface blebs and activates complement without the formation of MAC. It 
opsonizes and enhances phagocytosis of ACs and maintains macrophage expression 
of anti-inflammatory cytokine TGF-β (Gershov et al., 2000). The anti-inflammatory 
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effect of CRP is shown to be dependent on C1q and fH (Gershov et al., 2000). C1q 
also binds to IgM-opsonized ACs. This results in C3 deposition on ACs, which 
promotes clearance of ACs by phagocytosis (Ciurana et al., 2004; Ogden et al., 2005). 
This is evident by the observation that mice genetically deficient in soluble IgM 
develop lupus-like diseases (Boes et al., 2000; Ehrenstein et al., 2000).  
 
It is crucial that ACs are cleared rapidly before entering into secondary necrosis. 
Clearance of necrotic material is associated with stimulation of autoreactive B cells 
and release of pro-inflammatory cytokines exemplified by TNF-α (Gershov et al., 
2000; Urbonaviciute et al., 2008). Deficiency in C1q always associates with impaired 
clearance of ACs in mice and human, and often leads to autoimmunity.  
 
1.5 SLE  
 
1.5.1. Clinical and laboratory feature   
Systemic lupus erythematosus is a polygenic autoimmune disease that affects multiple 
organs with multifactorial etiology. The clinical presentation of SLE is diverse, 
ranging from rash and arthritis through anemia and thrombocytopenia to nephritis, 
seizures, serositis, and psychosis, but typically involves young women in childbearing 
age (Rahman & Isenberg, 2008). It is most prevalent in African-Americans with the 
occurrence being more than 200 cases per 100,000 persons, and less prevalent in 
Caucasians (Johnson et al., 1995).  
 
The most characteristic laboratory feature of SLE is the presence of autoantibodies 
against a variety of nuclear autoantigens, such as nucleosomes, small nuclear 
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ribonucleoproteins (snRNPs), cytoplasmic RNPs, and ribosomes (Tan, 1988). 
Chronically low levels of complement factors are also often associated with the 
activity of the disease. It has been reported that 93% of C1q deficient individuals and 
73% of C1r/s deficient individuals develop SLE (Amano et al., 2008; Kallel-Sellami 
et al., 2008; Lewis & Botto, 2006). A series of biomarkers for lupus nephritis were 
also identified. CD25 negative subset of T regulatory cells (Treg) are a potential 
candidate and showed inverse correlation with disease activity in the long-term 
(Bonelli et al., 2014). 
 
1.5.2. Pathogenesis   
Many environmental and genetic factors have been shown to be involved in the 
pathogenesis of SLE, revealing the polygenic nature of the disease (Deng & Tsao, 
2010). Environmental factors are able to trigger the onset of SLE in genetically 
susceptible individuals. In a number of case studies and population-based cohort 
studies, a number of environmental factors such as alcohol, ultraviolet light, 
hormones, virus infection, occupationally- and non-occupationally-related chemicals, 
have been advocated to induce SLE (Lisnevskaia et al., 2014).  
 
The genes that might be involved in lupus have been identified by genome sequencing 
within families in which multiple members suffer from lupus (Namjou et al., 2007; 
Wakeland et al., 2001). Of interest here is the null alleles that cause deficiencies of 
early complement components (C1q, C1r/s, and C4) are strong risk factors for SLE 
(M. J. Walport, 2002). Patients with hereditary complement deficiencies tend to have 
an early onset of the disease, more severe disease presentations, and loss of female 
predominance (M. C. Pickering et al., 2001). It is now widely believed that the 
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impaired ACs clearance caused by C1q deficiency and the resulting exposure of 
intracellular autoantigens account for the pathogenesis of SLE (Ogden et al., 2001; M. 
C. Pickering et al., 2001; Rahman & Isenberg, 2008). However, the involvement of 
C1r/s in SLE is still poorly understood.  
 
1.5.3. Therapies  
Due to the polygenic and heterogeneous nature of SLE, measuring and quantifying 
the disease severity among different organs are extremely difficult. Thus, 
development of new agents for SLE has lagged behind of other autoimmune disorders. 
Currently, mild disease is managed with NSAIDs, anti-malaria drugs and low-dose 
corticosteroids. Moderate to severe disease warrants the use of high-dose 
corticosteroids and immunesuppressive agents (Wallace, 2015). Targeted therapies 
have been studied for the past decades for a more effective management of refractory 
disease but no significant improvements were noticed in murine preparations. SLE 
patients’ rates of morbidity and mortality are still high despite the introduction of 
novel antibiotics, biological drugs, hypersensitive drugs, renal replacement therapy 
and immunosuppressive agent. A better understanding of SLE pathogenesis is 
essential to achieving more efficient and targeted therapies.  
 
1.6 HYPOTHESIS AND AIMS OF THE STUDY  
 
While C1q-mediated apoptotic cell clearance may contribute to its protective role 
against autoimmunity, the counter argument still stands. Firstly, multiple redundant 
mechanisms exist for apoptotic cell clearance, such as phosphatidylserine receptor-
mediated phagocytosis (Fadok et al., 1992; Hoffmann et al., 2001). In the liver, the 
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hepatocyte asialoglycoprotein receptor mediates engulfment of apoptotic hepatocytes 
by surrounding hepatocytes (Dini et al., 1992). The actual contribution of C1q to 
apoptotic cell clearance cannot be accurately determined as, in C1q deficiency, 
clearance of apoptotic cells is expected to take place through other mechanisms. 
Secondly, MBL is structurally similar to C1q and it also binds to apoptotic cells and 
enhances phagocytosis (Ogden et al., 2001). MBL deficiency is common but it is not 
associated with SLE pathogenesis (Super et al., 1989). Thirdly, C1r and C1s have no 
documented roles in the clearance of apoptotic cells but C1r/ C1s deficiency causes 
SLE.  
 
We propose that C1r/C1s protects against autoimmunity by “trimming” autoantigens 
or DAMPs that are exposed on cell apoptosis or necrosis. This could eliminate the 
immunogenicity of autoantigens and the pro-inflammatory activities of DAMPs. 
Historically, C1r and C1s are considered highly specific serine protease with C1r only 
cleaves C1s and C1s only cleaves C4 and C2 in the complement pathway. However, 
this long-held view is challenged by the prediction of several intracellular C1s 
substrates (F. K. Kerr et al., 2005). Due to the inaccessibility of these intracellular 
substrates by C1s, significance of this finding was not stressed by the authors. We 
consider that these proteins may become accessible during cell apoptosis or necrosis. 
C1s cleavage of these proteins in dead cells disrupts potential DAMPs and auto-
reactive epitopes to prevent autoimmunity.  
 
The aims of this project are: 
1) To evaluate accessibility of intracellular antigens to C1q during cell apoptosis. 
44 
2) To identify whether C1s cleaves intracellular proteins that become accessible 
in apoptotic cells; 
3) To examine whether C1s cleavage of these intracellular proteins inactivates 




Chapter 2 Materials and Methods  
 
2.1 REAGENTS, CHEMICALS AND BUFFERS 
 
2.1.1. Reagents and chemicals 
Table 2.1 provides details of the reagents and chemicals used throughout the study.  
 
Table 2.1 List of reagents and chemicals. (Catalogue numbers of critical reagents 
provided.) 




Mouse anti- nucleophosmin monoclonal 
antibody, clone FC82291 (B0556) 
Sigma-Aldrich (St. 
Louis, MO, USA) 
 




(Billerica, MA, USA) 
 
 Mouse anti-human C1q monoclonal 
antibody  
 
AbD Serotec  (Oxford, 
UK) 
 
 Mouse anti-polyhistidine monoclonal 
antibody, clone AD1.1.10 (MAB050) 
 

























 Mouse anti-topoisomerase II α 
monoclonal antibody 
 
Santa Cruz (Dallas, 
Texas, USA) 
 





















(Billerica, MA, USA) 
 
























 Rabbit polyclonal anti-LBR antibody 
 
Sigma-Aldrich (St. 
Louis, MO, USA) 
 










 PML Sigma-Aldrich (St. 
Louis, MO, USA) 
 
 Goat polyclonal anti-human C1q (A301) 
for western blot  
 
Quidel (San Diego, 
CA, USA) 
 
 Goat polyclonal anti-human C1s (A302) 
for western blot 






Alkaline phosphatase conjugated 





 Horseradish peroxidase conjugated 






 Alexa 488 conjugated goat anti-rabbit IgG 







 Cy3 conjugated goat anti-mouse IgG for Life Technologies 
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Chemicals Agarose (Seakem LE) 
 
Cambrex (East 
Rutherford, NJ, USA) 
 







 1) Bio-Rad Protein Assay (Dye Reagent 
Concentrate) (#500-0006) 
 











 BSA (common protein usage) 
 
Sigma-Aldrich (St. 
Louis, MO, USA) 
 










 Isopropyl β-D-1-thiogalactopyranoside 
 
Sigma-Aldrich (St. 





(Billerica, MA, USA) 
 
 Marker: GeneRuler 100 bp DNA ladder 
 
Thermo Scientific  
(Waltham, MA, USA) 
 
 Marker: PageRuler plus prestained protein 
ladder 
 
Thermo Scientific  















Louis, MO, USA) 
 
 VECTASHIELD antifade mounting 




Primers V5-tag synthesizing primers: 
 










Highlighted yellow: restriction site for 
Nco I 
Highlighted green: restriction site for Nhe 
I 
^: restriction enzyme cutting site 





 B23 cloning primers for His-tagged B23/ 
V5-tagged B23: 
 








Highlighted green: restriction site for Nhe 
I 
Highlighted blue: restriction site for 
BamH I 
^: restriction enzyme cutting site 





 R142A site directed mutagenesis primers: 
 













 R197A site directed mutagenesis primers: 
 












Highlighted purple: mismatch  
 
 R221A site directed mutagenesis primers: 
 













 PET28 a+ sequencing primers:  
 
Forward Primer (5’ to 3’) T7:  
TAATACGACTCACTATAGGG  
 











(Billerica, MA, USA) 
 
 Human C1s (activated two-chains), 




(Billerica, MA, USA) 
 
 Human complement C1q, serum purified 
(C1740) 
Sigma-Aldrich (St. 
Louis, MO, USA) 
 
 Human complement C1 inhibitor  
 
Sigma-Aldrich (St. 
Louis, MO, USA) 
 











Louis, MO, USA) 
 
 Ni-NTA agarose beads (#30230) Qiagen GmbH (Hilden, 
Germany) 
 
 SP sepharose high performance beads 
 




 Q sepharose fast flow beads 
 




 Superose 6 10/300 GL gel filtration 
column 
 






TMB substrate reagent set (BD 
OptEIATM) (#555214) 
 
BD (Becton, Dickson 
and company) 
Biosciences (Franklin 










 Nco I  Promega (Madison, 
WI, USA) 
 
 Nhe I Promega (Madison, 
WI, USA) 
 
 BamH I Promega (Madison, 
WI, USA) 
 
 T4 DNA Ligase and buffer 
 
New England Biolabs 
(Ipswich, MA, USA) 
 




















 L-glutamate  Caisson Laboratories 










 iScriptTM cDNA synthesis kit Bio-Rad (Hercules, 
CA, USA) 
 
 Qiagen plasmid Maxi kit 
 







2.1.2. Buffers  
Table 2.2 provides details of buffers used throughout the study.  
 
Table 2.2 List of buffers and their compositions. 
Buffers Compositions 
Annealing buffer  
 
1) 100 mM NaCl, and  
2) 50 mM HEPES. 
 
Adjust pH to 7.4.  
 
Blue silver stain  1) G-250 Coomassie dye 0.12% (w/v), 
2) Ammonium sulfate 10% (w/v), 
3) Phosphoric acid 10% (v/v), and 
4) Methanol 20% (v/v).   
 
Cleavage buffer (for C1s and C1 
complex) 
 
1) Tris 50 mM, 
2) NaCl 150 mM, and  
3) CaCl2 3.3mM.  
 
Adjust pH to 7.4.  
 
Filter sterilised through a 0.22 μm syringe filter unit. 
 
Competent cell buffer  1) PIPES 10 mM 
2) Glycerol 15% (v/v) 
3) CaCl2 60 mM 
 
Adjust pH to 7.0.  
 
Filter sterilised through a 0.22 μm syringe filter unit and 
store at 4oC 
 
DNA loading dye (6×) 1) 30% (v/v) glycerol,  
2) 0.25% (w/v) bromophenol blue, and   
3) Top up with distilled water. 
 
For denaturing DNA loading dye (6×), add in 0.6% (w/v) 
SDS. 
  
Homogenization buffer  1) 10 mM Tris,  
 QuikChange Site-Directed Mutagenesis 
Kit 
Stratagene (La Jolla, 
California, USA) 
 
 Multi-Core restriction buffer  Promega (Madison, 
WI, USA) 
 




2) 5.0 mM MgCl2, and  
3) 0.25 M sucrose 
 
Adjust pH to 7.4.  
 
Filter sterilised through a 0.22 μm syringe filter unit. 
 
Immunofluorescent staining 
blocking buffer  
 
1× PBS with BSA 5% (w/v). 
Laemmli Buffer (5× sample 
loading buffer for SDS-PAGE)  
 
1) Tris-HCl pH 6.8 250 mM (50% (v/v) of Tris-HCl pH 
6.8 500 mM), 
2) SDS 10% (w/v), and  
3) Bromophenol blue 0.05% (w/v). 
 
For reducing buffer, 0.6 M DTT was added fresh prior to 
use. 
 
LB broth 16 g of LB powder to 0.8 litre of distilled water and 
autoclaved.  
 
Final concentration of constituents (pH 7.5):  
1) Bacto-tryptone 1% (w/v), 
2) Yeast extract 0.5% (w/v), and 
3) NaCl 0.5% (w/v).  
 
100 μg/ml of ampicillin or 30 μg/ml of kanamycin was 
added for antibiotic selection after LB broth was cooled.  
 
LB agar 15 g/L of Bacto agar was added into the LB broth and 
autoclaved. 
  
100 μg/ml of ampicillin or 30 μg/ml of kanamycin was 
used prior to pouring onto petri dishes after cooling.  
 
Ni-NTA column binding buffer 1) Sodium phosphate 50 mM 
2) NaCl 350 mM, and  
3) Imidazole 10 mM. 
 
Adjust pH to 7.4.  
 
Filter sterilised through a 0.22 μm syringe filter unit. 
 
Ni-NTA column wash buffer 1) Sodium phosphate 50 mM 
2) NaCl 500 mM, and  
3) Imidazole 20 mM. 
 
Adjust pH to 7.4.  
 
Filter sterilised through a 0.22 μm syringe filter unit. 
 
Ni-NTA column elution buffer 1) Sodium phosphate 50 mM 
2) NaCl 500 mM, and  
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3) Imidazole 250 mM. 
 
Adjust pH to 7.4.  
 
Filter sterilised through a 0.22 μm syringe filter unit. 
 
Tris buffered saline (TBS) 1) Tris 50 mM, and 
2) NaCl 150 mM 
 





Diluted from 10× PBS (purchased from 1st Base, 
Singapore) with 0.22 μm filter sterile purified water, 
adjust pH to 7.4 with HCl, and filtered sterile in biohazard 
hood with 0.22 μm 1 liter filter unit using a vacuum pump. 
The 1X PBS was autoclaved prior to use.  
 
1× PBS final constituents:  
1) KH2PO4 1.76 mM,  
2) Na2HPO4 10.4 mM,  
3) NaCl 137 mM, and 
4) KCl 2.7 mM. 
  
0.05% PBST (ELISA wash 
buffer) 
 
1× PBS with Tween 20 0.05% (v/v). 
SDS running buffer (5×)  
 
For 1 litre:  
1) 15.1 g Tris, 
2) 72 g Glycine, and 
3) 5 g SDS. 
 
Dissolve the above constituents with distilled water to 1 
litre.   
 
1× TAE Diluted from 10× ultra-pure grade TAE (purchased from 
1st Base, Singapore) with distilled water to a 1× working 
solution. 
 
1× TAE final constituents (pH 8): 
1) Tris-acetate 40 mM, and  
2) EDTA 1 mM. 
 
0.1% (v/v) TBST (Western blot 
wash buffer) 
1) Tris 10 mM, and  
2) NaCl 150 mM. 
 
Adjust pH to 7.4. Tween 20 0.1% (v/v) added 
subsequently. 
 
Western blot blocking buffer 
(1×) 
1) Tris 10 mM, and 
2) NaCl 150 mM. 
 
Adjust pH to 7.4. Add subsequently: 
3) Tween 20 0.1% (v/v), and 
4) Bio-rad blotting grade blocker 5% (w/v) 
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Western blot stripping buffer 
(1×) 
1) Tris-HCl 62.5 mM, pH 6.8, 
2) SDS 2% (w/v), and 
3) 0.1 M β-mercaptoethanol. 
 
Western blot transfer buffer 
(10×) 
1) Tris 30.3 g, and 
2) Glycine 144 g. 
 
Dissolve the above constituents with distilled water to 1 
liter. 
    
Western blot transfer buffer (1×) 1) 10X western blot transfer buffer 100 ml, 
2) Methanol 200 ml, and   
3) 700 ml distilled water.    
 





2.2 CELL BIOLOGY TECHNIQUES 
 
2.2.1. Cell line culture 
All cell lines (Table 2.3) were obtained from American Type Culture Collection 
(ATCC, Manassas, VA, USA) and cultured in T-75 flasks with 20 ml of medium in 
humidified incubator at 37°C and 5% CO2.  
 
The cell lines were sub-cultured using trypsin/EDTA. The culture medium was first 
removed and the cells were washed with 1× PBS. PBS was then removed and 2.5 ml 
of 1× trypsin/0.5 mM EDTA (Sigma-Aldrich) was added and incubated for 90 
seconds at 37oC. The enzymatic digestion was stopped by adding in 5 ml of cell 
culture media and the cell suspension was centrifuged at 400× g for 5 minutes. 
Supernatant was discarded and the cell pellet was resuspended in 3 ml of cell culture 
media and the cells were seeded at a desired density in new T-75 flasks.  
 
For long term cryostorage, the cells were resuspended to a density of 0.5 - 1 ×107 
cells/ml in cell culture media. DMSO was added to the cell suspension to a final 
concentration of 10%. The cell suspension was then aliquoted into cryogenic vials 
(Nalge Nunc International A/S, Roskilde, Denmark), frozen at -80oC overnight and 
transferred to liquid nitrogen for long term storage. 
 
Table 2.3 List of cell lines used for the study. 





HeLa Epithelial cell  Cervix  1:6 
DMEM with: 
1) HI-FBS 10% (v/v), 
2) Penicillin 100 units/ml and 
Streptomycin 100 μg/ml, and  
3) L-glutamine 2mM.  
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HepG2 Epithelial cell  Liver 1:6 
DMEM with: 
1) HI-FBS 10% (v/v), 
2) Penicillin 100 units/ml and 
Streptomycin 100 μg/ml, and  




2.2.2. Induction of apoptosis 
HeLa cells were harvested and centrifuged at 400 g for 5 minutes and washed three 
times with 1× PBS. Subsequently, the cells were re-suspended in DMEM with 10% 
HI-FBS, 2 mM L-glutamine, 100 units/ml Penicillin and 100 μg/ml Streptomycin to a 
density of 1 × 105 cells/ml and 1 ml was seeded into each well of the 24-well culture 
plate with autoclaved coverslip placed on the bottom. Cells were washed three times 
with 1× PBS and changed to 200 μl of serum free DMEM with 100 units/ml Penicillin 
and 100 μg/ml Streptomycin. Apoptosis was induced by UV-irradiation (Spectroline 
Select XLE-1000 UV crosslinker outfitted with 254 nm lamp manufactured by 
Spectronics Corporation (Westbury, NY, USA)) at a dose of 500 mJ/cm2. The cover 
of the plate must be removed and must not cover the crosslinker sensor during the 
irradiation. After UV-irradiation, the media was carefully removed and 500 μl of fresh 
serum free DMEM with 100 units/ml Penicillin and 100 μg/ml Streptomycin was 
added. Cell was continued to culture in the humidified incubator at 37°C and 5% CO2 
for different periods before being fixed with 1% PFA for immunofluorescent staining. 
The control viable cells were prepared similarly without UV-irradiation.  
 
In some experiments, supernatant was collected for SDS-PAGE followed by Western 
blot analysis. In these experiments, cells were seeded at 4 × 105 cells/well instead of 1 
× 105 cells/well to obtain more protein from the culture supernatant. UV-irradiation 
was done as previously described. When harvesting the supernatant, only 450 μl was 
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harvested to avoid harvesting any cellular components. Supernatants were then 
centrifuges at 1000 g for 10 minutes to get rid of cell debris.   
 
2.2.3. C1 complex treatment of apoptotic HeLa cells   
HeLa cells were harvested and centrifuged at 400 g for 5 minutes and washed three 
times with 1× PBS. Subsequently, the cells were re-suspended in DMEM with 10% 
HI-FBS, 2 mM L-glutamine, 100 units/ml Penicillin and 100 μg/ml Streptomycin to a 
density of 4 × 105 cells/ml and 1 ml was seeded into each well of the 24-well culture 
plate. Cells were washed with PBS and changed to serum free DMEM with 100 
units/ml Penicillin and 100 μg/ml Streptomycin and induction of apoptosis was 
carried out as described with UVC irradiation. After UVC irradiation, the cells were 
incubated in 500 μl of media at 37°C in 5% CO2 for 6 hours. Viable control cells were 
treated similarly but not UV-irradiated. C1 complex (10 μg/ml diluted in PBS, Merck 
Millipore (Calbiochem), Billerica, MA, USA) or 1 × PBS was added into the ACs and 
viable controls. The cells were incubated at 37°C for 1 hour before the supernatant 
was harvested and cell debris was removed by centrifugation at 1000 g for 10 minutes 
at 4°C. 
 
2.2.4. Isolation of nucleolus from HeLa cell culture  
To study the interaction between C1q and nucleolus, nucleolus was isolated from 
HeLa cell culture. HeLa cells were cultured in 150-mm cell culture dishes to 90% - 
100% confluent. Cells were then harvested by adding in trypsin-EDTA, washed and 
re-suspended to density of 5 × 107 cells/ml in homogenization buffer (10 mM Tris, 
5.0 mM MgCl2, 0.25 M sucrose, pH 7.4) supplemented with a cocktail of protease 
inhibitors (Sigma- Aldrich). Cells were homogenized by pressing through 10 μm gap 
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in a Isobiotec Cell Homogenizer (Isobiotec Precision Engineering, Heidelberg, 
Germany). Homogenate was pelleted by centrifuging at 600 g for 10 minutes, and re-
suspended in 5 ml of sucrose buffer (10 mM Tris, 5.0 mM MgCl2, 2.2 M sucrose, pH 
7.4). The suspension was then centrifuged again at 50,000 g for 30 minutes to pallet 
the cell nuclei. Supernatant was discarded and pellet was re-suspended in 2 ml of the 
homogenization buffer (10 mM Tris, 5.0 mM MgCl2, 0.25 M sucrose, pH 7.4) and 0.2 
ml aliquots were sonicated for 18 cycles (UCD-200 Bioruptor, Diagenode s.a., Liege, 
Belgium) at maximal strength and 15/45-sec on/off intervals. Nucleus homogenates 
were then centrifuged for 5 minutes at 2,500 g. Pellet was re-suspended and re-
pelleted three times using 0.88 M sucrose buffer (10 mM Tris, 5.0 mM MgCl2, 0.88 
M sucrose, pH 7.4) by centrifuging for 5 minutes at 1000 g. The pellet was then re-
suspended in 0.5 ml homogenization buffer and centrifuged through a sucrose 
gradient (0.85 M to 2.5 M) at 33.000 rpm for 3 hours using the Himac CP 90WX 
preparative centrifuge and the PST40 rotor (Hitachi, Ltd., Tokyo, Japan). Fractions 
were collected from top to bottom forming 8 fractions (T1 – T8). The nucleolus was 
recovered in the pellet and resuspended in 0.4 ml of the homogenization buffer. 
Particularly, sonicated nuclei were found in bottom fractions.  
 
SDS-PAGE and Western blot analysis were then carried out to check the purity of the 
isolated nucleolus. To check the integrity of isolated nucleolus, fractions T1 – T8 and 
the pellet fractions were also coated on coverslips by spreading them evenly and 
incubate on ice for 5 minutes, followed by fixing with 1% PFA, and stained these 
fractions for nucleolar proteins.   
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2.2.5. C1q binding with nucleoli  
In some experiment, C1q was incubated with crude nucleoli to determine the binding 
of C1q with nucleoli. After the washing step using 0.88 M sucrose buffer, C1q (50 
μg/ml) was added into the crude nucleoli and incubated on ice for 1 hour. The mixture 
was then centrifuged through the sucrose gradient (0.85 M – 2.5 M) as described 
above. PBS was used as a negative control and incubated with the crude nucleoli. 
After the centrifugation, fractions were collected similarly as described and analyzed 
by SDS-PAGE followed by Western blot, as well as immunofluorescent staining.  
 
2.2.6. In-vitro digestion of nucleolar proteins by C1 complex  
To determine the in-vitro digestion of nucleolus proteins, human serum purified C1 
complex (Merck Millipore (Calbiochem), Billerica, MA, USA) and isolated nucleolus 
were used. All the reaction mixtures including the controls were prepared in 1.6 ml 
centrifuge tubes with the cleavage buffer (10 mM Tris, 150 mM NaCl, 3.3mM CaCl2). 
C1 complex was used at a concentration of 9.6 μg/ml and 25 μl of isolated nucleolus 
was used for each reaction. PBS was incubated with C1 complex or with nucleolus as 
control. The samples, including the controls, were incubated at 37°C for 2 hours in a 
Thermo Cycler (2720 Thermo Cycle, Life Technologies (Applied Biosystems) 
Carlsbad, California, USA). To determine the specificity of cleavage by C1 complex, 
C1 inhibitor (160 μg/ml) was used.  
 
In addition, in a separate experiment, the mixtures were incubated for different time 
(5, 15, 30 minutes) in the cleavage buffer at 37°C to determine the kinetics and 
cleavage pattern.  
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2.3 MOLECULAR BIOLOGY TECHNIQUES 
 
2.3.1. Nucleic acid quantification  
The concentration of nucleic acid was determined using Nonodrop ND-100 (Thermo 
Fisher Scientific, Wilmington, NC, USA). Sample type was selected as DNA-50 for 
double-stranded DNA and RNA-40 for RNA. The ratio of absorbance at 260 nm and 
280 nm was used to assess the purity of the sample. A minimum ratio of 1.8 for 
plasmid DNA and 2.0 for RNA was required.  
 
2.3.2. Total RNA isolation and purification  
Total RNA was extracted from HeLa cells using the Nucleospin RNA II (Clontech, 
Mountain View, CA) kit following manufacturer’s protocol. HeLa cells were lysed 
with 350 μl buffer RA1 and 3.5 μl β-mecapthoethanol and mixed vigorously. 350 μl 
70% ethanol was then added to the cell lysate and vortex twice for 5 seconds each. 
The mixture was transferred to the RNA column and centrifuged for 30 seconds at 
11,000 x g. Flow through was discarded and 350 μl membrane desalting buffer was 
added and centrifuged for 1 minutes at 11,000 x g. 95 μl DNase reaction mixture was 
added to the column membrane and incubated at room temperature for 15 minutes. 
Reaction was stopped by adding in 200 μl buffer RA2. The column was centrifuged 
for 30 seconds, washed twice with 600 μl and 250 μl buffer RA3 and centrifuged for 
30 seconds and 2 minutes respectively. Lastly, purified RNA eluted by incubating 
with 40 μl nuclease-free water for 1 minute and centrifugation at 16,000 g for 1 
minute into a fresh 1.6 ml microcentrifuge tube. RNA concentration was determined 
using the Nanodrop spectrophotometer (Thermo Scientific, Waltham, MA) and the 
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A260/280 ratio was typically above 2.1. The isolated RNA was stored in -80oC for 
long-term storage.  
 
2.3.3. Reverse transcription  
First strand cDNA was generated by reverse transcription (RT) from RNA using 
iScriptTM cDNA synthesis kit (Bio-Rad). The reaction mix (20 μl) was prepared with 
the following constituents: 
1) 0.2 - 1.0 μg of RNA  
2) 4 μl of 5 x iScript reaction mix  
3) 1 μl of iScript reverse transcriptase  
4) nuclease-free water top up to 20 μl.  
 
The Thermo Cycler (2720 Thermo Cycle, Life Technologies (Applied Biosystems) 
Carlsbad, California, USA) was setup with the following protocol: 
1) 25oC for 5 minutes, 
2) 42oC for 30 minutes,  
3) 85oC for 5 minutes  
4) Maintain at 4°C until removal from Thermo Cycler for storage.  
 
cDNA was diluted to 100 μl total volume with nuclease-free water and stored in -
20oC for long term storage.  
 
2.3.4. Polymerase Chain Reaction (PCR)  
PCR reaction (50 μl) for cloning of B23 was prepared with the following constituents: 
1) 5 μl of Pfu (Pyrococcus furiosus) DNA polymerase 10 × buffer containing MgS04,  
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2) 1 μl of dNTPs, 
3) 1 μl each of 10 μM of forward and reverse primers, 
4) 2 μl of cDNA sample, 
5) 0.3 μl of Pfu DNA polymerase (3 units/μl), and  
6) nuclease free water top up to final volume of 50 μl. 
 
The Thermo Cycler (2720 Thermo Cycle, Life Technologies (Applied Biosystems) 
Carlsbad, California, USA) was setup with the following protocol: 
1) Initial denaturation of 95°C for 5 minutes, 
2) 95°C for 1 minute,  
3) Annealing temperature specific for the specific primers (55 – 58 °C) for 1 minute,  
4) Extension temperature 72°C for 2 minutes,  
5) Repeat for a total of 25 cycles for 2 to 4,  
6) Final extension at 72°C for 10 minutes, and  
7) Maintain at 4°C until removal from Thermo Cycler for storage.  
 
The annealing temperature used was 2°C below the Tm (melting temperature) of the 
pair of primers. The extension time for a particular PCR reaction was dependent on 
the length of the amplified target sequence (2 minutes/kb of expected DNA products 
for Pfu DNA polymerase). 
 
2.3.5. Agarose gel electrophoresis  
DNA was resolved with agarose gel containing GelGreen stain (1:20,000×  dilution) 
in 1×  TAE using a Hoefer HE 33 mini horizontal submarine unit (Hoefer, Inc. 
Holliston, MA, USA) at 80 Volts. The % (v/v) agarose gel used was dependent on the 
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separation required. 1.2 % (v/v) agarose was used for separation of PCR product and 
primers/templates.    
 
Briefly, for a 1.2% (v/v) agarose, 0.6 g of agarose was added to 50 ml of 1× TAE 
buffer and heated to 100°C using a microwave. The mixture was swirled gently to 
ensure that the agarose had completely melted with no particulates of agarose or 
bobbles seen. The mixture was cooled to below 60°C and 1.2 μl of GelGreen stain 
was added and gently mixed by swirling. The agarose mixture was poured into a 
cassette with a plastic comb at one end. Upon solidifying, the agarose gel was placed 
into the electrophoresis unit and submerged in 1× TAE buffer. Samples were mixed 
with 6× DNA loading dye prior to being loaded into the wells.  
 
Electrophoretic separation was carried out at 80 Volts, and stopped when the 
bromophenol blue dye front was about 1 cm from the bottom edge of the horizontal 
agarose gel. The gels were visualised via UV illuminator with ChemiDoc MP Imager 
(Bio-Rad, Hercules, CA, USA) and the images captured digitally with a CCD 
(Charge-Coupled Device) camera unit. 
 
2.3.6. Purification of DNA from agarose gel/solution 
Gel band purification was carried out after PCR reaction from plasmid or restriction 
endonucleases digestion of the insert and plasmid for cloning. Solution purification 
was carried out after PCR reaction from cDNA. The purification was carried out 
using the Illustra GFX PCR DNA and Gel band Purification kit in accordance to 
manufacturer’s protocol.  
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Briefly, after electrophoretic separation, the agarose gel was viewed under UV trans-
illumination. Desired band was cut and transffered into a 1.6 ml microcentrifuge tube 
and weighed. 100 μl of the kit’s capture buffer (minimum 300 μl) was added for every 
0.1 g of excised gel and heated to 60°C with gentle shaking. The melted gel sample 
mixture was transferred to the kit’s column and incubated for 1 minute, and 
centrifuged at 16,000 g for 30 seconds.  The column was washed with 500 μl wash 
buffer and centrifuged at 16,000 g for 30 seconds and flow through in the collection 
tube was discarded. The column was incubated with 40 μl of nuclease free water for 1 
minutes and the purified DNA eluted by centrifugation at 16,000g for 1 minute into a 
fresh 1.6 ml microcentrifuge tube. 
 
For purification of PCR product in solution, 500 μl of capture buffer was added to the 
PCR reaction mixture of up to 100 μl. The subsequent steps were as stated above for 
the DNA purification from agarose gel. 
 
2.3.7. Restriction endonuclease digestion  
The double restriction digestion was performed for the PCR product and pET28 a+ 
expression plasmid. The constituents of the reaction mixture (50 μl) were as follows: 
1) 30 μl of PCR sample or 1 μg of plasmid (for each ligation reaction to be carried 
out next),  
2) 5 μl of 10× restriction buffer (Multi-Core (Promega. Madison, WI, USA)),  
3) 1.5 μl restriction enzyme (10 units/ml), and  
4) Top up to 50 μl with nuclease free water. 
 
Incubate the mixture at 37°C for 4 hours in the Thermo Cycler.  
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2.3.8. Ligation of DNA insert into vector  
DNA ligation of restriction enzymes digested insert and vector was carried out in 10 
μl ligation reaction volume with T4 DNA ligase and T4 DNA ligase buffer. Typically, 
the amount of DNA insert to vector was calculated with the following equation for a 
molar vector to insert ratio of 1:3. For instances where ligation was not successful, the 
ratio was adjusted to 1:10: 
Amount of insert (ng) =




The 10 μl reaction mix constituted the following: 
1) X μl of vector to be used,  
2) Y μl of vector as calculated,  
3) 0.1 μl of T4 DNA ligase enzyme,  
4) 1 μl of T4 DNA ligase buffer, and  
5) Top up to 10 μl with nuclease free water. 
 
The reaction was carried out at room temperature for 3 hours.  
 
2.3.9. Site-directed mutagenesis (SDM) 
To introduce mutations into the DNA sequence of a plasmid, QuikChange site-
directed mutagenesis kit (Stratagene) was used according to manufacturer’s manual. 
A pair of mutagenic primers containing the desired mutation and annealing to the 
same sequence on the opposite strands of the plasmid were required for each SDM. 
The mismatch was to be placed in the middle of the primers, with at least 7 bp 
flanking on each side. Primers were between 25 to 45 bp in length with Tm of 78oC 
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and above (Tm=81.5 + 0.41(%GC) – 675/N - % mismatch, N stands for primer length 
in bp).  
 
The 50 μl reaction mix constituted the following: 
1) 5 μl of 10× reaction buffer,  
2) 10 ng of plasmid as calculated,  
3) 125 ng of each mutagenic primer,  
4) 1 μl of dNTP mix,  
5) Top up to 50 μl with nuclease free water, and  
6) 1 μl of pfuTurbo DNA polymerase.  
 
The Thermo Cycler (2720 Thermo Cycle, Life Technologies (Applied Biosystems) 
Carlsbad, California, USA) was setup with the following protocol: 
1) Initial denaturation of 95°C for 30 seconds, 
2) 95°C for 30 seconds,  
3) Annealing at 55°C for 1 minute,  
4) Extension temperature 68°C for 6 minutes (for pET-28 vector containing B23 
gene),  
5) Repeat for a total of 16 cycles for 2 to 4,  
6) Maintain at 4°C until removal from Thermo Cycler for storage.  
 
Following this, 10 U of Dpn I was added into each reaction to digest the methylated, 
non-mutated parental DNA by incubating at 37oC fro 1 hour. 1 μl of the Dpn I-treated 
DNA was then used for transformation of XL1-Blue supercompetent cells.  
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2.3.10. Preparation of competent cells  
The Escherichia coli strain DH5α, TOP10, or BL21 (Invitrogen, Carlsbad, California, 
USA) was incubated in 5 ml LB broth overnight at 37°C with 200 rpm shaking. 
Dilute 5 ml of bacteria culture into 400 ml LB broth and grow at 37°C until OD 600 
reaches 0.4 – 0.6.  
 
Centrifuge at 3,000 rpm for 10 minutes withouth break at 4oC to pellet down the 
bacteria. Re-suspend the pellet in 200 ml cold competent cell buffer (10 mM PIPES, 
15% Glycerol, 60 mM CaCl2, pH 7.0) and transfer into four pre-chilled 50 ml falcon 
tubes. Incubate the suspension on ice for 30 minutes and centrifuge at 2,500 rpm for 5 
minutes without break. Discard supernatant and re-suspend each pellet in 2 ml cold 
competent cell buffer. Incubate on ice for 1 hour and aliquot 100 μl into each pre-
chilled 1.6 ml tube and fast-freeze in dry ice. Transfer to -80oC for long-term storage.  
 
2.3.11. Bacterial transformation with plasmid DNA  
The Escherichia coli strains DH5α, TOP10 (Invitrogen, Carlsbad, California, USA) 
and XL1-Blue (Stratagene) were used for transformation and propagation of plasmid 
DNA. The Escherichia coli strain BL21 (Invitrogen, Carlsbad, California, USA) was 
used for expression of recombinant protein from transformed plasmid.  
 
The competent cell in a 1.6 ml microcentrifuge tube was thawed on ice. 3 μl of the 
ligation reaction was added into 50 μl of competent bacteria cells and tapped to mix. 
The mixture was then incubated on ice for 30 minutes. Heatshock  was done at 42°C 
in a water bath for 90 seconds (DH5α, BL21) or 45 seconds (XL1-Blue, TOP10), and 
immediately put back on ice for 2 minutes. 200 μl warm of SOC medium (Sigma-
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Aldrich, St. Louis, MO, USA) was added into the tube  and the mixture shake on a 
shaking platform at 200 rpm for 30 minutes at 37°C. After the incubation, bacteria 
was pelleted by centrifuging at 4,000 rcf and 100 μl of SOC media supernatant was 
discared. The pellet was the re-suspended in the remaining media and spread onto an 
LK plate and incubated overnight at 37°C. For DH5α, incubation of 16 – 18 hours is 
necessary and for BL21, incubation of 14 hours will be sufficient.  
 
2.3.12. Colony PCR 
Colony PCR was done after the antibiotic had sucssessfully selected the clone with 
kanamycin resistancy and prior to the purification of plasmid using Wizard Plus SV 
Minipreps DNA purification kit.  
 
In brief, 2 - 5 bacterial colony would typically be picked with a sterile 10 μl pipette tip 
and each inoculated into 2 mls of LB broth with kanamycin. After culturing for 6 
hours, aliquot 50 μl of the culture into PCR tube and centrifuge at 16,000 g, 4oC to 
pellet down the bacteria. Discard the supernatant and heat up the pellet in Thermo 
Cycler at 95oC for 5 minutes. Remove the last bit of liquid inside the tube after the 
incubation, and cool down to room temperature.  
 
Set up colony PCR reaction master mix (25 μl) constituted the following: 
4.1 12.5 μl GoTaq Green Master Mix, 
4.2 1 μl of 10 μM T7 forward primer,  
4.3 1 μl of 10 μM T7 terminator primer,  
4.4 Top up to 25 μl with nuclease free water. 
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Aliquot 10 μl of master mix into each tube and re-suspend the pellet. The Thermo 
Cycler (2720 Thermo Cycle, Life Technologies (Applied Biosystems) Carlsbad, 
California, USA) was setup with the following protocol: 
1) Initial denaturation of 95°C for 5 minutes, 
2) 95°C for 30 seconds,  
3) Anneal at 55°C) for 1 minute,  
4) Extension temperature 72°C for 1 minute,  
5) Repeat for a total of 25 cycles for 2 to 4,  
6) Final extension at 72°C for 5 minutes, and  
7) Maintain at 4°C until removal from Thermo Cycler.  
 
Resolve the sample on a 1.2% (w/v) agarose gel. Those with desired band size of 
slightly larger than the DNA insert would be chosen to culture overnight for 
purification of plasmid.  
 
2.3.13. Purification of plasmids from transformed bacteria  
Wizard Plus SV Minipreps DNA purification system was used in the small-scale 
purification of plasmid for DNA sequencing of bacterial clones bearing the insert 
DNA sequence. 
 
In brief, the remaining bacteria culture for the positive clones bearing the insert were 
inoculated in 5 ml of LB broth with kanamycin overnight. The bacteria were pelleted 
with centrifugation at 4,000 g for 5 minutes and the culture medium was removed by 
pouring. The pellet was re-suspended in 250 μl of cell re-suspension solutionand 
transferred into a 2 ml microcentrifugation tube. 250 μl of cell lysis buffer and 10 μl 
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of alkaline protease solution were added with mixing by inversion 4 times. Mixture 
was incubated at room temperature for 5 minutes and 350 μl of the neutralisation 
solution was added with mixing by inversion. Centrifugation was done at 16,000 g for 
10 minutes at room temperature. The supernatant was then carefully decanted into the 
spin column with the collection tube and centrifuged at 16,000 g for 1 minute at room 
temperature. The flow through was discarded from the collection tube. The column 
was washed twice, first with 750 μl of wash buffer followed by centrifugation at 
16,000 g for 1 minute and then with 250 μl of wash buffer and centrifugation for 2 
minutes at 16,000 g. Each time, the flow through was discarded. After the last wash, 
the spin column was transferred onto a sterile 1.6 ml microcentrifuge tube. The 
plasmid was eluted from the column with 35 μl of nuclease free water and subsequent 
centrifugation at 16,000 g for 1 minute. The concentration of plasmid was determined 
via Nanodrop and plasmid was stored at -20°C.  
 
2.3.14. DNA Sanger Sequencing  
Sanger DNA sequencing reaction was carried out with BigDye Terminator Cycle 
Sequencing kit version 3.1 (Life Technologies, Applied Biosystems, Carlsbad, 
California, USA) following manufacturer’s protocol with some minor variation. 
Briefly, the 20 μl reaction was prepared as followed: 
1) 1 μl of 5 μM sequencing primer, 
2) 3 μl of sequencing buffer, 
3) 300 ng of DNA sample,  
4) Top up with nuclease free water to 18 μl, and  
5) Add 2 μl of BigDye reaction premix.  
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The sequencing cycling was done with the following setup: 
1) Denaturation at 96°C for 30 seconds,  
2) Annealing of primer at 50°C for 15 seconds, 
3) Extension at 60°C for 4 minutes, and  
4) Repeat cycle from 1 to 3 for 35 cycles and  
5) Remain at 4°C until removal from Thermal Cycler.  
 
DNA sequencing reaction required clean-up to remove the unincorporated ddNTPs, 
enzyme and salt. The reaction mixture was transferred to a 1.6 ml microcentrifuge 
tube for ethanol DNA precipitation and clean-up. The 100 μl reaction was prepared as 
followed: 
1) 20 μl sequencing reaction mixture, 
2) 3 μl of 3 M sodium acetate pH 4.6, 
3) 63 μl of 100% ethanol,  
4) 14 μl of nuclease free water. 
 
The precipitation was carried out at -20°C for no less than 30 minutes. Centrifugation 
was subsequently done at 18,000 g for 30 minutes with the Eppendorf 
microcentrifuge 5424 (Eppendorf, Hamburg, Germany) at 4oC. The supernatant was 
aspirated and the DNA pellet washed with 500 μl of 70% ethanol and centrifuged at 
18,000 g for 10 minutes at 4oC. The ethanol was aspirated completely and the pellet 
was air-dried in room temperature for 10 to 15 minutes. The sample was stored at -
20°C until it was delivered to the sequencing laboratory. 
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2.3.15. Oligo annealing and generation of double-stranded V5-tag DNA  
To generate double-stranded V5-tag DNA with restriction enzyme sticky end, two 
complementary oligonucleotides were synthesized. The forward oligo contains V5 
gene mRNA sequence, 5’ and 3’ overhangs corresponding to the cutting sites at two 
ends (Nco I and Nhe I respectively). The reverse oligo contains the reverse 
complimentary sequence of V5 mRNA, 5’ and 3’ overhangs of Nhe I and Nco I 
respectively.  
 
The annealing reaction mixture was prepared as follows: 
1) 1 μl of each oligonucleotied (3μg/μl in nuclease free water), and 
2) 48 μl of annealing buffer. 
 
The mixture was boiled at 100oC for 5 minutes, and was left to cool down to below 
37oC. The annealed oligos did not require further purification or digestion. 
 
2.3.16. Cloning of B23 gene into pET-28 a+ vector  
Cloning primer pairs specific for B23 were synthesized (Section 2.1.1). The B23 gene 
would be inserted into a pET-28a+ vector with a pre-existing 5’ DNA sequence 
encoding a His-tag followed by a thrombin cleavage site between the Nco I and Nde I 




Figure 2.1 Multiple cloning site for pET-28a+. A schemetic overview of the multiple 
cloning site of vector pET-28a+. Nhe I and BamH I sites were used for inserting of B23 gene 
sequence. His-tag and thrombin cleavage sits inbetween Nco I and Nhe I sites were replaced 
with V5-tag sequence for cloning of V5-tagged B23. 
 
For His-tagged B23, Nhe I and BamH I sites were used for inserting of B23 gene 
sequence (Table 2.1). For the 5’ forward primer, the design was as followed: 3 
nucleotides to allow restriction enzyme to sit on, Nhe I restriction site sequence (not 
found in B23 gene), 5’ end of gene of interest starting with ATG start codon with 
extension to a suitable length into gene. For the 3’ reverse primer, the design was as 
such: 3 nucleotides to allow restriction enzyme to sit on, BamH I restriction site (not 
found in B23 gene), TAA (stop codon), reverse complement of 3’ end of B23 gene of 
a suitable length. The stop codon would stop the translation before the second His-tag 
sequence in the victor to prevent the incorporation of the His-tag into the C-terminal 
end of the protein.  
 
The primers were checked for specificity, primer dimer interactions, secondary 
structures and matching melting temperatures. The B23 gene was amplified from the 
HeLa cDNA in a PCR reaction and resolved by 1.2% agarose gel electrophoresis to 
check that it was of the correct length. The PCR product was purified with the Illustra 
GFX PCR DNA and Gel band Purification kit. Restriction digestion was performed as 
described for the vector and PCR product separately, separated by agarose gel 
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electrophoresis, purified and ligated as described above. After ligation, transformation 
of competent bacterial cells was carried out. Colonies were screened using T7 primer 
and T7 terminator. Positive colonies were expanded and plasmids were purified and 
sent for sequencing.  
 
For V5-tagged B23, B23 gene insert was generated as described above. 
Oligonucleotides of V5-tag with Nco I and Nhe I sticky ends were synthesized and 
annealed. Vector was digested using Nco I and BamH I. Digested vector, B23 gene 
insert and double-stranded V5-tag DNA were ligated and transformed into competent 
bacteria cells. Colony PCR, extraction of plasmids and DNA sequencing were carried 




2.4 PROTEIN CHEMISTRY TECHNIQUES 
 
2.4.1. Protein quantification 
Protein quantification was determined with the Bradford assay using the Bio-Rad 
protein assay kit. In brief, standard BSA solution was serial diluted, starting with 
concentration of 400 μg/ml to 6.25 μg/ml and a final blank. 10 μl of each standard and 
the protein samples were added, in duplicates, into the wells of a 96-well (flat bottom) 
microtiter plate. The 5× dye reagent was diluted (1 part dye to 4 parts distilled water) 
and syringe filtered through a Millex-HV (33 mm) Syringe Filter Unit with a 0.45 µm 
PVDF membrane. 
 
200 μl of the dye was added to each well and incubated at room temperature for 5 
minute. Absorbance was measured at 595 nm with the Model 680 Microplate reader 
(Bio-Rad. Hercules, CA, USA.). A standard curve was constructed by plotting the 
known BSA concentrations versus absorbance at 595 nm and sample concentrations 
determined from the curve. 
 
2.4.2. Preparation of cell lysate   
HeLa cells were harvested by scraping from cultural flask and washed thrice with 
PBS. Supernatant was discarded and pellet was kept. Cold lysis buffer (Biosource, 
Camarillo, CA) supplemented with Protease Inhibitor Cocktail (250 μl per 5 ml cell 
lysis buffer, Sigma-Aldrich) was added to the cells. The volume of cell extraction 
buffer depends on the cell number and expression of target protein and level of 
phosphorylation. A suitable starting concentration is 108 cells per ml extraction buffer. 
The mixture was incubated on ice for 1 hour. The cell lysates were vortexed every 10 
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minutes to ensure lysis is complete. After the incubation, the cell lysates were 
centrifuged at 4oC at 13,000 rpm for 10 minutes to remove insoluble material. The 
supernatant was then transferred to a clean tube and kept at -80oC for long-term 
storage.  
 
In some experiment, cells were re-suspended in PBS to desired concentration and 5× 
Laemmli buffer was added with DTT. The mixture was then boiled to 95oC for 5 
minutes. The insoluble material was removed by centrifuged at room temperature at 
13,000 rpm for 10 minutes. 
 
2.4.3. SDS-PAGE electrophoretic separation of proteins 
For all samples with different treatment conditions, equal and comparable sample 
volumes were used. DTT was diluted to distilled water to concentration of 0.6 M. 
This was prepared fresh on the day of usage if reduction of disulphide bonds was 
required. 1 part of the DTT and 2 parts of the 5× Laemmli buffer were added to 6 
parts of sample.  The samples were heated at 100°C for 5 minutes and centrifuged to 
collect all the condensation on the cap of the 1.6 ml microcentrifuge tube before 
loading into the wells of the SDS-PAGE gel.  
 
Table 2.4 Preparation of gel for SDS-PAGE. 
Constituents  Stacking gel 12.5% 15%  
Distilled water  
 3.05 ml  3.17 ml  2.35 ml  
1.5 M Tris pH 8.8  
 -x 2.5 ml 2.5 ml 
0.5 M Tris pH 6.8  
 1.25 ml  -x -x 
10% (w/v) SDS 
 50 μl 100 μl 100 μl 
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30% (w/v) acrylamide Bis-acrylamide solution 
(Acrylamide: Bis-Acrylamide Ratio: 37.5: 1) 
 
0.65 ml  4.16 ml  5 ml 
10% (w/v) Ammonium persulfate 
 25 μl 50 μl 50 μl 
Tetramethylethylenediamine (TEMED)   
 5 μl 5 μl 5 μl 
 
Fixed percentage resolving gel with a stacking gel layer, of the dimension of 83 by 73 
mm (width × height), was casted using the mini-PROTEAN casting module with a 
1.5 mm spacer plate. 2 percentages were used: 12.5% for separation of proteins with a 
molecular weight of approximately 20 to 100 kDa and 15% for separation of proteins 
with a molecular weight of approximately 5 to 70 kDa (Table 2.5 for gel 
compositions). Electrophoresis was carried out at 60 Volts until the required 
resolution was achieved as assessed by the migration of the Bromophenol blue dye 
front.  
 
2.4.4. Coomassie blue sliver stain  
Blue silver stain is a colloidal Coomassie stain and was prepared as previously 
described (Candiano et al., 2004). It has a detection limit of approximately 1 ng of 
protein, in-between that of the conventional silver staining and Coomassie stain. After 
resolving the proteins with SDS-PAGE, the gel was soaked and washed thrice with 
distilled water for 10 minutes each with shaking to remove the SDS from the proteins. 
Subsequently, the gel was soaked in the Blue silver stain overnight for no less than 12 
hours, and subsequently de-stained with repeat changes of distilled water.  
 
2.4.5. Western blot  
The resolved proteins on SDS-PAGE were electroblotted onto a PVDF membrane 
with the Bio-Rad Mini Trans-Blot Cell bathed in chilled 1X western blot transfer 
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buffer (Table 2.2) and an icepack on a magnetic stirrer. The transfer was typically 
done at a constant voltage of 100 Volts for 2 hours. After transfer, the membrane was 
blocked with Western blot blocking buffer (Table 2.2) for 1 hour with gentle shaking 
(100 rpm) on an orbital shaking platform. The blocked membrane was then incubated 
overnight with the primary antibody diluted to desired concentration in the blocking 
buffer overnight at 4°C on an orbital shaking platform. The membrane was first rinsed 
and then washed thrice for 10 minutes each with 0.1% TBST and incubated with 
secondary antibody conjugated with alkaline phosphatase enzyme (at 1:5000 - 
1:20,000 dilution) or horseradish peroxidase (at 1:5000 - 1:20,000 dilution) in the 
blocking buffer for 1 hour at room temperature with shaking at 100 rpm. The 
membrane was rinsed and washed thrice for 10 minutes each with 0.1% (v/v) TBST. 
For secondary antibody conjugated with alkaline phosphatase enzyme, membrane was 
incubated with 800 μl (per membrane) of the Immun-Star AP Chemiluminescent 
substrate for 2 minutes. For secondary antibody conjugated with horseradish 
peroxidase, membrane was incubated with 800 μl of peroxide solution and luminol 
solution mixed at 1 : 1 ratio. Subsequent detection was done by chemiluminscence 
exposure of X-ray film. 
 
For re-probing of membrane with another primary antibody, the membrane was 
washed thrice for 5 minutes with 0.1% (v/v) TBST on an orbital shaker and then 
bathed in 10 ml or more of western blot stripping buffer (Table 2.2) to completely 
soak the membrane in a sealed plastic bag. Stripping was done at 50°C (water bath) 
for 20 to 30 minutes dependent on the intensity of the prior signal with occasional 
agitation. The membrane was then retrieved carefully and washed thrice with 5 
minutes washes with 0.1% (v/v) TBST and then blocked in the blocking buffer for 1 
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hour. The stripping efficacy could be tested with the addition of chemiluminescent 
substrate in the absence of antibodies. After the stripping, the membrane could be 
used for re-probing with a new primary antibody. 
 
2.4.6. Immunofluorescence staining   
Hela cells were seeded in a 24-well plate with coverslip overnight at 105 cells/well. 
The next day, cells were washed thrice with PBS, fixed with 1% (w/v) PFA in PBS 
for 30 minutes and washed thrice with PBS to remove all traces of PFA. The cells 
were then permeabilized with permeabilizing buffer (1% (w/v) Triton X-100 in PBS) 
for 1 hour at room temperature. Primary antibody was diluted in 5% (w/v) BSA to 
desired concentration. Each coverslip was incubated with 15 μl of diluted primary 
antibody on parafilm for 1 hour at room temperature. Excess antibody was removed 
by washing the coverslips thrice with permeabilizing buffer. Next, secondary 
fluorochrome-conjugated antibodies, diluted in 5% (w/v) BSA, was added and 
incubated for 1 hour at room temperature in the dark. The coverlips were washed five 
times with permeabilizing buffer and mounted on glass slide using VectaShield 
mounting medium with DAPI (Vector Laboratories Inc., Burlingame, CA). Excess 
mounting media was removed using clingwipe. Glass slides were cleaned with 70% 
ethonal and dried prior to use. Coverslips were sealed with clear nail polish.  
 
In some experiment where UV-irradiation was done to induce HeLa cell apoptosis, 
cells were not permeablized. Hence, the washing steps were carried out using PBS 
instead of permeablizing buffer containing detergent.  
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The stained cells were examined using the Olympus Fluoview FV1000 confocal 
microscope and analyzed by the Imaris 7.6.4 software.  
 
2.4.7. Enzyme Linked Immunosorbent Assay to determine SLE patients’ serum B23 
level 
The SLE patients’ serum B23 levels were determined using sandwich ELISA. The 
patients’ sera stored in -80°C were thawed prior to usage and diluted 10× with PBS. 
 
100 μl of the diluted polyclonal rabbit anti-B23 antibody (0.1 μg/ml) was coated in 
each well in the 96-well ELISA plate. Plate was then blocked with 0.1% (v/v) PBS-
Tween 20 for 1 hour at room temperature. Positive (purified B23, 1 μg/ml) and 
negative (serum from healthy donor) controls along with the test samples were 
transferred into the individual well and incubated for 1 hour at room temperature. 
After incubation, the wells were emptied and wash thrice using 0.05 % (v/v) PBS-
Tween 20. The wash buffer was left in the well for 30 to 60 seconds per washing 
cycle and the liquid disposed completely by tapping it on an absorbent paper with the 
wells facing downwards to remove residual buffer. 100 μl of the diluted monoclonal 
mouse anti-B23 antibody (0.1 μg/ml) was then incubated for 1 hour and washing was 
done thrice as described above. 
 
After washing off the antibody, 100 μl of the enzyme conjugate (HRP-labelled anti-
mouse IgG) was added into each well and incubated at room temperature for 1 hour. 
The enzyme conjugate was then emptied and washed thrice as described above. 
Subsequently, 100 μl of the substrate solution was added into each well and incubated 
for around 15 minutes at room temperature away from direct sunlight. 50 μl of stop 
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solution was then added into each micro-well and absorbance at 450 nm measured 
within 30 minutes. 
 
2.4.8. Prokaryotic recombinant protein expression  
pET-28a+ plasmids containing the correct B23 insert sequence (His-tagegd B23 or 
V5-tagged B23) were transformed into BL21 competent cells. The transformed cells 
were spread onto LB-kanamycin agar plates for overnight (14 hours) incubation at 
37oC. A colony was picked and incubated overnight in 50 mL LB starter cultures with 
30 µg/ml of kanamycin added prior to incubation. On the next day, the starter culture 
were poured into 1 L of LB media with 30 µg/ml of kanamycin and incubated for an 
estimated period of 2 hours, until the OD600 of the culture reached 0.6 - 0.8. A small 
aliquot was taken and the OD value was taken down for normalization of SDS-PAGE 
loading. Isopropyl β-D-1-thiogalactopyranoside (IPTG) was then added to the cell 
culture to a concentration of 1 mM, before 3 hours incubation to induce protein 
expression. After the incubation, OD600 would typically reach 1.2 and cells were 
harvested by centrifugation at 4600 rpm at 4ºC for 15 minutes in 100 ml aliquots. 
Supernatant was discarded and pellet was kept at -20oC for storage until further use.  
 
2.4.9. Nickel-Nitrilotriacetic acid resin purification of polyhistidine tagged protein 
Purification of the His-tagged B23 protein from BL21 was done with the Ni-NTA 
resin (Qiagen GmbH. Hilden, Germany). The following reagents were prepared 
(syringe filtered sterilise with a 0.22 μm filter unit). 
1) Binding buffer: Sodium phosphate 50 mM, NaCl 350 mM, and Imidazole 10 mM 
(pH 7.4).   
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2) 1× Ni-NTA wash buffer: Sodium phosphate 50 mM, NaCl 500 mM and Imidazole 
20 mM (pH 7.4). 
3) 1× Ni-NTA elution buffer: Sodium phosphate 50 mM, NaCl 500 mM and 
Imidazole 250 mM (pH 7.4). 
 
The bacteria pellet (from 100 ml of culture) was thawed on ice for 15 minutes. At the 
same time, binding buffer was pre-chilled at 4oC. Tap the bottom of tube to break the 
pellet, and 10 ml of cold binding buffer was poured into the tube to re-suspend the 
pellet. Sonication of the bacteria was done using the sonicator at 70 % amplitude, 5/5 
second on/off cycle for approximately 7 minutes on ice until the suspension became 
clear. Sonication was to be paused cool down the suspension when tube became warm. 
Centrifuge was carried out at 20,000 rpm for 30 minutes at 4oC. Supernatant was 
transferred to another tube and repeat the centrifugation again. Both supernatant and 
pellet were kept for SDS-PAGE analysis. Recombinant His-tagged B23 was found to 
be present in the supernatant, and was then subjected to Ni-NTA column purification.   
 
In brief, 1 ml of the Ni-NTA resin slurry was aliquot out from the storage bottle into a 
15 ml conical base tube and allowed to stand for 10 to 15 minutes. After the resin had 
settled, the storage medium (approximately 50% of the volume of slurry) was 
removed. 10 ml of sonicated supernatant was added to the Ni-NTA resin. 2 ml of 
binding buffer was added to top up the volume. Gentle rotatory mixing was done 
overnight at 2 to 3 rpm at 4°C to allow for protein binding to the nickel base resin. 
 
After the overnight incubation, the mixture was decanted into the gravity flow Poly-
Prep chromatography columns (Bio-rad. Hercules, CA, USA), which would trap the 
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Ni-NTA resin. The flow through was collected for analysis to determine the adequacy 
of binding. Washing was done twice each with 20 CVs of the Ni-NTA bead with the 
1× wash buffer (according to the amount of resin which was used in proportionate to 
the amount of expression medium). After washing, the protein was eluted with 1× Ni-
NTA elution buffer with each elution fraction of 1 CV (500 μl). The flow through, 
two washing fractions and four elution fractions were analysed by SDS-PAGE and 
subsequently blue silver staining to determine purity.   
 
Mutant His-tagged B23 was purified following the same protocol.  
 
2.4.10. Ion-exchange column purification of V5-tagged protein 
Sonication of V5-tagged B23 was done in 50 ml of TBS per 100 ml of bacteria 
culture instead of the binding buffer. After sonification, V5-tagged B23 was found to 
be in the supernatant. The first step purification of the V5-tagged B23 protein from 
sonication supernatant was done with SP sepharose and Q sepharose (GE Healthcare, 
Little Chalfont, Buckinghamshire, UK). The following reagents were prepared 
(syringe filtered sterilise with a 0.22 μm filter unit). 
1) 1× TBS: Tris 10 mM, NaCl 150 mM (pH 7.4). 
2) 1.8× TBS: Tris 10 mM, NaCl 270 mM (pH 7.4). 
3) 3× TBS: Tris 10 mM, NaCl 450 mM (pH 7.4) 
 
15 ml of SP-sepharose beads was packed into a clean gravity flow Poly-Prep 
chromatography columns (Bio-rad. Hercules, CA, USA).  The storage medium was 
allowed to flow through, and column was then equilibrated with 3 CVs (45 ml) of 
pre-chilled 1× TBS. 100 ml of sonication su
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flow through was collected. Washing was done with 20 CVs (300 ml) of the 1× TBS. 
After washing, the protein was eluted with 1.8× TBS with each elution fraction of 0.5 
CV (7.5 ml). The first five elution fractions were combined.  
 
Similarly, 15 ml of Q-sepharose beads was packed into a clean gravity flow Poly-Prep 
chromatography columns, and equilibrated with 3 CVs (45 ml) of pre-chilled 1.8× 
TBS. The combined elution fractions from SP-sepharose column was added into the 
column and allowed to pass through slowly. Column was washed with 10 CVs (150 
ml) of 1.8× TBS and protein was eluted with 3× TBS with each elution fraction of 0.5 
CV (7.5 ml). The flow through, washing fraction and elution fractions from SP-
sepharose column and Q-sepharose column were analysed by SDS-PAGE and 
subsequently blue silver staining to determine purity.  Four elution fractions were 
combined and concentrated to 1 ml using a concentrator (Millipore, m.w cut-off 10 
kDa).  
 
2.4.11. Gel-filtration column purification of His-tagged B23 and V5-tagged B23 
The His-tagged B23 protein fraction eluted by 250mM imidazole elution buffer with 
the highest protein concentration and the V5-tagged B23 concentrated from Q-
sepharsoe elution fractions were used to be further purified by the gel filtration 
Superose 6 10/300GL column (GE Healthcare, Piscataway, NJ) according to the 
manufacturer’s protocol. Superose 6 provided separation of proteins with molecular 
weights of 5 – 5,000 kDA. The column was first equilibrated with 1.5 CV of the TBS 
buffer. 250 μl of the concentrated B23 elution fraction was injected into the column. 
Column was running at flow rate of 0.5 ml per minute and proteins were separated 
according to the molecular weight and native confirmation. A total of 1.5 CV (36 mls) 
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of TBS buffer was used and 36 fractions were collected (A1 – A15, B1 – B15, C1 – 
C6). The absorbance graph generated showed peaks indicating the FPLC fractions 
containing different amount of proteins of various molecular weights. The FPLC 
fractions were then electrophoresed on SDS-PAGE gels for blue silver staining to 
identify amount of B23 in each fraction and purity of the protein. 
 
2.4.12. in-vitro digestion of B23 
To determine the in-vitro digestion of B23, human serum purified C1 complex 
(Merck Millipore (Calbiochem), Billerica, MA, USA) and prokaryotic expressed B23 
were used. BSA from Sigma-Aldrich (St. Louis, MO, USA) was used as a negative 
control and complement C4 protein (Merck Millipore (Calbiochem), Billerica, MA, 
USA), a known C1s substrate, was used as a positive control of cleavage. All the 
reaction mixtures including the controls were prepared in 1.6 ml microcentrifugation 
tubes with the cleavage buffer as described in table 2.2. C1 complex was used at a 
concentration of 9.6 μg/ml and the concentrations of B23, C4 and BSA were at 25 
μg/ml. The samples, including the controls, were incubated at 37°C for 2 hours in a 
Thermo Cycler (2720 Thermo Cycle, Life Technologies (Applied Biosystems) 
Carlsbad, California, USA).  
 
In addition, C1 complex (range of concentration: 0.15 to 19.2 μg/ml) comparison of 
C1s alone (range of concentration: 1 to 61 μg/ml) digestion of His-tagged B23 (25 
μg/ml) in the cleavage buffer was done to determine the kinetics. C1 complex (9.6 
μg/ml) digestion of V5-tagged B23 (25 μg/ml) was done to determine the cleavage 
pattern. Purified His-tagged B23 mutant proteins (25 μg/ml) were used to incubate 
with C1 complex (9.6 μg/ml) to evaluate the cleavage sites.  
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2.5 BIOINFORMATICS TECHNIQUE: C1S PROTEASE MODEL 
The Prediction of Protease Specificity (PoPS) is an online computational 
bioinformatics software that models protease specificity and allows for the creation of 
protease models, using the primary sequences of the protease (Boyd et al, 2005). 
PoPS can be used to predict and rank likely cleavages on a substrate and within the 
entire human proteome. It also takes into account the secondary and tertiary structures 
to exclude the unlikely cleavage sites. A model specific for the C1s protease was 
previously created by a senior researcher in our lab based on the C1s substrate 
specificity study done by Kerr and colleagues (Kerr et al, 2005). To construct the C1s 
model, the subsequent information was required: the number of subsites within the 
active site of C1s, the specificity profile of each subsite and the weight of each subsite. 
The specificity profile of each subsite ranged between -5 to +5, where negative values 
indicated negative influence on binding of that residue for that subsite. A hash symbol 
(#) indicated amino acids that prevented cleavage of that subsite. The weight of the 
subsite reflected the relative importance of the residue in determining cleavage.  
 
To make the C1s model, four non-prime subsites (S1 to 4) and four prime subsites (S’1 
to 4) were entered into PoPS. To acquire the specificity profile of each subsite amino 
acid, the occurrence rate of amino acids at the P4 to P’4 positions with a fixed P1 
arginine residue from 93 phage sequences that were cleaved by C1s, was first 
obtained from the research by Kerr and colleagues (Kerr et al, 2005). Next, the Δσ 
values were calculated using the following formula: 
Δσ =




In the formula, n stands for the total number of phage sequences analysed in the study 
(93). The Δσ value reflected the difference between the observed frequency Obs (χ), 
and the expected frequency, P(χ). Expected frequency is calculated by the ratio of 
number of allowed synonymous codons encoding amino acid and 31, which is the 
theoretical occurrence of amino acid x based on the coding of the octamer sequence 
(Table 2.5).  
 
Table 2.5 Number of allowed synonymous codons (total=31). (Adapted from Song, 
Matthews et al. 2011). 
 Amino acid 




2 1 1 1 1 2 1 1 1 3 
Amino acid 




1 1 2 1 3 3 2 2 1 1 
 
A Δσ value exceeding one implied that a specific amino acid was overrepresented at 
that subsite. To standardize the Δσ values of all amino acid residues for that subsite, 
the Δσ was divided by the largest Δσ value of that subsite and adjusted to 5. For the 
specificity profiles used to make the C1s model, any negative Δσ value was assigned 
a value of zero instead. This was because the absence of particular amino acids on the 
phage sequences meant a lack of cleavage by C1s, and not that the amino acids 
negatively influenced the cleavage. The arginine residue at P1 position was given a 
weight of five. The weights of the other subsites were standazed against 5 by dividing 
their Δσ with the Δσ of the P1 arginine and multiplying it by five.  
 
The three components were used to create the scoring matrix. The main PoPS 
program interface allowed user to determine the number of non-prime and prime 
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subsites along with its vector weight. The product of the weight for a subsite and the 
matrix entry was calculated for each amino acid residue at S4 to S’4. The score was 
obtained by summing all products together (Boyd et al, 2005).  
 
Besides the primary sequences of C1s and its potential substrate, other factors were 
also considered, such as the secondary and tertiary structure of the cleavage site and 
accessibility of C1s to the cleavage site. Sites that had no secondary structure and 
more exposed were more susceptible to C1s proteolysis. A three-dimensional model 
of the substrate was acquired from the Protein Data Bank through PoPS and the 
accessibility of every amino acid was calculated by PoPS using the Define Secondary 
Structure of Proteins algorithm (Kabsch & Sander, 1983). The secondary structure 
that each residue participated in would be shown in the output window. The cleavage 
score would appear in grey font if PoPS determined that at least one amino acid of P4-
P4´ positions was inaccessible. 
 
2.6 STATISTICAL ANALYSIS 
Most experiments were performed three times and the figures presented are 
representative of these experiments unless stated otherwise. Data were expressed as 
mean values of experimental triplicates ± standard error.  
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Chapter 3 The complement protein C1q recognizes defined subnuclear 
regions in apoptotic cells 
 
3.1 INTRODUCTION  
 
Physiologically, complement protease C1s functions in the form of C1 complex and 
its activation and cleavage of antigens relies first of all on C1q binding to or being 
nearby the antigens (K. Reid, 1986). By defining the region where C1q binds to 
intracellularly, it provides clues on where C1q intracellular ligands and C1s substrate 
potentially lie in the cells.  
 
In this part of the study, we aimed to establish an experimental platform that is 
suitable for microscopic detection of C1q binding to subcellular regions following the 
process of cell apoptosis. The platform is designed considering it maximal relevance 
to the physiological conditions associated with SLE pathogenesis. With the system 
established, we then proceeded to examine the interaction between C1q and its 
potential intracellular ligands.  
 
3.2 INDUCTION OF APOPTOSIS BY ULTRA-VIOLET (UV) IRRADIATION 
 
3.2.1. HeLa cells underwent reproducible apoptosis upon UV irradiation 
Apoptotic cells are one of the major sources of self-antigens that elicit autoantibodies 
in SLE patients. To detect the intracellular binding regions of C1q in apoptotic cells, 
apoptotic cells were generated by UV irradiation. The primary reasons why UV 
irradiation was used to induce apoptosis are: 1) it requires no addition of drugs, which 
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may interfere with downstream experiments and 2) exposure to UV light is an 
important environmental trigger for SLE butterfly rash. Therefor, it is physiologically 
relevant to induce apoptosis by UV-irradiation in this context.  
 
To generate apoptotic cells, HeLa cells were cultured on coverslips in 24-well plate at 
105 cells/well. Cells were then washed and UV-irradiated at 500 mJ/cm2 (Spectroline 
Select XLE-1000 UV Crosslinker, UVC, 254 nm lamp) in serum-free medium. 
Subsequently, the irradiated cells were cultured at 37oC and 5% CO2 for 1 hour, 3 
hours, 6 hours, 12 hours or 24 hours to induce apoptosis. Cells were fixed, washed 
and mounted on glass slides using medium containing DAPI that stains the DNA (Fig 
3.1 b-f). These cells were not permeablised with detergent.. As controls, cells that 
were not UV-irradiated were permeabilized before mounting with DAPI-containing 
medium (Fig 3.1 a). On UV irradiation, HeLa cells underwent apoptosis and 
significant cell shrinkage, rounding and nuclear condensation were apparent 1-3 hr 
after UV irradiation (Fig. 3.1). These were probably due to caspase activation and the 
breakdown of cytoskeleton and other cellular molecules. There were also increasing 
amount of apoptotic blebs..  
  
 
Figure 3.1 Induction of apoptosis in HeLa cells. HeLa cells were UV-irradiated (b-f) at 500mJ/cm2 in serum-free DMEM supplemented with 1% 
(w/v) penicillin/streptomycin to induce apoptosis. After UV-irradiation, cells were cultured at 37oC and 5% CO2 for 1hr, 3hr, 6hr, 12hr or 24hr before 
being fixed with 1% (v/v) PFA for 30 min. Cells were not permeablized. Control cells (a) were not UV-irradiated, and were fixed with 1% PFA for 30 
min and permeablized with 1% Tx-100 for 1hr. Significant nuclear shrinkage, chromatin condensation and cell blebs were observed as characteristic 





3.2.2. Immunofluorescence analysis of HMGB1 localization, a potential C1s substrate 
protein 
HMGB1 is a DNA chaperone that binds to the minor groove of DNA double helix and is 
believed to help DNA folding. It is a known danger-associated molecular pattern (DAMP) 
that is released from late apoptotic cells in association with nucleosomes and these HMGB1-
nucleosomes induce lupus-like conditions in mice (Urbonaviciute et al., 2008). Using the cell 
apoptosis assay developed, we proceeded to characterize HMGB1 subcellular localization in 
normal and apoptotic cells. Knowledge on intracellular localization of HMGB1 and its 
progressive changes during apoptosis could provide important information on accessibility of 
most nuclear regions to C1q complex. 
 
3.2.2.1. Detection of HMGB1 localization in normal cells  
By immunofluorescence staining of HeLa and HepG2 cells (Fig. 3.2), HMGB1 was found in 
four subcellular regions. Majority of HMGB1 was detected in the nucleolus as intensive 
granular signals. Staining in the rest of the nucleus was weaker but ubiquitous. The 
cytoplasm was mostly void of HMGB1, except for a restricted peri-nuclear region where 
HMGB1 was detected as intensive vesicular signals. Intermediate staining near plasma 
membrane was also detected. A 3D model was constructed based on stacked sequential 
section images collected to highlight the most significant signals in nucleolus and peri-
nuclear regions.  RNA polymerase II (RNAPII) signals were used as a reference (Fig 3.2). 
 
3.2.2.2. Detection of HMGB1 localization in apoptotic cells  
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HeLa cells were UV-irradiated to induce apoptosis. Cells were fixed at different time points 
and then stained with the HMGB1 antibody. Cells were not permeablised, except for control 
cells that were not UV-irradiated. Overall, HMGB1 staining in HeLa cells showed 
progressively decreasing intensity during apoptosis. The vesicular peri-nuclear HMGB1 
signals in the cytoplasm disbursed into nearby cytoplasmic regions following apoptosis (Fig. 
3.3 b-f). The nucleolus HMGB1 signals also decreased with the progression of apoptosis. By 
24 hours, majority of HMGB1 signals was dispersed.  
 
This showed that during apoptosis, membrane integrity was lost at early stages and therefore 
intracellular antigens became accessible to antibodies within the first hour of UV irradiation 
without detergent permeablization. The fact that HMGB1 levels were markedly reduced 24 
hours after UV irradiation was consistent with a previous report of HMGB1 release to culture 
supernatant from late apoptotic cells (Scaffidi et al., 2002). Nonetheless, results showed that 
UV-irradiation of cell apoptosis was suitable for studying C1q binding and C1s cleavage of 






Figure 3.2 Subcellular localizations of HMGB1. HeLa cells (Aa) or HepG2 cells (Ab) were 
cultured overnight in 24-well plates on coverslips. Cells were fixed in 1%(w/v) PFA for 30 min and 
permeablized with 1%(v/v) Tx-100 for 1hr. Cells were then incubated with a rabbit anti-HMGB1 
antibody and a mouse anti-RNAP II antibody, followed by goat anti-rabbit (Alexa 488) and goat anti-
mouse (Cy3) secondary antibodies. Magnified images were captured to observe more details (B). A 
3D model was built using Imaris (C). Images were captured using Olympus Fluoview FV1000 and 
analyzed by the Imaris 7.6.4 software. Scale bars represent 10 μm. 
  
 
Figure 3.3 Subcellular localization of HMGB1 in apoptotic HeLa cells. HeLa cells were UV-irradiated (b-f) in serum-free DMEM supplimented with 1% 
(w/v) penicillin/streptomycin at 500mJ/cm2 to induce apoptosis. After UV irradiation, cells were cultured at 37oC and 5%CO2 for 1hr, 3hr, 6hr, 12hr or 24hr 
before being fixed and HMGB1 detection by immunofluorescent staining. Cells were fixed with 1% (v/v) PFA for 30 min but not permeablized. Control cells 
(a) were not UV-irradiated, and were fixed in 1% PFA for 30 min and permeablized with 1% Tx-100 for 1hr before staining for HMGB1. Images were 




3.3 C1Q RECOGNIZES DEFINED SUBCELLULAR REGIOINS IN 
APOPTOTIC HELA CELLS 
 
3.3.1. C1q lacks nuclear binding in permeabilized, non-apoptotic HeLa cells 
Both permeablized non-apoptotic HeLa cells (Fig 3.4) and apoptotic HeLa cells (Fig 
3.5) were used to evaluate C1q binding. HeLa cells were seeded on coverslip  
 
Figure 3.4 Detection of C1q binding in HeLa cells. HeLa cells were seeded on coverslips in 
24-well plate overnight before being fixed in 1% (w/v) PFA. Cells were either not 
permeablised, or permeablised with 1% (v/v) or 5% (v/v) Triton X-100. Cytoplasm binding 
was detected for detergent permeablised cells. But cell nuclus was mostly void of C1q 
staining. Images were captured using Olympus Fluoview FV1000 and analyzed by the Imaris 
7.6.4 software. Scale bar represents 30 μm.   
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overnight. After fixation in 1% PFA and permeablization with 1% or 5% (v/v) Triton 
X-100, these cells were incubated for 1 hour with C1q (10 μg/ml) (Fig 3.4). Non-
permeablized cells were used as control.  
 
With 1% detergent permeablization, C1q showed predominant cytoplasmic and 
peripheral binding. No nuclear binding was detected. We then increased Tx-100 to 
5% (v/v) for cell permeabilization and the binding pattern remained the same. Binding 
remained cytoplasmic and peripheral without nuclear staining. Without detergent 
permeablization, there was no intracellular C1q binding detected. Some dotty signals 
were detected outside the cell periphery but the signals were weak. DAPI staining was 
weak in these fixed but non-permeablized cells. In general, C1q showed 
predominantly cyctoplasmic binding in permeabilized non-apoptotic cells, but lacked 
nuclear binding.  
 
3.3.2. C1q showed nuclear binding in late apoptotic HeLa cells 
Most autoantibodies found in SLE patient sera recognise nuclear proteins. Although 
C1q did not show nuclear binding in permeablized normal cells, we asked whether 
C1q would bind to the nuclei in apoptotic cells. The lack of C1q binding in nuclei 
could be due to the lack of C1q ligands in the nuclei or because C1q was unable to 
penatrate the nuclear chromatins to reach its ligands.  
 
To study C1q binding to apoptotic HeLa cells, cells were seeded overnight on 
coverslips and were UV-irradiated (dose of 500 mJ/cm2, λ=254 nm) to induce 
apoptosis. Cells were then incubated at 37 °C in 5% CO2 for various time periods (1 
hour, 3 hours, 6 hours, 12 hours, and 24 hours) and then fixed in 1% (w/v) PFA. Cells 
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were then incubated for 1 hour with C1q (10 μg/ml). After washing, bound C1q was 
detected by incubation for 1 hour with a mouse anti-C1q antibody followed by 
incubating for 1 hour with goat anti-mouse IgG (Cy3) as secondary antibody. Cells 
were mounted and examined by confocal microscopy. In the first 3 hours after UV 
irradiation, C1q showed bound predominantly at the cell periphery and inside the 
cytoplasm as for permeabilised, non-apoptotic cells (Fig. 3.5 a, b). After 6 hours, C1q 
bound predominanty inside the nuclei with little cytosplasmic binding (Fig 3.5 c). The 
nuclear binding sites for C1q were well-defined with spherical shapes. With further 
progress of apoptosis, these defined C1q binding sites became diffused (Fig. 3.5 d, e). 
This shows that, if apoptotic cells are not cleared rapidly, intracellular cytoplasmic 
and nuclear antigens, which may become accessible to immune cells, also become 
accessible to C1q. The defined C1q binding sites in the nucleus were both spherical 
and surrounded by heterochromatins, resembling the nucleolus (Fig 3.5 c, indicated 
by arrows). This is intriguing because nucleolus is rich in autoantigens that are 
associated with SLE.  
 
These results showed that, in late apoptosis, C1q was able to bind to or near the 
nucleolus. This was not observed in normal HeLa cells even after permeabilization 
with high concentrations of Triton X-100. This could be due to two reasons: 1) C1q 
ligands were absent in normal nuclei but it was induced late in apoptosis, or 2) 
Nucleoli are C1q ligands irrespective of apoptosis but they were not accessible to C1q 
in non-apoptotic cells. To examine whether C1q binds to the nucleolus, we then 
proceeded to two lines of experiments: 1) to examine the integrity of nuclear lamina 
in apoptotic and non-apoptotic cells and 2) to isolate nucleoli from normal cells and 
examine C1q interaction with these isolated nucleoli.  
  
Figure 3.5 C1q binding to apoptotic HeLa cells. HeLa cells were UV-irradiated in serum-free DMEM supplimented with 1% (w/v) penicillin/streptomycin 
at 500mJ/cm2 to induce apoptosis. After UV irradiation, cells were cultured at 37oC and 5% CO2 for 1hr, 3hr, 6hr, 12hr or 24hr (a-e). Cells were fixed with 1% 
(w/v) PFA for 30 min but not permeablized. After fixation, cells were then incubated with C1q (10 μg/ml in PBS) for 1hr at room temperature and detected 
using mouse anti-C1q antibody followed by goat anti-mouse IgG (Cy3) secondary antibody. 100× (A) and 300× (B) magnifications were used. Images were 
captured using Olympus Fluoview FV1000 and analyzed by the Imaris 7.6.4 software. Scale bars represent 10 μm. 
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3.3.3. C1 complex shows similar binding in apoptotic and non-apoptotic HeLa cells 
C1q circulates in serum in the form of C1 complex. To examine whether C1 complex 
bind to apoptotic cells in a similar manner as C1q, HeLa cells were UV irradiated and, 
after 1 and 6 hours, fixed and incubated with C1 complex. Cells fixed 1 hour after UV 
irradiation was considered early apoptotic cells and those fixed 6 hours after UV 
irradiation were considered late apoptotic cells.  
 
 
Figure 3.6 C1 binding to apoptotic HeLa cells. HeLa cells were UV-irradiated in serum-
free DMEM supplimented with 1% (w/v) penicillin/streptomycin at 500mJ/cm2 to induce 
apoptosis. After UV irradiation, cells were cultured at 37oC and 5% CO2 for 1hr (A) or 6hr 
(B). Cells were fixed with 1% (w/v) PFA for 30 min but not permeablized. After fixation, 
cells were then incubated with C1 complex (10 μg/ml in 5% BSA) for 1hr at 4oC, and 
detected using mouse anti-C1q antibody and goat anti mouse IgG (Cy3). Images were 
captured using Olympus Fluoview FV1000 and analyzed by the Imaris 7.6.4 software. Scale 
bar represents 10 μm. 
 
With early apoptotic cells (1 hour), C1 complex bound predominantly to the 
cytoplasm and showed no nuclear binding (Fig. 3.6). This binding pattern was similar 
to that obtained with C1q. With late apoptotic cells (6 hour), C1 complex was 
detected predominantly in nucleolar regions like C1q. This showed that C1q binding 
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to these inner nuclear structures in apoptotic cells could also recruit the C1r and C1s 
proteases to these structures.  
 
3.3.4. Nuclear lamina shows impairment in late apoptotic HeLa cells 
C1q and C1 binding to nucleolus in late but not early apoptotic cells could be due to 
the lack of these ligands in early apoptotic cells or their inaccessibility by C1q and C1 
complex. Here we evaluated the integrity of nuclear lamina in early and late apoptotic 
cells by staining the nuclear lamina protein lamin B1 (LB1) (Fig 3.7). Staining of LB1 
showed that the nucleus shrunk substantially between 1-3 hours after UV irradiation 
but the layer of nuclear lamina appeared continuous and intact (Fig 3.7 A a-c). By 6 
hours, the size of the nucleus was not further substantially reduced but the layer 
appeared weakened (Fig 3.7 A d). It was particularly obvious that dented area 
developed on the nuclear lamina by 6 hours (Fig 3.7 A d-f). LB1 intensity was 
significantly reduced over the dented area, suggesting significant impairment of 
nuclear lamina at the dented region.  
 
Similarly, lamin B receptor (LBR) was similarly stained in these cells. The intensity 
of the LBR signals also decreased following the progress of apoptosis, showing 
discontinuity in certain regions or even disruptions in the dented areas (Fig 3.7 B). 
These together suggested the possibility that the nuclear lamina was disrupted 
following the progress of apoptosis, which rendered C1q and C1 access to inner 
nuclear regions. However, whether C1q ligands were constitutively present in 
nucleolus or these ligands were only induced in late apoptotic cells, remained unclear. 
 
  
Figure 3.7 Nuclear lamina markers in apoptotic HeLa cells. Hela cells were UV-irradiated to induce apoptosis. After UV irradiation, cells were cultured at 
37oC and 5% CO2 for up to 24 hours. Control cells were not UV-irradiated (Aa, Ba). After fixation, cells were then detected using rabbit anti-LB1 antibody 
(A) or rabbit anti-LBR anibody (B), followed by goat anti rabbit IgG (Alexa 488). Arrowheads indicate the impairment observed on nuclear lamina. Images 
were captured using Olympus Fluoview FV1000 and analyzed by the Imaris 7.6.4 software. Scale bars represent 10 μm. 
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3.4 C1Q BINDS TO PURIFIED NUCLEOLUS 
 
3.4.1. Purification of HeLa cell nucleolus 
To examine whether C1q ligands are present in non-apoptotic cell nucleoli, a protocol 
was developed to isolate these nuclear bodies were isolated following an established 
protocol. HeLa cells were re-suspended in a homogenization buffer (10 mM Tris, 0.25 
M sucrose and 5.0 mM MgCl2, pH 7.4) and homogenized by pressing through a 10-
μm gap in a homogenizer. Nuclei were pelleted by centrifuging at 600 g for 10 min 
and further purified by centrifugation through 2.2 M sucrose. The nuclei were 
sonicated in the homogenization buffer and centrifuged for 3 hours at 33,000 rpm 
through a sucrose gradient (0.7M, 0.85M, 1.2M, 1.5M, 1.7M, 2.2M and 2.5M, as 
shown in Fig 3.8 A), using the P40ST rotor (Hitachi). Fractions were collected from 
top to bottom forming 8 fractions (T1-T8). The nucleoli were recovered in the pellet 
and re-suspended in the homogenization buffer. Other nuclear chromatin fragments 
were found in high-density fractions. By Western blot analysis (Fig 3.8 B), the 
nucleolar granular center proteins mucleophosmin 1 (NPM1 or B23) and nucleolin 
(NCL) were both detected in fractions T7 (2.2 M) and T8 (2.5 M), as well as in the 
pellet fraction. To check the purity and integrity of isolated nucleolus, we coated 
fractions T7 and T8, and the pellet fraction on coverslips, and stained these fractions 
for B23 and HMGB1. Staining showed that the isolated nucleoli were present in the 
pellet fraction, and nuclear debris was detected in T7, T8 fractions (data not shown). 
In the pellet (Fig 3.8 C), little non-nucleolus materials were detected, showing that the 
isolated nucleoli were of high purity. Meanwhile, HMGB1 remained as granular 
signals inside the lumen of nucleoli, showing the overall structural integrity of the 
isolated nucleoli. Likewise, a layer of heterochromatin remained on the surface of the 
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isolated nucleolus, which again showed that the isolated nucleoli were structurally 
intact.   
 
 
Figure 3.8 Isolation of nucleoli from HeLa cell culture. (A) All sucrose gradient fractions 
were collected from top to bottom, namely T1-T8 and pallet fraction. (B) Western blot 
analysis of nucleolus components in sucrose gradient fractions. Nucleolus markers B23 and 
NCL were found in fractions T7, T8 and the pellet. (C) IF staining of DNA (blue), HMGB1 
(green) and B23 (red) showed intact nucleolus present in the pellet. Images were captured 
using Olympus Fluoview FV1000 and analyzed with the Imaris 7.4 software. Scale bars 
represent 10 μm.  
 
3.4.2. C1q binds to isolated nucleoli as determined by sucrose gradient 
centrifugation 
To examine whether C1q bound to nucleolus isolated from non-apoptotic cells, we 
incubated C1q (50 μg/ml) with the sonicated nuclei, which were pre-treated with 
DNase so as to reduce the possibility that C1q bound to nucleolus surface DNA. After 
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incubation, the binding was examined by sucrose gradient ultracentrifugation (Fig 3.9 
A a). Soluble C1q was not expected to sediment through the sucrose gradient, but C1q 
that bound to nucleolus was expected to co-sediment with nucleolus to the pellet 
fraction. Subsequently, C1q was detected in the pellet and was also detected in 
fractions T7 and T8 by Western blotting (Fig 3.9 B a). As a control, C1q alone was 
centrifuged through the same sucrose gradient. In this case, C1q was only detected in 
the top T1-T3 fractions. Materials in fractions T7, T8 and the pellet were also stained 
for C1q by immunofluorescence microscopy (Fig 3.9 C D). Five μl from each fraction 
was coated on the coverslip by incubating on ice for 5 minutes. C1q was detected 
using a mouse anti-C1q antibody followed by goat anti-mouse IgG (Cy3). Results 
showed that nucleoli in the pellet fraction had C1q bound on the surface (Fig 3.9 C). 
C1q was found to bind near but not to the DNA regions. C1q was also found in 
fractions T7 and T8, which located close to, but distinctly from, the DNA regions (Fig 
3.9 D). Therefore, nucleolar DNA was not recognized by C1q, which probably bound 
to other nucleolus ligands. 
 
Overall, these results supported our hypothesis that C1q ligands are constitutively 
present in the nucleolus but they were only accessible to C1q in late apoptosis.   This 
may also be true with the C1 complex and, in this case, C1q could mediate the 




Figure 3.9 Detection of C1q binding with nucleus fractions by sucrose gradient 
centrifugation. (A) Sonicated nuclei was treated with DNase and then incubated with C1q 
(Sigma, 50μg/ml) for 1 hour at 4oC. The mixture was then put on sucrose gradient for 
centrifugation at 33,000g for 3 hours. (B) Western blot analysis against C1q was performed. 
C1q was detected in fractions T7, T8 and the pellet. (C) IF staining of pellet fraction. C1q was 
found to bound to the surface of nucleolus. (D) IF staining of T7 (a) and T8 (b) fractions. C1q 
was also detected in these fractions together with digested heterochromatin. Images were 
captured using Olympus Fluoview FV1000 and analyzed with the Imaris 7.6.4 software. 




3.4.3. Evaluation of potential C1q ligands by immunofluorescence staining  
So far, we have demonstrated that C1q bound to nucleolus in late apoptotic cells and 
also bound to purified nucleolus. It showed that C1q ligands exist constitutively in the 
nucleolus. Next, we performed co-staining of C1q with several nucleolus markers to 
examine whether some of these nucleolar proteins may be C1q ligands (Fig 3.10).  
 
Immunofluorescence staining was performed with purified nucleolus (Fig 3.10 A, B) 
or apoptotic HeLa cells (Fig 3.10, C-E).  The nucleolus markers nucleolin (NCL) (Fig 
3.10 A), B23/NPM1 (Fig 3.10 D), fibrillarin (Fig 3.10 B), nucleolar protein HMGB1 
(Fig 3.10 C) and the nuclear lamina protein LB1 (Fig 3.10 E) were used to co-stain 
with C1q. Among them, NCL, B23 and HMGB1 are known autoantigens or DAMP in 
SLE (Bianchi, 2007; Li et al., 1989). From the confocal images, LB1 and C1q showed 
no overlap staining. NCL and fibrillarin were both detected in the nucleolus together 
with C1q. However, neither colocalized with C1q. Instead, fibrillarin seemed to avoid 
nucleolar regions, which were bound by C1q. HMGB1 and B23 showed partial 
colocalization with C1q (Fig 3.10 D, merge). For HMGB1, C1q clearly bound to 
broader area where HMGB1 was absent. B23 appeared to colocalize with C1q 
completely in the nucleolus. However, B23 translocate to the cytoplasm where C1q 
binding was not detected. It was still not conclusive which nucleolar proteins were the 




Figure 3.10 Co-staining of C1q and its potential ligands. (A,B) Co-staining of C1q and 
NCL/fibrillin using purified nucleoli of HeLa cells. Purified nucleoli were coated on 
coverslips by incubating on ice for 5 minutes. Nucleolus was then fixed and treated with 1% 
(v/v) Triton X-100 for 1 hour before incubating wirh C1q (10 μg/ml). (C-E) Co-staining of 
C1q and HMGB1/B23/LB1 in apoptotic HeLa cells. HeLa cells were UV-irradiated and 
continued to incubate at 37oC and 5% CO2 for 6 hours. After fixation, cells were then 
incubated with C1q (10 μg/ml) for 1 hour at room temperature. Images were captured using 






3.5 SUMMARY  
 
In this part of the study, we started first by establishing a platform for the generation 
of apoptotic cells suitable for microscopic evaluation of C1q ligands. HeLa cell 
apoptosis induced by UV irradiation gave rise to apoptotic cells. The avoidance of 
drug-induced apoptosis meant not to affect the downstream experiments with these 
cells and it also reflected the fact that UV light exposure is a known environmental 
risk that causes SLE flare. C1q binding to these apoptotic cells was then performed to 
examine the localization of intracellular C1q ligands. It is known that C1q binds to 
DNA and we were particularly interested in whether C1q binds to DNA in apoptotic 
cell nucleus. In non-apoptotic cells that were permeablized with detergent, C1q bound 
predominantly to the cortical cytoskeletal and cytoplasmic regions, exhibiting no 
binding to the nucleus. With progressing UV-induced apoptosis, C1q binding regions 
started to move gradually from peripheral cellular regions to eventually the nucleolus. 
C1 complex showed similar binding pattern to apoptotic cells as C1q. Although C1q 
showed no nucleus binding in permeabilised non-apoptotic cells, we postulated that 
C1q ligands exist constitutively in the nucleus but they only become accessible upon 
apoptosis. We indeed observed that the nuclear lamina showed impairment in late 
apoptotic cells, which may render nucleolus accessible to C1q. The presence of C1q 
ligands in non-apoptotic nucleolus was confirmed by isolating nucleolus from HeLa 
cells and direct C1q binding to these structures. We also evaluated a number of 
abundant nucleolar proteins as potential C1q ligands, but none exhibited complete 
colocalization with C1q. These findings together suggested that C1q ligands existed 
intracellularly and they became available to C1q and C1 complex during apoptosis in 
a progressive manner. This highlights the possibility that, while C1q binding to these 
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ligands may facilitate the phagocytosis, the fact that C1 complex also bound to these 
structures suggest the possibility of activation of C1r and C1s and degradation of 
autoantigens in these structures. This could potentially contribute to protecting hosts 
against autoimmunity.  
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Chapter 4 Identification of Novel C1s substrates in apoptotic cells 
 
4.1 INTRODUCTION  
Complement C1s deficiency is a strong risk factor for SLE (M. C. Pickering et al., 
2001). Although C1r/s deficiency happens rarely, up to 73% of all C1r/s-deficient 
individuals developed SLE (Amano et al., 2008; Kallel-Sellami et al., 2008). The 
causal relationship between C1r/s deficiency and SLE pathogenesis is poorly studied. 
C1s has been recognized as a complement-specific protease whose substrates are 
limited to C4 and C2. But it doesn’t help to explain how C1r/s deficiency could cause 
SLE. What caught our attention was the discovery of other non-complement C1s 
substrates over the years (W. H. Busby, Jr. et al., 2000; Eriksson & Nissen, 1990; 
Naito et al., 2012; Nissen et al., 1990; Yamaguchi et al., 1990) and also the prediction 
that many intracellular proteins contain C1s cleavage sites based on a phage display 
study (F. K. Kerr et al., 2005). This led to our hypothesis that C1r/C1s protects 
against autoimmunity by “trimming” autoantigens or DAMPs that are exposed on 
apoptotic or necrotic cells, which are known to cause autoimmunity. Elimination of 
immunogenic antigens and pro-inflammatory DAMPs are considered to reduce 
autoimmunity. We have demonstrated in the previous chapter that C1q, as well as C1 
complex, can be recruited to the nucleolus at late apoptosis. It has been reported that 
the nucleolus is particularly rich in autoantigens (Tan, 1988; Welting et al., 2003).  
 
To test this hypothesis, the following specific lines of experiments were performed:  
1) To identify potential C1s substrate using bioinformatics tools;  
2) To identify whether C1s cleaves intracellular proteins that are exposed or 
released from apoptotic cells; 
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3) To evaluate the cleavage of nucleolar proteins by incubating purified nucleolus 
with C1 complex or the C1s protease;   
4) To identify the putative substrates by incubating purified proteins with C1 
complex/C1s and 
5) To delineate potential cleavage sites on the identified C1s substrates. 
 
4.2 C1s BIOINFORMATICS MODEL 
 
4.2.1. Cleavage scores of known C1s substrates 
PoPS is a freely accessible online bioinformatics tool that allows the creation of 
protease models using primary protease sequences (Boyd et al., 2005). PoPS can be 
used to predict cleavage sites on substrate within the entire human proteome giving 
scores based on the primary sequences. It can also be connected to Protein Data Bank 
(PDB) for prediction and alignment of secondary or tertiary structures of substrate 
proteins to facilitate assessment of particular sites for their accessibility by the 
proteases. A C1s-specific model was previously constructed by a colleague in the lab 
(Dr Joo Guan Yeo, see section 2.5). Each amino acid was given a normalized weight 
representing the relative importance of the residue in determining cleavage at P4-P4’. 
For known or predicted C1s substrates, sequences were entered in PoPS individually 
and cleavage scores of each substrate were calculated using the C1s model. The 
cleavage sites on all known substrates have been well calibrated (F. K. Kerr et al., 
2005; Naito et al., 2012). The C1s model predicted all known cleavage sites on these 
substrates correctly with the highest scores being returned (from 38.3 to 46.9, Table 
4.1).  













Accessibility Reference  
Complement C4 
(AAB67980) R756-A757 GLQR-ALEI 40.1 
GLQR-ALEI  
 - - TT   . . . .  0 NO  
(F. K. Kerr et 
al., 2005) 
Complement C2 
(AAB97697) R243-K244 SLGR-KIOI 46.9 
SLGR-KIQI  
- -  - -  - - - -  
2e-97  YES 
(F. K. Kerr et 
al., 2005) 
C1 inhibitor  
(CAA30314) R466-T467 SVAR-TLLV 38.3 
 
SVAR-TLLV 
EEEE   . . EE  
2e-30  NO  








R792-A793 NVGR-ANGL 40.4 
 
NVGR-ANGL 
S .  S .   EEEE 
2e-54  NO  
(Naito et al., 
2012) 
 The dash symbol “-” between two single letter amino acid codes represented the cleavage site.  
 - : assumed to be accessible  
T: hydrogen bond turn  
E: extended strand  
S: bend  





The accessibility of the predicted cleavage sites was further evaluated using automatic 
data mining from PDB. A cleavage site will be labeled potentially inaccessible if any 
one single residue from P4 to P4’ falls in a secondary structure. From Table 4.1, only 
complement C2 was predicted accessible with no definite secondary structure that 
could hinder the interaction between the C1s active site and the whole cleavage site 
from P4 to P4’. The rest were predicted to be buried in strand, bend or hydrogen bond 
turn at two or more residues involved. This conflicted with the fact that these proteins 
are known to be cleaved by C1s at those particular sites. However, this does not mean 
that the secondary structure prediction was not useful because 1) only helical structure 
impedes enzyme-substrate interaction completely and 2) other factors need to be 
taken into consideration, for example, interaction with exosites may facilitate 
cleavage when the interaction between enzyme active site and cleavage site is not 
optimal.  
 
4.2.2. Identification of novel C1s substrate 
The search in human proteome by Kerr et al. using PoPS returned numerous hits of 
potential substrate based on their primary amino acid sequences (F. K. Kerr et al., 
2005). The large number of hits required further selection before meaningful results 
could be obtained. Previously, the result was analyzed based on the cellular 
localization of the proteins, and categorized into intracellular proteins or extracellular 
proteins. Intracellular proteins were removed because of the global inaccessibility of 
C1s to intracellular proteins. Interesting candidates were selected based on their 
importance in inflammation and verified individually.  
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In our study, intracellular proteins are of great interest because our data so far have 
demonstrated that intracellular sites, including the cytoplasm and the nucleus, can be 
accessed by C1 complex when cell apoptosis progress to late stage. C1q binding to its 
ligand is a prerequisite for subsequent C1s activation and cleavage of substrate. C1q 
can bind to a structure directly (Nissen et al., 1990), or indirectly through opsonins 
(Eriksson & Nissen, 1990; Naito et al., 2012).  
 
Potential C1s substrates were expected to have the following features: 1) these 
proteins are related with SLE, being either a DAMP or autoantigen found frequently 
in SLE patients; 2) these proteins are subcellularly in close proximity to a C1q 
binding region in apoptotic cells; 3) these proteins are abundant and are convenient to 
detect by Western blotting.  
 
More specifically, we would: 1) screen the candidate substrate for potential C1s 
cleavage sites; 2) verify the cleavage sites using purified or recombinant substrate 
proteins; 3) delineate the cleavage sites by site directed mutagenesis; 4) examine the 
physiological relevance of the cleavage.  
 
4.3 DETECTION OF CELLULAR PROTEIN RELEASE DURING APOPTOSIS 
 
4.3.1. Detection of protein release from apoptotic cells  
During cell apoptosis, cellular proteins can be released at different stages as danger 
signals to induce cytokine production or as autoantigens to induce autoantibodies 
production. If C1s substrates are released during cell apoptosis, C1 complex recruited 
to apoptotic cells could potentially cleave those proteins at the site where they are 
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released. If these were not cleaved within apoptotic cells, circulating C1 complex 
could cleave them in the serum to eliminate their immunogenicity.  
 
We started by examining the release of intracellular proteins after UV-irradiation. 
HeLa cells were seeded in 24-well plates at 4 × 105 cells/well. After overnight culture, 
cells were washed and UV-irradiated at 500 mJ/cm2 in serum-free DMEM 
supplemented with 100 units/ml of Penicillin and 100 μg/ml of Streptomycin. 
Subsequently, cells were continued in serum-free DMEM (500 μl/well) for 1 hour, 3 
hours, 6 hours, 8 hours 12 hours or 24 hours. Supernatants were collected and 
centrifuged at 1000 g for 10 minutes before analysis on 12.5 % SDS-PAGE gels (Fig 
4.1). Supernatants were similarly collected from cells without UV-irradiation.  
 
 
Figure 4.1 Detection of protein release from apoptotic HeLa cells.  HeLa cells were 
seeded in 24-well plate at 4 × 105 cells/well and were UV-irradiated to induce apoptosis. Cells 
were then incubated for different time periods to induce apoptosis. 1-6 represents incubation 
of 1 hour, 3 hours, 6 hours, 8 hours, 12 hours and 24 hours respectively. Control cells were 
not UV-irradiated. Samples were separated on 12.5% SDS-PAGE and stained with blue silver. 
Protein release from apoptotic cells was more significant than that from control cells. 
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In general,  cells that were not irradiated showed no significant protein release after a 
prolonged 24-hour incubation. The only protein released, which was detected at  
prominent levels, was approx. 70 kDa, which was also observed in apoptotic cell 
supernatants. For apoptotic cells, little cellular proteins were released at the early 
stages of apoptosis (up to 3 hours), not higher than the background levels observed in 
the  supernatants of non-irradiated cells. After 6 hours, apoptotic cells showed 
increasing levels of protein release until 24 hours. It indicated continuous release of 
intracellular proteins into the supernatants during apoptosis. 
 
Next, we went on to determine the identity of released proteins by Western blotting. 
Fifteen antibodies were used each was specific for a cellular protein of interest (Table 
4.2). Supernatant of 24-hour apoptotic cells was used in the Western blot. As control, 
cell lysate was generated using non-irradiated HeLa cells using SDS buffer as 
described in section 2.4.2. The two samples were examined side by side. The amount 
of supernatant in each lane was equivalent to proteins released from 19,200 apoptotic 
cells. Cell lysate in each lane was equivalent to 30,000 cells. Proteins were transferred 
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All 15 proteins were detected in the HeLa cell lysate and 11 were detected in the 
apoptotic cell supernatant (Fig 4.2). Among proteins that were detected in the AC 
supernatant at significant levels were B23 and HMGB1. Among nuclear lamina 
proteins, LB1, LBR and NPC were detected at low levels and LA/C was not detected. 
Nuclear lamina exhibited impairment during cell apoptosis but remained prominent. 
The cytoskeleton protein vimentin was also released but the size of the released form 
was smaller than that found in the cell lysate. This is in line with the knowledge that 
vimentin is proteolytically cleaved by caspases at several sites during cell apoptosis 
and it promotes cell apoptosis (Morishima, 1999). Four proteins that were not 
detected in the supernatant were Lamin A/C (nuclear lamina), RNA polymerase II 







Figure 4.2 Western blot analysis of protein released from apoptotic HeLa cells. 24-hour 
apoptotic HeLa cell supernatant was collected. Viable HeLa cells were lysed using hot SDS 
buffer. Samples were loaded side by side on SDS-PAGE gel (10%, 12.5%, or 15%) running 
under reducing condition followed by Western blot analysis using 15 antibodies. (A) 11 
proteins were detected in ACs supernant of different level of abundance. (B) Four proteins 
were not detected in the ACs supernatant at 24 hours post UV-irradiation.  
 
120 
Simularly, supernatants collected at different time points of a 24 hour apoptosis 
experiment were separated on SDS-PAGDE and analysed by Western blotting using 
the 11 antibodies that detected cellular proteins in the 24-hour apoptotic supernatant 
(Fig 4.3). Among all proteins tested, B23 was the most abundant and was released the 
earliest by 6 hours (Fig 4.3 A). NPC and HP1γ were also released at 6 hours, but the 
levels were much lower compared to B23 (Fig 4.3 A). NCL, HMGB1 and the 
centromere protein B (CenPB) were released by 8 hours (Fig 4.3 B). The rest of the 
proteins were only detectable after 12 hours (Fig 4.3 C D).  With this, the interaction 
between C1 complex and proteins released by apoptotic cells was investigated. 
 
Figure 4.3 Proteins released into apoptotic HeLa cells at different time points. Apoptotic 
HeLa cell supernatants of 1 hour, 3 hours, 6 hours, 8 hours, 12 hours and 24 hours post UV-
irradiation were collected. Viable HeLa cells supernatant was collected as negative control. 
Samples were loaded on SDS-PAGE gel (10%, 12.5%, or 15%) under reducing condition 
followed by Western blot analysis using the 11 antibodies that were proven to have detected 
corresponding protein in the ACs supernatant. Proteins were detected in ACs supernatant at 6 
hours (A), 8 hours (B), 12 hours (C) or 24 hours (D) after UV-irradiation.  
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4.3.2. C1 complex cleaves proteins released from apoptotic HeLa cells  
HeLa cells were seeded at 4 ✕ 5 cells/well in 24-well plate before being UV-
irradiated in serum-free DMEM and incubated at 37oC and 5% CO2 for 6 hours. As 
control, cells were similarly cultured without UV-irradiation. At 6 hours, 10 μl of 
purified C1 complex (10 μg/ml diluted in PBS) or, as a control, PBS, was added into 
the apoptotic and normal cell cultures. After incubation at 37oC and 5% CO2 for 1 
hour, culture supernatants were harvested and centrifuged for 10 min at 1000g at 4°C 
to remove cell debris. Samples were then analyzed by SDS-PAGE under reducing 
conditions and proteins were visualized by blue silver staining. Loss or intensity 
reduction of bands after C1 complex treatments as compared with supernatants that 
were not C1-treated indicated possible cleavage of target proteins by C1 complex.  
 
In C1 complex-treated supernatant, four bands showed reduction in intensity as 
indicated by arrows in Figure 4.4. HMGB1 was previously identified as a potential 
substrate of C1s. However, band intensities at the 25-kDa region were not 
significantly reduced after C1 treatment. This could be due to insufficient amount of 
HMGB1 in the apoptotic supernatant to be detected by blue silver staining. It is also 
possible that HMGB1 was masked by the presence of a more abundant protein with 




Figure 4.4 Detection of C1 cleavage of cellular proteins in apoptotic HeLa cells. Blue 
silver staining of apoptotic and control cell supernatants incubated with or without C1 
complex (9.6 μg/ml). Arrows indicate protein bands with an intensity reduction.  
 
4.3.3. Loss of proteins in C1 complex treated nucleolus  
In the last chapter, it was demonstrated that C1q could bind to isolated nucleolus. One 
consequence of C1q binding to cell debris it phagocytosis as previously reported 
(Ogden et al., 2001). Considering that C1q binding to its ligands will inevitably lead 
to the activation of C1r and C1s proteases, it also raised the possibility that C1q 
binding to nucleolus activates C1r/C1s and causes cleavage of nucleolar proteins.  
 
To examine the interaction between C1 complex and nucleolar proteins, purified 
nucleoli were incubated with C1 complex. C1 was first diluted to 38.4 μg/ml in 
digestion buffer (10 mM Tris, 150 mM NaCl and 3.3 mM CaCl2, pH 7.4). 12.5 μl of 
diluted C1 was then mixed with 25 μl of purified nucleolus and 12.5 μl of digestion 
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buffer in a 1.6 ml microcentrifuge tube. Where C1 inhibitor was used, C1 inhibitor 
was first diluted to 640 μg/ml. 12.5 ul of diluted C1 inhibitor was then added into a 
1.6 ml microcentrifuge tube containing 12.5 μl of C1 complex and mixed thoroughly. 
25 μl of nucleolus was then added into the same tube. Ac controls, nucleolus, C1 
complex or C1 inhibitor was individually topped up to 50 ul with digestion buffer, 
and incubated at 37oC and 5% CO2 for 2 hours as for the other samples. The reaction 
was stopped by addition of SDS-PAGE buffer containing 50 mM DTT and incubating 
at 37oC for 30 minutes. Samples were then analyzed by SDS-PAGE separation and 
blue silver staining (Fig 4.5 A).  
 
After 2 hours of incubation without C1 complex, most nucleolar proteins still 
remained intact (Fig 4.5 A). After C1 complex being added, many of the nucleolar 
proteins were cleaved as shown by the general reduction in band intensities. This was 
inhibited when C1-Inh was present because the band intensities were restored. This 
strongly indicated that the cleavage of nucleolus proteins was due to the activity of 
C1s instead of other proteases possibly co-purified with C1 complex. 
 
Cleavage of nucleolar proteins by C1 complex was almost complete with 2 hours 
incubation. Hence the incubation time was reduced to 5 minutes, 10 minutes, and 30 
minutes in order to view the process of protease cleavage (Fig. 4.5 B). Nucleolar 
proteins showed no visible degradation if nucleoli were incubated without C1 
complex. When C1 complex was added, protein degradation was noticeable after 5 
minutes incubation. A 35-kDa band showed reduced intensity. By 30 minutes, the 
reduction in intensity was more significant. When C1-Inh was added, nucleolar 
protein cleavage was not observed.  
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The observed nucleolar protein cleavage was apparently mediated by C1 proteases 
because it was effectively inhibited by the specific C1-Inh excluding the possibility 
that contaminating proteases in C1 caused the cleavage. Based on these results, it 
showed that some nucleolar proteins are sensitive to C1 complex cleavage. It would 
be interesting to investigate whether some autoimmunogenic nucleolar proteins are 
cleaved by C1, which inactivate their autoreactive epitopes to prevent the activation 
of autoreactive B cells.  
 
 
Figure 4.5 Degradation of nucleolar proteins by C1 complex. (A) Purified nucleoli were 
incubated with C1 complex (9.6 μg/ml) in the presence or absence of C1-Inh (160 μg/ml) at 
37oC for 2 hours. The intensity dropped significantly indicating nucleolus proteins were 
effectively cleaved. (B) Purified nucleoli were incubated with C1 complex (9.6 μg/ml) in the 
presence or absence of C1-Inh (160 μg/ml) at 37oC for 5, 15 or 30 minutes. Cleavage of 
nucleolus protein by C1 complex was rapid. Cleavage can be inhibited by C1-Inh.  
 
4.4 B23, A NOVEL SUBSTRATE FOR C1s 
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4.4.1. B23 is an autoantigen involved in SLE 
B23 is an abundant nucleolar protein. It was first identified in rat liver cells by two-
dimensional polyacrylamide gel electrophoresis (Orrick et al., 1973). Human B23 
gene is 23 kb on chromosome 5q35 consisting 12 exons that can be transcribed into 
three variants. B23 variant 1 is the longest variant consisting of 294 amino acids (Fig 
4.6 A). B23 consists of four distinct domains with different functional properties: the 
N-terminal core domain (oligomerization domain), the acidic stretches, the basic 
domain and the C-terminal aromatic domain (Frehlick et al., 2007; Hingorani et al., 
2000; Okuwaki, 2008; Okuwaki et al., 2001) (Fig 4.6 B). It has been reported to be an 
autoantigen associated with SLE (Li et al., 1989).   
 
 
Figure 4.6 Domain organization of B23. (A) Amino acid sequence of B23 from N-terminus 
to C-terminus. (B) Schematic illustration of B23 domain organization: N-terminal core 
domain (oligomerization domain), the acidic stretches, the basic domain and the C-terminal 
aromatic domain.   
 
Sandwich ELISA was performed to detect the serum level of B23 in SLE patients 
(Fig 4.7). Polyclonal rabbit anti-B23 was coated on ELISA plate at 0.1 μg/ml in PBS. 
Plate was then blocked with 0.1% (v/v) PBS-Tween 20 before incubating for 1 hour 
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with SLE patient sera that were diluted 10 times in blocking buffer. Patient sera were 
categorized into two groups based on the level of C1q autoantibody detected: high 
C1q autoantibody (A, C, D, F, H, I, K, T, W, Z) and low C1q autoantibody (G, L, M, 
N, O, R, S, U, V, X). As a negative control, plates were incubated with similarly  
diluted normal serum. Purified B23 was incubated at 1μg/ml as positive control. 
Bound B23 was detected with a monoclonal anti-B23 antibody and subsequently a 
secondary goat anti-mouse IgG (HRP).  
 
As shown in Figure 4.7, the plate showed low background binding to normal serum. 
Elevated level of B23 in all SLE patient sera was observed. In one of the sera 
containing higher level of B23, the absorbance was close to positive control (1 μg/ml). 
These results showed that B23 was undetectable in normal serum but it was detectable 
in SLE patient sera, suggesting impairment in apoptotic cell clearance and excessive 
release of cellular proteins, including nucleolar proteins, from apoptotic cells. The 
serum B23 detected could be either apoptotic bodies or soluble protein. C1q 
autoantibody levels in these SLE patient sera did not show significant correlation with 
the serum B23 levels in these samples.  
 
In general, this was in line with previous finding of B23 autoantibodies in SLE patient 




Figure 4.7 Detection of B23 in SLE patient sera. ELISA plate was coated with polyclonal 
rabbit anti-B23 antibody (0.1ug/ml) and incubated with 10 times diluted SLE patient sera. 
Healthy serum was used as negative control and purified B23 (1 μg/ml) was used as positive 
control. Elevated serum B23 level was detected across all SLE samples.  
 
4.4.2. B23 partially colocalized with C1q in apoptotic HeLa cells  
We further examined the relative cellular localization of B23 in HeLa and 
hepatocellular carcinoma HepG2 cells. B23 was predominantly detected on the outer 
boundary of nucleolus (Fig 4.8 A). Co-staining  with HMGB1 in these cells detected 
HMGB1 inside the lumen of nucleolus, which was enclosed by B23 (Fig 4.8 A). The 
B23 signal was under the heterochromatin and appeared to define an outer boundary 
of nucleolus.  
 
Next, B23 was co-stained in C1q-bound apoptotic HeLa cells (Fig 4.8 B). Cell 
apoptosis was induced by UV-irradiation. C1q and B23 showed no staining of non-
irradiated cells that were not detergent permeablized (Fig 4.8, B a). One hour after 
UV irradiation (Fig 4.8, B b), C1q showed binding in the cytoplasm, but not in the 




Figure 4.8 C1q colocalizes with nucleolus protein B23. (A) IF staining of DNA (blue), 
HMGB1 (green) and B23 (red) in HeLa cells (upper panel) and HepG2 cells (lower panel). 
B23 defined the outer surface of nucleolus. (B) IF staining of C1q (red) and B23 (green) in 
apoptotic HeLa cells. C1q colocallized with B23 in late apoptotic HeLa cell nucleolus, but 
C1q did not colocalize with the cytoplasmic B23. Images were captured using Olympus 
Fluoview FV1000 and analyzed with the Imaris 7.6.4 software.  Scale bars represent 10 μm.  
 
hours (Fig 4.8, B c), B23 signals began to translocate from the nucleus to the 
cytoplasm and C1q also started to bind to the nucleolus where a fraction of B23 
remained. By 6 hours (Fig 4.8, B d), C1q bound intensively to nucleolus where it 
colocalized with B23. When apoptosis progressed beyond 6 hours, both C1q binding 
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and B23 staining began to defuse from the nucleus and the colocalization of the two 
proteins became partial (Fig 4.8, B e,f). C1q did not appear to colocalize with 
cytoplasmic B23, which suggested that B23 was probably not a ligand for C1q. 
Colocalization of C1q and B23 in the nucleolus might also mean that they were in 
close proximity with each other. C1q either only bound to the nucleolar form of B23 
or it simply bound near B23 in nucleolus.  
 
4.4.3. Identification of potential C1s cleavage sites on B23 
We have previously set three criteria for the screening of candidate C1s substrates in 
this study: 1) SLE autoantigens or DAMPs; 2) cellular proteins that localize closely to 
C1q-bound regions or structures in apoptotic cells; 3) abundant cellular proteins 
which have multiple binding partners. B23 fits into all three criteria: its exposure and 
eventual release into extracellular environment and detection in SLE sera, its reported 
autoantibody in autoimmune disease patients (Li et al., 1989), and its partial co-
localization with C1q. It is also abundant with a central role in regulating multiple 
cellular events. Using PoPS and the C1s bioinformatics model described above, B23 




Figure 4.9 Predicted C1s cleavage sites on B23. B23 amino acid sequence from N-terminus 
to C-terminus. Domains are highlighted in different colors. The 7 cleavage sites predicted by 
PoPS were marked with inverted triangles (▼). The secondary structure as determined by 
PDB was shown below primary sequence.  
  
A total of 7 C1s cleavage sites were predicted on B23 and these are labeled by 
inverted triangles with the scores labeled in brackets (between 25.0 and 33.1779, Fig. 
4.9). Secondary structures predicted with PDB were shown under the amino acid 
sequence. Among the 7 cleavage sites, Arg45 and Arg101 were buried in Beta sheet, 
whereas the other five sites were likely to be accessible due to the absence of 
significant secondary structure. Arg277 had the lowest prediction score (25.0) because 
its P4-P4’ are all not favorable for C1s cleavage. Arg13 is likely to be exposed but the 
prediction scores was low and its P2’ was involved in beta sheet formation, which 
may hinder interaction between the C1s active site and the substrate. Arg197 had a low 
score because although exposed, only P4’ is favorable for C1s cleavage but not P1’ or 
P2’ which are of the highest impact. Arg142 was the most likely cleavage site because 
the predicated score was the highest without secondary structure being predicted in 
P4-P4’. In theory, it is accessible by C1s and favors C1s cleavage. Arg221 was the 
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second most possible cleavage site as it had the second highest score and also lacked 
secondary structure.  
 
4.4.4. B23 in purified nucleolus was cleaved by C1 complex and C1s 
We next went on to verify the predicted cleavage by incubating purified nucleolus 
with C1 complex and B23 cleavage was judged by Western blotting (Fig 4.10). 
Reaction was set up as previously described in section 4.3.3. Purified nucleoli were 
incubated with C1 complex (9.6 μg/ml) at 37oC for 2 hours. Western blotting was 
performed using monoclonal antibody against B23 and polyclonal antibody against 
C1s. When nucleolus was incubated alone without C1 complex, B23 remained intact 
as a 35-kDa protein and no degradation was detected. When nucleoli were incubated 
with C1 complex, B23 was completely degraded leaving no fragment. Meanwhile, 
C1s was detected in its enzymatically active two-chain form (56 kDa and 27 kDa). 
When C1-Inh was included, C1 complex appeared to be effectively inhibited as C1s 
was detected in its single-chain proenzyme form (83 kDa). B23 degradation was also 
diminished. When C1 complex was incubated alone, C1s was also activated. The 
autoactivation of C1r probably occurred through intramolecular autocatalysis 




Figure 4.10 C1 cleavage of B23 in purified nucleolus. Purified nucleolus was incubated 
with C1 complex (9.6 μg/ml) in the presence or absence of C1-Inh (160 μg/ml) at 37oC for 2 
hours. Western blot analysis using mouse anti-B23 antibody showed that B23 was completely 
cleaved after incubating with C1 complex. C1-Inh blocked B23 degradation by C1 complex. 
C1s was also inhibited from being activated into its two-chain active form (56 kDa and 27 
kDa) when C1-Inh was present.  
 
The inhibition of B23 degradation by C1-Inh suggested that C1s was most likely 
responsible for B23 degradation. The reason that no defined B23 fragments were 
detected after nucleolus incubation with C1 is not fully understood. It is possible that, 
after C1s first initiated the cleavage at certain sites, the dense nucleolar structure 
might unwind leading to exposure of nucleolar proteases that further degrade the B23 
fragments into non-detectable ones. Secondly, B23 was detected with a monoclonal 
antibody and the B23 fragment that bears the epitope may be too short for effective 
detection. These require further verification with purified B23. In general, these 




4.4.5. Recombinant B23 was cleaved by C1s and C1 complex 
  
4.4.5.1. Purification of recombinant B23 from the E. coli expression system  
To better characterize C1s cleavage of B23, prokaryotic expression of B23 was made 
and recombinant B23 was purified. B23 was cloned into the pET-28a+ vector with N-
terminal His-tag and transformed into E.coli BL21. His-tagged B23 expression was 
induced at the logarithmic growth phase by adding IPTG to 1 μM. Cells were lysed 
by sonication at 70% amplitude for 10 minutes in cold TBS (10 mM Tris and 150 mM 
NaCl, pH 7.4). Cell debris was pelleted by centrifugation for 30 minutes at 20,000 
rpm and 4oC, and the supernatant was harvested. As a control, E.coli BL21 was 
transformed with the pET28 vector that lacks the B23 gene insert. SDS-PAGE 
(12.5%) shows that from E. coli BL21 transformed with the B23 gene, the level of a 
35 kDa protein was elevated in cell lysates and supernatants (Fig 4.11 A). Supernatant 
was then incubated with Ni-NTA resin.  
 
Majority of proteins in the supernatant passed through the Ni-NTA column without 
binding. Column was then washed with 50 mM imidazole and eluted using an elution 
buffer containing 250 mM imidazole (Fig 4.11, B). Majority of the bound proteins 
were eluted in the first fraction in which a major 35-kDa band, equivalent to B23, and 
low levels of lower molecular materials were detected (Fig 4.11, B). This was further 








Figure 4.11 Purification of B23 from E.coli culture. E.Coli BL21 was transformed with 
pET28 vector containing B23 gene sequence. B23 protein expression was induced as shown 
by SDS-PAGE blue silver staining (indicated by arrows) (A). Supernatants were then loaded 
on Ni-NTA column for purification. His-tagged B23 was eluted in the first elution fraction 
(B). E1 was then passed through Superose 6 gel filtration column (C). Fractions having the 
highest absorbance as indicated in C were loaded on SDS-PAGE (12.5%) and blue silver 
staining showed that protein was relatively pure (D). 
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4.4.5.2. Recombinant B23 was cleaved by C1s  
Purified His-tagged B23 (25 μg/ml) was incubated with C1 complex (9.6 μg/ml) in a 
cleavage buffer (10 mM Tris, 150 mM NaCl, 3.3 mM CaCl2, pH 7.4) for 2 hours at 
37°C. After 2 hours incubation with C1 complex, the 35-kDa B23 band disappeared 
and several smaller fragments appeared as judged by blue silver staining (Fig 4.12 A). 
B23 cleavage was completely inhibited when C1-Inh was incubated in the reaction 
(160 μg/ml) (Fig 4.12 A). When C1-Inh concentration in the reaction was titrated 
down, the B23 cleavage by C1 complex was restored in a C1-inh dose-dependent 
manner over a period of 2 hours (Fig 4.12 B). The fact that B23 fragments produced 
by C1 complex were distinct and it could be inhibited by C1-Inh, suggested that the 
cleavage was specific attributing to the activity of C1s.  
 
 
Figure 4.12 His-tagged B23 was cleaved specifically by C1 complex. (A) C1 complex 
digestion of His-tagged B23 yielded several distant bands. Cleavage was blocked when C1 
inhibitor was incubated together. (B) The inhibition of cleavage by C1 inhibitor was dose 
dependent. Reaction mixtures were separated with 15% SDS- PAGE under reducing 
condition (DTT).   
 
136 
4.4.5.3. C1 complex cleaves His-tagged B23 in a dose-dependent manner  
Purified B23 (25 μg/ml) was the incubated with different concentrations of C1 
complex (from 19.2 μg/ml to 0.15 μg/ml) for 2 hours at 37°C in the cleavage buffer. 
B23 cleavage was assessed by Western blotting. As the concentration of C1 complex 
increases, His-tagged B23 was increasingly cleaved, yielding an increasing amount of 
cleavage product. The most distinct B23 cleavage products seen by blue silver 
staining were three fragments with one being 25 kDa and two other fragments of 
approx.17 kDa (Fig 4.13 A).  
 
 
Figure 4.13 C1 cleavage of His-tagged B23 was dose dependent.  C1 complex digestion of 
His-tagged B23 yielded two distant bands that contained the C-terminal of the protein, which 
can be detected by mouse anti-B23 antibody. The cleavage of His-tagged B23 by C1 complex 
was dose dependent. Reaction mixtures were separated with 15% SDS- PAGE under 
denaturing condition (DTT) (A) and western blot detections were done with mouse 
monoclonal anti-B23 (B).  
 
By Western blotting, the smaller fragments were detected by the monoclonal mouse 
anti-B23 antibody, which recognizes the C-terminus of B23. The decreasing intensity 
of full length His-tagged B23 and increasing intensity of B23 fragments generated 
with the increasing amount of C1 complex, were consistent with blue silver staining. 
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This suggested that the two B23 fragments contained the C-terminal end of His-
tagged B23. The evaluation of C1s cleavage sites on His-tagged B23 will be further 
discussed in section 4.4.6. 
 
4.4.5.4. B23 was more efficiently cleaved by C1 complex compared with 
purified C1s  
His-tagged B23 (25 μg/ml) was also incubated with purified, activated C1s at 
different concentrations (from 61 μg/ml to 1 μg/ml, serial diluted) for 2 hours at 37°C 
in the cleavage buffer. B23 was cleaved by C1s into distinct fragments (Fig 4.14). 
However, even when C1s concentration was used at 61 μg/ml, the cleavage of His-
tagged B23 remained incomplete. B23 cleavage was more effective with C1 and 
complete cleavage was achieved with even less C1 (19.2 μg/ml). Considering C1 
complex has a much larger molecular weight comparing to C1s and each C1 contains 
two C1s molecules (790 kDa and 83 kDa respectively), the molarity of activated C1s 
used was 15 times more than that with C1 complex in these experiments. This 
suggested that C1s is catalytically more active or it makes better contacts with 
substrate when it is in the context of C1 complex.  
 
It is also noted that there were differences in B23 fragments generated after cleavage 
with C1 and C1s. Previously when C1 complex was used, three fragments were 
generated (Fig 4.13), whereas here only one distinct fragment can be defined under 
blue silver staining (around 25 kDa). There could be two possibilities: 1) multiple 
cleavage sites were predicted on B23 and C1s may cleave the protein in a sequential 
manner.  Since C1s cleavage was less efficient compared to C1 complex, incubation 
for 2 hours with C1s may only cause limited cleavage of B23 so that only a larger, 
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intermediate B23 fragment was generated at this stage or 2) the cleavage occurred 
much slower with C1s as only a fraction of His-tagged B23 was cleaved and therefore 




Figure 4.14 C1s cleaves His-tagged B23 less efficiently as compared to C1 complex. 25 
μg/ml of prokaryotic expressed His-tagged B23 was incubated with activated C1s (from 61 
μg/ml to 1 μg/ml, serial diluted) for 2 hours at 37°C. The reaction mixtures were subsequently 
separated by 15% SDS-PAGE under reducing condition (DTT). His-tagged B23 was not 
completely cleaved after 2 hours incubation even when C1s was used at a higher 
concentration (61 μg/ml).  
 
4.4.5.5. C1 complex cleaves C4 and B23 into characteristic fragments  
To further verify the proteolytic specificity of C1 complex, it was incubated with its 
well-defined substrate C4 in comparison with His-tagged B23 and BSA (Fig 4.15). 
No cleavage was observed on BSA by C1 complex. C4 was cleaved at its 
139 
characteristic C4 α-chain. It was expected to yield two fragments: a small C4a (9 
kDa), which is too small to view on SDS-PAGE, and a larger α ,́ which migrates 
slightly faster than the original α-chain (K. Reid, 1986). This was observed in this 
experiment although the cleavage of C4a was partial (Fig 4.15). β- and γ-chains were 
not cleaved as expected and they are expected to be linked with α ́-chain via disulfide 
bond to form C4b. His-tagged B23 was almost completely digested and this gave rise 
to two bands of approx. 18 kDa and potentially slmaller fragments overlapping with 
the front dye. When C1-Inh was included, cleavage of B23 and C4 were both largely 
blocked. Hence, the cleavage of His-tagged B23 by C1 complex reflects a specific 
property of C1 proteases or C1s.  
 
 
Figure 4.15 C1 complex cleaves C4 and B23 into characteristic fragments. C4, His-
tagged B23 and BSA were incubated with C1 complex at 37°C for 2 hours. C1s cleaved C4 
α-chain to a C4a peptide (not detected) and α  ́polypeptide (marked with ←) as expected. His-
tagged B23 was efficiently cleaved yielding distinct fragments. However, C1s did not cleave 




4.4.6. Evaluation of C1s cleavage sites on recombinant B23 
To determine whether B23 was cleaved at the sites predicted by PoPS, recombinant 
V5-tagged B23 was used as substrate. Purified V5-B23 was coated on ELISA plate at 
100 μg/ml. Unbound protein was washed away and then C1 complex was added at 2.4 
μg/ml in the cleavage buffer. After incubation at 4oC for 3 hours with gentle shaking, 
cleavage buffer was added. Unbound C1 complex was washed off and the plate was 
then incubated at 37oC for 2 hours. Proteins were eluted using 5 × SDS loading buffer 
containing DTT and incubated at 37oC for 30 minutes before SDS-PAGE analysis.  
 
Western blot analysis was carried out using three different antibodies, which 
recognize different regions on V5-tagged B23 (Fig 4.15 AB). Using a monoclonal 
mouse antibody against the C-terminus of B23, two distinct fragments of approx. 11 
kDa and 17 kDa were detected. With polyclonal rabbit anti-B23 antibody, which 
detect two acidic domains in the middle of the B23 molecule, two major 24 kDa and 
17 kDa bands and one minor 16 kDa band were detected. With a monoclonal antibody 
against the N-terminal V5 tag, two major bands of 24 kDa and 18 kDa were detected.  
 
The most likely C1s cleavage sites on B23, as predicted by PoPS, are highlighted by 
black triangles in Fig 4.16 C. These fragments are estimated to be 17.45 kDa, 8.6 kDa 
and 8.27 kDa if cleavage is complete (http:// 
www.bioinformatics.org/sms/prot_mw.html). Considering the full-length protein 
appeared to be larger on the gel than predicted, the actual fragments generated after 
cleavage were expected to be no smaller than the calculated sizes. Epitopes 
recognized by the antibodies were highlighted in different colors. As the mouse anti-
B23 and anti-V5 antibodies detect the extreme C-terminal and N-terminal ends of the 
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V5-B23, any fragment generated by C1s cleavage would not be detected 
simultaneously by both antibodies. This was exactly what was observed in this 
experiment.  
 
Overall, the results can be interpreted as follows: 1) the 17 kDa fragment detected by 
mouse anti-B23 antibody and 18 kDa fragment detected by mouse anti-V5 antibody 
were likely to compliment each other by a cut at R142 (generating F1 and F2+F3); 2) 
the 24 kDa fragment detected by rabbit anti-B23 antibody and 25 kDa fragment 
detected by mouse anti-V5 antibody were likely to be the same fragment (slightly 
differences in sample migration was expected on difference gel), and it could 
complement the 11kDa fragment detected by mouse anti-B23 antibody. The cleavage 
was unlikely to have occurred at R221 because that would generate a 26.06 kDa 
fragment and an 8.27 kDa fragment instead. In this case, the cleavage seemed to be 
occurring at R197, which gave rise to two fragments of 23.5 kDa and 10.83 kDa.  
 
In summary, from the in-vitro digestion of V5-tagged B23, it was determined that C1s 
cleaves B23 at two or more sites and they were likely to be R142 and R197. Based on 
these results, we went on to evaluate C1s cleavage sites on B23 by site directed 
mutagenesis on R142 and R197. Since R221 scored highly by PoPS, and was located 





Figure 4.16 Cleavage of V5-tagged B23 was consistent with PoPS predicted cleavage 
sites. (A) Western blot analysis of C1s cleavage products of B23. Multiple fragments were 
detected using different antibodies. (B) Schematic overview of V5-B23 domain organizations 
and epitopes covered by different antibodies. (C) PoPS predicted two major cleavage sites at 
R142 and R221 (highlighted with black inverted triangle). The complete cleavage at these two 
sites will yield the generation of three fragments: F1, F2 and F3. Based on the Western blot 
analysis (A), cleavage was unlikely to occur at R221 but more likely to occur at R197 
highlighted with a grey inverted triangle.  
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4.4.7. Evaluation of C1s cleavage sites on His-tagged B23 by site directed 
mutagenesis  
Site directed mutagenesis was performed on expression plasmid pET-28a+ carrying 
B23 genes with an N-terminal His tag. Four constructs were created: R142A, R197A, 
R221A and triple mutation containing all three mutated sites. Mutant proteins were 
purified following the method described in section 4.4.5.1. The purity of the proteins 
was assessed by SDS-PAGE followed by blue silver staining (Fig 4.17).  
 
 
Figure 4.17 Purification of His-tagged B23 mutant proteins. Four mutant proteins were 
purified using the same method as the WT His-tagged B23. Fractions from Superose 6 gel 
filtration column were analyzed on SDS-PAGE to assess purify of the proteins.  
 
C1 complex (9.6 μg/ml) was then incubated with four mutant proteins and wild type 
(WT) His-tagged B23 (25 μg/ml) at 37oC for 24 hours (Fig 4.18). By blue silver 
staining (Fig 4.18 A), the 35kDa bands disappeared after incubation with C1 complex, 
indicating all proteins including WT and all four mutants were cleaved by C1 
complex. However, different cleavage products were generated. For WT, mutants 
R197A and R221A, cleavage pattern seemed to be the same with two visible 
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fragments generated around 17 kDa. For mutant R142A and the triple mutant, only 




Figure 4.18 C1 cleavage of His-tagged B23 and mutant proteins. C1 complex (9.6 μg/ml) 
was incubated with His-tagged B23 and four mutants (25 μg/ml). (A) Blue silver staining 
showed that R142A and triple mutant had different cleavage product (indicated by arrows) as 
compared to WT. (B) Western blot analysis using mouse anti-B23, rabbit anti-B23 and goat 
anti-C1s antibodies.  
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Western blot showed consistent results with blue silver staining (Fig 4.18 B). Overall, 
cleavage patterns for WT, R197A and R221A were similar. Using monoclonal mouse 
anti-B23 antibody, an 11 kDa fragment was detected across all samples, but were 
strongest for R142A and the triple mutant. Polyclonal rabbit antibody detected two 
bands around 25 kDa and was also particularly strong for R142A and the triple 
mutant. This clearly indicated that mutation at R142 had an impact on how C1s would 
cleave the protein. Single mutation at R197 and R221 did not seem to affect the 
cleavage. However, triple mutations at all three sites seemed to render C1s cleavage 
more than single mutation at R142.  
 
 
Figure 4.19 Detection of C1 cleavage of His-tagged B23 and mutants at various time 
points. His-tagged B23 or the triple mutant (25 μg/ml) was incubated with C1 complex (9.6 
μg/ml) for 30minutes, 2 hours or 24 hours. The reaction mixtures were subsequently 
separated by 15% SDS-PAGE under reducing condition (DTT) and Western blot detection 
with monoclonal mouse anti-B23, polyclonal rabbit anti-B23 and polyclonal goat anti-C1s 
antibodies was done after transfer onto PVDF membrane.  
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Next, we compared C1 cleavage of wild type His-tagged B23 with triple mutant 
protein (Fig 4.19). 25 μg/ml of protein was incubated with 9.6 μg/ml of C1 complex 
at various time points (30 minutes, 2 hours, and 24 hours). The mutant protein was 
more resistant to C1 cleavage (Fig 4.18, using monoclonal mouse anti-B23). By 30 
minutes, majority of WT His-tagged B23 was cleaved whereas mutant protein wasn’t 
effectively cleaved until 2 hours. B23 was likely to be cleaved in a step-wise manner 
since multiple cleavage sites were predicted. The 17kDa fragment was first generated 
but soon started to disappear, possibly further cleaved into smaller fragments or 
degraded during prolonged incubation. The 11kDa fragment however, seemed to be 
more resistant and degraded only after the 17kDa had degraded. For mutant protein, 
the 17 kDa fragment wasn’t detectable after 2 hours either. However, the smaller 
fragment accumulated instead of being cleaved or degraded during prolonged 
incubation. This indicated that the 11kDa cleavage product of the mutant was more 
resistant to enzymatic degradation. Using polyclonal rabbit anti B23 antibody, 
cleavage products were detected at a higher amount as compared to WT His-tagged 
B23 at each time point, which could also be an indicator of higher resistance to 
degradation considering the full length protein was actually cleaved much more 
slowly. The cleavage of both WT and mutant B23 was completely blocked by adding 
in 160 μg/ml of C1-Inh to the reaction prior to 37oC incubation. This ensured that the 
enzymatic process was initiated by C1 complex.  
 
In summary, mutation of all three potential C1s cleavage sites did not block C1 
cleavage of the mutant His-tagged B23. In general, the number and size of the 
cleavage products remained the same. This however, did increase the resistance of the 
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protein, including its cleavage products, to the enzymatic digestion of C1. Mutation of 
R142 was likely to affect C1s cleavage the most, while single mutation of R197 or R221 
did not have major effect on the cleavage. Hypothetically, although not reported, it is 
possible that C1s might cleave B23 at sites other than arginine, for example lysine 
sharing similar structure and charge with arginine. This could explain why mutation 
of arginine did not block the cleavage but mutation on R142, which was right next to a 
lysine residue, affected cleavage efficiency greatly, while mutations of the other two 
arginine residues that are further away from any lysine residue did not render the 
kinetics of cleavage. 
  
4.4.8. The role of C4 in mediating C1s cleavage 
C4 and C2 are known substrates of C1s in the initiating steps of complement classical 
pathway. Physiologically, C4 plays an important role in initiating subsequent 
enzymatic reactions because the cleavage of C2 by C1s requires the binding of C4b to 
C2 (K. Reid, 1986; K. B. Reid et al., 1986). In our study, B23 is also cleaved by C1s. 
It would be interesting to investigate whether C4 or C4b plays a role in mediating C1s 
cleavage of B23. If C4b could bind to B23, it will mimic the relationship between 
C4b and C2, which could possibly enhance the cleavage efficiency. 
 
C4 was included in the cleavage reaction to examine its effect on the cleavage (Fig 
4.20). ELISA plate was first coated with 10 μg/ml of IgG to enhance the activation of 
C1 complex in the subsequent experiment. C1, C4 and B23 was then mixed quickly to 
final concentration of 4.8 μg/ml, 25 μg/ml and 50 μg/ml respectively and added into 




Figure 4.20 C4 in mediating C1s cleavage of B23. His-tagged B23 (25 μg/ml) was 
incubated with C1 complex (9.6 μg/ml) in the presence or absence of C4 for 2 hours at 37oC. 
Different amount of C4 were used (A, 25 μg/ml; B, 300 μg/ml). The reaction mixtures were 
subsequently separated by SDS-PAGE under reducing condition (DTT) and Western blot 
detection with monoclonal mouse anti-B23 and polyclonal goat anti-C1s antibodies was done 
after transferred onto PVDF membrane. 
 
Western blot analysis (Fig 4.20 A) showed that B23 was cleaved as expected when 
C1 was present, and C4 alone did not cause cleavage of B23. When C1 and C4 were 
incubated together with B23, less B23 was cleaved judging by the stronger band at 35 
kDa, but the difference was not significant. We then increased the amount of C4 used 
in the reaction to 300 μg/ml, which was closer to its physiological concentration (400 
μg/ml) (Fig 4.20, B). However, this seem to have slowed down the C1s cleavage of 
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B23 more because the 35 kDa band was stronger when C4 was present with C1 
compared to when B23 was incubated with C1 alone. These results indicated that C4 
is more likely to compete with B23 in C1s cleavage rather than to help speed up the 
cleavage. This also indicated the specificity of C1s cleavage of B23. 
 
4.4.9. Evaluation of C1q interaction with V5-tagged B23 
In chapter 3, it was demonstrated that C1q co-localized with apoptotic cell nucleolus 
and could bind to purified nucleolus. Co-staining of C1q and B23 showed partial co-
localization. B23 is an abundant nucleolar protein with important functions and often 
used as a nucleolus marker. If C1q could bind to B23, the presence of B23 in 
nucleolus would increase the possibility of C1 complex being recruited to nucleolus 
in the event of cell apoptosis. When B23 is exposed and released into apoptotic 
supernatant, it could attract C1 complex to the protein itself or to any protein complex 
in which it is part of. This could increase the chance of subsequent enzymatic 
cleavage of potential immunogenic nucleolar proteins by C1s. Thus, with purified V5-
tagged B23, we next examined C1q interaction with V5-tagged B23 by ELISA.  
 
Purified V5-tagged B23 was coated on ELISA plate at various concentrations for 
evaluation of C1q binding. Plate bound B23 was detected by incubation with the 
monoclonal mouse anti-V5 antibody (Fig 4.21 A, blue bar). The coated fractions were 
also incubated with C1q (50 μg/ml) for 3 hours at room temperature and bound C1q 
was detected using the monoclonal mouse anti-C1q antibody and a secondary goat 
anti-mouse IgG (HRP) (Fig 4.21 A, red bar). The absorption at 450 nm of bound C1q 
was generally in line with the profile of the coated B23. More C1q was detected when 





Figure 4.21 Detection of C1q binding with purified V5-tagged B23 using protein coated 
at various concentration. (A) V5-tagged B23 was coated on ELISA plate with progressively 
decreasing concentration as labeled on X-axis. PBS was coated on plate as negative control.  
Blue bar: monoclonal anti-V5 antibody was used to detect the coated V5-B23. Red bar: 
monoclonal anti-C1q antibody was used to detect the amount of C1q bound to V5-B23. Green 
bar: monoclonal anti-C1q antibody was used to detect the cross-reactivity with V5-B23 
without C1q added. (B) C1q was coated on ELISA plate with progressively decreasing 
concentration as labeled on X-axis. PBS was coated on plate as negative control.  Blue bar: 
monoclonal anti-C1q antibody was used to detect the coated C1q. Red bar: monoclonal anti-
V5 antibody was used to detect the amount of V5-B23 bound to C1q. Green bar: monoclonal 
anti-V5 antibody was used to detect the cross-reactivity with C1q without V5-B23 added. Y-
axis shows the absorbance at 450nm.  
 
could cross-react with proteins coated on the plate, we incubated anti-C1q antibody 
with coated B23 without adding in C1q. No significant signals were detected, 
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showing that there was no cross-reaction between the anti-C1q antibody and the 
coated B23 (Fig 4.21 A, green bar).   
 
Similarly, C1q was also coated on the plate at various concentrations and purified V5-
tagged B23 was added to evaluate the binding. The absorption for coated C1q was 
barely detectable, and exhibited only background absorption when the concentration 
went below 0.25 μg/ml (Fig 4.21 B, blue bar). However, absorption of bound V5-
tagged B23 showed a gradual decreasing trend from 0.25 μg/ml to 0 μg/ml C1q 
coating (Fig 4.21 B, red bar). The anti-V5 antibody had no cross-reaction with coated 
C1q (Fig 4.21 B, green bar).  
 
Although the absorbance of protein added was generally in line with the amount of 
protein coated on plates, it was only so when very small amount of protein was used 
to coat the plate. When higher amount of protein was used to coat the plate (more than 
1 μg/ml), the absorbance decreases as more protein was added (data not shown). This 
was far below the binding capacity of the ELISA plate (1 μg per well). Small amount 
of protein coated on plate may actually affect the stability of the assay. Thus, constant 
and sufficient amount of protein was coated on the plate to saturate the binding 
capacity of the plate while the other protein of decreasing concentration was added in 
to evaluate the interaction. First, V5-tagged B23 was coated on plate at 16 μg/ml. 
After washing and blocking, C1q was added in at decreasing concentrations (10 μg/ml, 
1 μg/ml, 0.1 μg/ml and 0.01 μg/ml). Anti-C1q antibody showed no cross-reaction 




Figure 4.22 Evaluation of C1q binding with purified V5-tagged B23 using protein coated 
at constant amount.  (A) V5-tagegd B23 was coated on ELISA plate at 16 μg/ml. PBS was 
coated on the plate as negative control. C1q was added to incubate with coated V5-B23 at 
decreasing concentration as labeled on X-axis Blue bar: monoclonal anti-C1q antibody was 
used to detect the bound the amount of C1q bound to V5-B23. Green bar: monoclonal anti-
C1q antibody was used to detect the cross-reactivity with V5-B23 without C1q added. (B) 
C1q was coated on ELISA plate at 16 μg/ml. V5-B23 was added to incubate with coated C1q 
at decreasing concentration as labeled on X-axis. PBS was coated on the plate as negative 
control.  Red bar: monoclonal anti-V5 antibody was used to detect the amount of V5-B23 
bound to C1q. Green bar: monoclonal anti-V5 antibody was used to detect the cross-reactivity 
with C1q without V5-B23 added. Y-axis shows the absorbance at 450nm.  
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added in (Fig 4.22 A, blue bar). When C1q was coated and V5-tagged B23 was added 
in decreasing concentrations, decreasing trend was observed in absorbance at lower 
concentrations (Fig 4.22 B, red bar). This could be due to different sensitivities of the 
anti-V5 and anti-C1q antibodies.  
 
In summary, the data obtained so far was not sufficient to conclude the binding 
between C1q and V5-tagged B23. Only when small amount of protein was coated 
(0.25 μg/ml and below), the correlation can be observed (Fig 4.21). Otherwise, 
reversed trend can be observed (data not shown). When plate was coated with 
saturating amount of V5-B23 and C1q was added, the absorbance of bound C1q can 
be consistent the amount of C1q added (Fig 4.22 A). When saturating amount of C1q 
was immobilized and B23 was added, no clear trend was observed (Fig 4.22 B). It is 
possible that C1q could be binding to V5-B23, but the results also indicated the 
existence of other forms of interactions at the same time that accounts for the results 
observed. 
 
4.5 IDENTIFICATION OF OTHER C1S SUBSTRATES 
 
It was demonstrated in previous sections that C1q could bind to purified nucleolus 
and C1s cleaved nucleolar proteins including B23. By western blotting, nucleolar B23 
was completely cleaved after 2 hours incubation with C1 complex, and the cleavage 
was completely blocked by the addition of C1 inhibitor (Fig 4.10). We continued to 
probe for other abundant nucleolar protein such as nucleolin (NCL). Cleavage of 







Figure 4.23 Detection of C1s cleavage of other nucleolar proteins. PoPS was used to 
screen for C1s cleavage sites on NCL (A) and histone H3.1 (B). Candidate cleavage sites 
were highlighted with inverted triangle. (C) Purified nucleolus was incubated with C1 
complex (9.6 μg/ml) in the presence or absence of C1 inhibitor (160 μg/ml) at 37oC for 2 
hours. Western blot analysis using polyclonal rabbit anti-NCL antibody and rabbit polyclonal 
anti-histone H3 antibody showed that NCL was completely cleaved by C1 complex while H3 
was largely resistant.   
 
Without incubating with C1 complex, NCL in nucleolus exhibited multiple bands at 
around 70 kDa (Fig 4.23). After nucleolus was incubated with C1 complex (9.6 
μg/ml), NCL was completely cleaved. When C1-Inh (160 μg/ml) was incubated 
together with C1 complex and nucleolus, cleavage of NCL was strongly inhibited. For 
histone H3, only a minor fraction was cleaved after C1 complex treatment. And the 
cleavage was blocked when C1-Inh was present. Two bands (56 kDa and 27 kDa) 
were detected by C1s antibody indicating it was highly activated after incubation. 
These results showed that although C1 complex was highly activated and cleaves 
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certain nucleolar proteins very rapidly, some proteins could be resistant to C1s 
cleavage, for example histone H3.  
 
This is in agreement with the PoPS prediction that NCL has multiple sites predicted to 
be accessible and cleavable by C1s (Fig 4.23 A). Histone H3 also has a few predicted 
cleavable sites but hardly accessible based on the secondary structure at the particular 
site (Fig 4.23 B). Also, as total histone H3 consists of many variants and prediction 
was only done for H3.1, it is possible that other H3 variants are more sensitive to C1s 
cleavage compared to H3.1.  
 
4.6 SUMMARY  
 
In the previous chapter, C1q binding to the nucleolus of late apoptotic cells raises the 
hypothesis that the binding may activate C1s, which may lead to subsequent cleavage 
of nucleolar proteins. In this part of the study, C1s cleavage of cellular proteins were 
tested and investigated in detail.  
 
ACs release cellular proteins at different stages as danger signals or autoantigens. C1s 
cleavage of these circulating proteins may help to protect against autoimmunity. Our 
data showed that ACs release cellular protein progressively (Fig 4.1). Incubation of 
C1s with ACs leads to the cleavage of cellular proteins, which was shown by the 
reduction of several bands intensity detected in the ACs supernatant (Fig 4.4). 
Western blot analysis of ACs supernatant revealed many nuclear proteins, including 
some nucleolar proteins, were released into ACs supernatant. Isolated nucleolus was 
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then incubated with C1 complex and it was shown that nucleolar proteins were 
cleaved in a time-dependent manner (Fig 4.5).  
 
B23 is an abundant nucleolar protein with multiple important functions. It has been 
shown to be an autoantigen correlated with one subset of SLE patients positive in aCL 
(Fig 4.7) (Li et al., 1989). Moreover, it largely colocalized with C1q in late apoptotic 
HeLa cell nucelolus (Fig 4.8). These results raised the possibility that B23 may be 
cleaved by C1s, which can be recruited to cell nucleolus by C1q during late apoptosis.  
PoPS prediction on B23 using C1s bioinformatics model scored highly on several 
potential cleavage sites  (Fig 4.9). Using purified nucleolus, we demonstrated that 
B23 was cleaved by C1s (Fig 4.10). Using recombinant B23, C1s cleavage of B23 
was shown to be dose-dependent (Fig 4.13), and specific (Figs 4.12, 4.15). We have 
also shown that C1s cleaves more efficiently in the context of C1 complex, which is 
its physiological form (Fig 4.14). We also evaluated the predicted cleavage sites by 
performing site-directed mutagenesis on the three potential cleavage sites of WT His-
tagged B23 and examined C1s cleavage of the mutants. The triple mutant was shown 
to be more resistant to C1s cleavage but the cleavage was not completely blocked 
(Figs 4.18, 4.19). By including C4 in the cleavage experiment, C1s cleavage of B23 
became less efficient (Fig 4.20), indicating that C4b may not be involved in mediating 
C1s cleavage of B23. C1q interaction with B23 was evaluated using ELISA (Figs 
4.21, 4.22). Results indicated that C1q may be binding to B23 but other form of 
interaction could exist. Finally, another nucleolar protein NCL was also shown to be 




Chapter 5 Discussion  
 
5.1 C1Q BINDING TO APOPTOTIC NUCLEOLUS AND ITS IMPLICATION 
IN APOPTOTIC CELL CLEARANCE 
The immune system is constantly exposed to apoptotic cells. Complement system, as 
an important arm of innate immunity, plays a critical role in maintaining self-
tolerance. C1q, as the recognition unit of the classical complement pathway, has been 
actively investigated on its role in maintaining tolerance, especially in C1q-mediated 
apoptotic cells clearance. C1q enhances apoptotic cell clearance in multiple 
mechanisms including C3b-dependent and C3b-independent opsonizations. In human, 
deficiency of C1q almost always leads to the pathogenesis of autoimmune disease 
SLE (Lewis & Botto, 2006). In murine model, knockout of C1q is found to be 
associated with excessive amount of apoptotic bodies in mice kidney and blood 
circulation (Urbonaviciute et al., 2008).  
 
The association of C1q deficiency with autoimmunity in terms of apoptotic cell 
clearance is definite. Up to date, C1q interaction with ACs has been studied 
extensively, and a few C1q ligands on ACs have been reported and characterized 
(Korb & Ahearn, 1997; Ogden et al., 2001). However, the nature of the C1q binding 
with ACs requires further characterization. In this project, we first introduced 
apoptosis in HeLa cells by UV irradiation, and investigated the subcellular 
localization of C1q binding and the temporal changes in the course of the apoptosis 
progressively from early stages to late stages. Surprisingly, C1q did not seem to bind 
extensively to DNA, although it is reported as one of the C1q ligands and highly 
immunogenic when it is released in the form of nucleosome (Jiang et al., 1992). 
159 
Instead, C1q binds to three subcellular regions progressively during the cell apoptosis: 
cell peripheral structure during early apoptosis, defused binding in cytoplasm during 
intermediate phase of cell apoptosis, and nucleolus during late cell apoptosis (Fig 3.5).  
 
C1q was found to bind predominantly to the cell peripheral structure 1 hour after UV-
irradiation (Fig 3.5 a). It has been reported that C1q binds to monomeric actin 
demonstrated by in vitro assay using purified human C1q and actin from rabbit 
skeletal muscle, chicken gizzard muscle and ascaris body wall (Nishioka et al., 1982). 
Here, the exact molecule or structure that C1q binds to is not determined. But it is 
highly possible that C1q is binding to an actin structure, judging by the staining 
pattern that resembles the shape of a network, which could be demonstrated by co-
staining of cytoskeletal markers with C1q in the future experiment.  
 
The staining pattern also shows certain similarities with Clec9A binding to damaged 
cells (Zhang et al., 2012). Clec9A is a DAMP receptor conserved from mouse (CD8+ 
DCs) to human (CD141+ DCs). Mouse CD8+ DCs, functionally equivalent with 
human CD141+ DCs, are particularly efficient in the uptake and processing of 
apoptotic materials, bridging innate immunity and adaptive immunity (Shortman & 
Heath, 2010). They are able to efficiently cross-present exogenous antigens via MHC 
class I, leading to either a inflammatory or tolerance response (Shortman & Heath, 
2010). The DAMP receptor Clec9A is reported to bind to its ligands and lead to the 
activation of a potent immune response (Caminschi & Shortman, 2012; Zhang et al., 
2012). In the event of cell apoptosis, Clec9A binds to dead cells via the exposed actin 
filaments and induce potent antibody production. It is believed that Clec9A only binds 
to dead cells during a short window period, when the cell membrane is ruptured but 
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the cytoskeleton is still intact from caspases proteolysis (Zhang et al., 2012). This 
window period, for HeLa cells, most likely corresponds to the 1 – 3 hours after UV-
irradiation (Fig 3.5). During this period, C1q is able to penetrate the cell membrane to 
gain access to the cytoplasm. The staining pattern of C1q at this time is still largely 
vesicular at cytoplasm, revealing the presence of abundant cytoplasmic materials. 
This raises the possibility that cytoplasmic structures, including actin filaments, are 
still relatively preserved from being demolished by caspases. Whether C1q and 
Clec9A share the same ligands in apoptotic HeLa cells is still uncertain. If, by any 
chances, they share the same binding sites, the competitive binding of C1q to these 
ligands may reduce the chance of the cells being taken up by CD8+ DCs (or CD141+ 
DCs) and subsequent potent autoantibody production. If they recognize different 
structures in cytoplasm, efficient apoptotic cell clearance mediated by C1q can still 
protect the host from autoimmunity by removing apoptotic cells via multiple 
pathways before they are exposed to Clec9A recognition. Albeit in different ways, 
C1q helps to protect against autoimmunity, and C1q deficiency will logically lead to 
the onset of autoimmune diseases. 
 
At 6 hours post UV-irradiation, C1q localizes predominantly and almost exclusively 
to the apoptotic cell nucleolus (Fig 3.5 c). Cytoskeleton is dispersed at 6 hours after 
UV-irradiation. No binding to chromatin is observed. This is unexpected because 
chromatin is already exposed at this point, but C1q seems to avoid binding to its 
ligand DNA. The binding of C1q with nucleolus heightens the importance of C1q in 
the event of autoimmunity because nucleolus is particularly rich in autoantigens.  
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The binding of C1q with nucleolus was later demonstrated by sucrose gradient 
centrifugation (Fig 3.9). After collecting all sucrose fractions, soluble C1q was only 
found on the top two fractions (0.25 M sucrose layer and 0.7 M sucrose layer). C1q 
incubated with crude nuclei extract was found to co-sediment with nucleolus at the 
bottom forming a pellet. Immunofluorescence staining revealed that C1q binds to the 
outer boundary of the chromatin, forming a circular structure outlining the nucleolus 
(Fig 3.9 C). The binding pattern is slightly different from that of C1q binding in 
apoptotic cells (Fig 3.5 c) and permeablized nucleolus (Fig 3.10 A, red). Although 
nucleolus has not been reported as a structure whose integrity is dependent on lipids, 
detergent permeablization of nucleolus does seem to affect C1q binding pattern in it. 
In non-permeablized nucleolus, C1q binds only to the periphery. In detergent 
permeablized nucleolus, C1q binds diffusely in the nucleolus. In apoptotic cell 
nucleolus, C1q binding mainly to the peripheral of nucleolus, but diffused binding 
towards the inner region of nucleolus can be seen in certain spots. Together, these 
indicate that 1) nucleolus is a well-packed structure that is largely resistant to external 
force (dense sucrose gradient centrifugation) and apoptosis; 2) detergent is able to 
disrupt the organization of nucleolus to certain extent, allowing C1q to either access 
the inner region of nucleolus, or re-organizing the ligand distribution in nucleolus so 
that the C1q binding pattern inside nuclelolus is changed; 3) by 6 hours after UV-
irradiation, nucleolus still remain mostly intact, except that C1q binds to more inner 
regions due to the two possible reasons raised above.  
 
The attempt in finding C1q nucleolar ligands was inconclusive (Fig 3.10). Five 
potential ligands were chosen based on their subcellular localization:  NCL and B23 
as nucleolus granular component (GC) markers (Fig 3.10 A, D), fibrillarin as 
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nucleolus dense fibrillar component (DFC) marker (Fig 3.10 B), HMGB1 
representing nucleolar proteins that also diffusely localized in nucleoplasm (Fig 3.10 
C), and LB1 chosen as a nuclear lamina marker (Fig 3.10 E). C1q either partially co-
localized with them (NCL, B23, HMGB1), stay in void regions within nucleolus 
(fibrillarin), or does not show any associations in localization at all (LB1). As a 
charge derived PRM, C1q can engage a broad range of ligands belonging to different 
categories (lipid, protein, and nucleic acid) (Table 1.1), Hence, elucidating C1q 
binding partner(s) in apoptotic cells becomes extremely difficult (Cooper, 1985; 
Tenner et al., 1984). To identify C1q binding partners, further investigation is 
required (for example, to examine C1q binding with RNA).  
 
5.2 OBSERVATION OF NUCLEAR DENT DURING CELL APOPTOSIS  
During cell apoptosis, a dent in apoptotic nucleus was observed under DAPI staining 
(Fig 3.7, arrow heads). This particular structure was not seen reported in other studies. 
Chromatin seems to collapse towards the center of nucleus, and the intensity of DAPI 
staining at the dented structure was considerably weaker as compare to the adjacent 
heterochromatin. The dented chromatin was in association with the collapse and the 
loss of nuclear lamina integrity at the site (Fig 3.7). LBR staining revealed a structure 
similar to “nuclear bleb”. The nuclear lamina lipid bilayer is separated, one being 
stretched outwards into a bleb, and another collapsing towards the inner chromatin 
region.  
 
To investigate the nature of the bleb, immunofluorescence staining of apoptotic HeLa 
cells was performed. IF staining against uric acid (UA), a metabolic product of 
nucleotides and an alarmin in sterile inflammation, predominantly lights up the 
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boundary of the bleb (appendices). Carboxyfluorescein succinimidyl ester (CFSE) 
labeling of the amino acids in apoptotic cells showed no staining inside the bleb 
(appendices). Staining of ER marker calnexin showed ER membrane was not 
involved in the formation of the bleb (appendices). DAPI staining showed no DNA 
staining inside the bleb (Fig 3.8, appendices). Acridine orange (AO) staining of RNA 
also avoided the bleb region (appendices).  
 
Taken together, the bleb seems to be largely void of amino acids, DNA and RNA. 
DNA and RNA staining could have a permeability issue because the chemical was 
incubated after the formation of blebs, which is encircled by uric acid crystals. To 
solve this issue, DNA and RNA labeling could be done in viable cells before UV-
irradiation in future experiments. The exact mechanism with regards to how the 
nuclear bleb/chromatin dent is formed is unclear. The results indicate that the 
formation of the nuclear dent is unlikely due to nuclear fragments being released 
because nuclear materials will be expected to be enclosed in the bleb (Charras et al., 
2008; Martelli et al., 2001). Chromatin fragmentation could be one possible reason 
leading to the collapse of one side of the apoptotic cell nuclear, and the peeling-off of 
single lipid layer on nuclear lamina. However, the reason for the collapse at particular 
region in the apoptotic nucleus is unclear, and the implication requires further 
investigation. 
 
5.3 NUCLEOLAR AUTOANTIGENS AND C1Q-MEDIATED SELF 
TOLERANCE  
In this study, we found that C1q binds predominantly to apoptotic cell nucleolus (Fig 
3.5) and purified nucleolus from viable cells (Fig 3.9). Nucleolus is the most 
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predominant structure in a cell nucleus. It contains three sub-compartments: fibrillar 
centre (FC), dense fibrillar component (DFC), and granular component (GC), each 
having distinct protein composition and functions. For example, RNA polymerase I, 
responsible for rRNA synthesis, accumulates in the FC, whereas fibrillarin, a protein 
involved in the methylation of rRNA, is predominantly localized in DFC, and B23 is 
found mainly in GC (Lam et al., 2005).  Proteomic studies have revealed at least 700 
proteins in the purified nucleoli, and the number is still increasing 
(www.lamondlab.com/Nopdb) (Lam et al., 2005).  
 
The clinical manifestations in SLE are accompanied by huge numbers of 
autoantibodies, mainly against nuclear autoantigens. The serum ANA titer has 
become one of the criteria for SLE diagnosis. A literature search of autoantibodies in 
SLE in PubMed disclosed hundreds of autoantibodies reported. Autoantibodies differ 
a lot on their binding characteristics and disease prevalence. Autoantibodies can be 
targeting various autoantigens present in nucleolus, cytoplasm or lipid structures. 
Some are commonly seen in SLE patients whereas others are reported only in a few 
cases. From the list of SLE autoantigens, the nuclear autoantigens that exhibit high 
prevalence in SLE, or play central roles in regulating cellular activities, are 
summarized in Table 5.1. The pathogenicity is measured by the correlation between 
autoantibody titers and disease activity.   
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Table 5.1 Nuclear autoantigen and their disease prevalence. (Adapted from Sjerer et al., 
2004) 
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 ND, not determined;  
aCL, anticardiolipin; 
dsDNA, double-stranded DNA; 
SS-A, Sjögren's-syndrome-related antigen A; 
SS-B, Sjögren's-syndrome-related antigen B 
 
The link between complement and adaptive immunity has been studied intensively 
during the past decades. Classical complement components C4, C3, CR1 and CR2 are 
known to play a role in regulating the activation of B- and T-cells (Carroll, 2004a). It 
has been demonstrated using immunoglobulin transgenic murine model that 
deficiency in C4 or CR1 led to B-cell anergy (Carroll, 2004a; Prodeus et al., 1998). 
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Similarly, a hypothesis was raised that C1q may help to maintain self-tolerance by 
directing self-antigens to thymus and bone marrow, and help to enhance negative 
selection (Carroll, 2004b). Our data is particularly relevant and also heightens the 
tolerance hypothesis because, for the first time, C1q is found bind to a specific 
subcellular structure, nucleolus, which is abundant in self-antigens (especially RNA 
associated autoantigens, according to Table 5.1) found in SLE patients. The binding 
could potentially “deliver” nucleolus to the developing B-cells and eventually lead to 
colony deletion to ensure an efficient B-cell tolerance. When C1q deficiency occurs, 
B-cells in the bone marrow could lack exposure to self-antigens, including antigens 
from nucleolus. This could account for the loss of B-cell tolerance and the production 
of autoantibodies against nucleolar proteins. To test this hypothesis, experiments will 
be carried out to monitor autoreactive T-cell and B-cell levels in C1q-/- mice.  
 
We have demonstrated that C1q is able to bind to nucleolus, recruiting C1 complex to 
the site of cell apoptosis. With current data, it is yet not sufficient to conclude which 
molecules are C1q directly binding to (Figs 3.10, 4.21, 4.22). Of all nuclear proteins 
tested, IF staining of C1q and B23 in apoptotic HeLa cells showed most 
colocalization (Figs 3.10, 4.7 B). But using ELISA  to examine C1q interaction with 
recombinant B23 showed inconclusive results (Fig 4.17, 4.18). C1q has a wide range 
of binding partners (Cooper, 1985), and interaction between C1q and its ligands is 
highly dependent on electrostatic interactions. Given that C1q is a highly basic 
molecule and B23 contains a highly acidic domain, it is possible that C1q interacts 
with B23 through its acidic domain. However, the acidic domain of B23 locates next 
to its basic domain, which may repel C1q from binding to B23 when it gets in close 
proximity depending on the way of folding. The ELISA result showed that binding 
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seems to occur when small amount of B23 was used to coat the plate (Fig 4.20 A). 
Once exceeding a certain limit, less C1q was detected to bind to the plate when more 
C1q was added in. This suggests that it is likely that multiple forms of interactions 
exist. It is also possible that post-translational modification is required for the binding 
to occur given that B23 undergoes a number of phosphorylation in mammalian cells, 
which is absent in our prokaryotic expression system.  
 
5.4 REVEALING C1S NUCLEOLAR SUBSTRATES 
In chapter 4, we demonstrated the cleavage of several nucleolar proteins by C1s/C1 
complex. C1s cleavage of a predominant nucleolar B23, which was also found to be 
an autoantigen involved in SLE, was investigated in detail. C1s has been recognized 
as a complement specific protease, whose substrates are strictly limited to the 
complement system (C4, C2, C1-Inh). Although non-complement substrates have 
been discovered (W. H. Busby, Jr. et al., 2000; Eriksson & Nissen, 1990; Naito et al., 
2012; Nissen et al., 1990; Yamaguchi et al., 1990), the discovery of nucleolar 
substrates of C1s is significant because it helps to explain the perennial question as to 
why C1r/s deficiency causes SLE.  
 
Besides C1q binding to nucleolus during late apoptosis (Fig 3.5), a similar binding 
pattern for C1 complex in apoptotic HeLa cells was also observed (Fig 3.6). C1 
complex bound to vesicular structure in the cytoplasm 1 hour after UV-irradiation, 
and slowly moved to the nucleolus by 6 hours after UV-irradiation. Using isolated 
HeLa cell nucleolus, C1s cleavage of nucleolus proteins was investigated by adding 
C1 complex at 9.6 μg/ml and incubating at 37oC for up to 2 hours (Fig 4.5). A number 
of nucleolus proteins were cleaved. Subsequent Western blot analysis using anti-B23, 
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anti-NCL and anti-H3 antibodies showed C1s effectively cleaved nucleolar protein 
B23 and NCL, but H3 was largely resistant, which is consistent with the prediction 
provided by PoPS using C1s bioinformatics model (Fig 4.22).  
 
Cleavage of B23 was investigated in detail using recombinant His-tagged B23. C1s 
cleavage of B23 is specific because 1) by adding in sufficient amount of C1-Inh (160 
μg/ml), C1s cleavage of B23 was blocked (Fig 4.12); 2) the inhibitory effect of C1-
Inh on C1s cleavage is dose-dependent (Fig 4.12); 3) C1s cleaves C4 at predicted 
position and generated a lower band of expected size (Fig 4.15); 4) C1s cleaves C4 
and B23, but does not cleave BSA (Fig 4.15). This is important because the serum 
purified C1 complex contains a very small amount of serum proteins that were co-
purified as stated by manufacturer. The possibility that some other serum proteases 
were acting as the active enzyme and cleaving the proteins must be excluded before 
we proceed to the next step to characterize the nature of the enzymatic cleavage and 
to evaluate the cleavage product. 
 
We demonstrated that C1s cleaves B23 in a dose-dependent manner, by using 
different amount of C1 complex in the incubation with B23 (Fig 4.12). C1s was more 
efficient in cleavage when it is in complex with C1q and C1r forming C1 complex. 
Even at a lower concentration, C1 complex cleavage of B23 was still more efficient as 
compared to using activated C1s alone (Fig 4.13). In fact, C1 complex circulates in 
the serum at a concentration of 180 μg/ml, which is almost 10 fold of the highest 
concentration used here. This indicates that serum C1 complex, at a higher 
concentration, is expected to perform the cleavage more efficiently. 
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Potential cleavage sites on B23 was predicted by calculating cleavage scores using an 
established C1s model in PoPS. Each site was evaluated based on the primary amino 
acid sequence and secondary structure. Using recombinant B23, sizes of cleavage 
products were evaluated and matched to the predicted sites (Fig 4.16). Site directed 
mutagenesis on the three Arg (single mutation and triple mutation of all three sites 
were performed) that are most likely to be C1s targets are performed. Mutation of all 
three sites did not completely abolish C1s cleavage. But the smaller fragment, likely 
to result from cleavage at R221 or R197, was more resistant towards C1s proteolysis 
(Figs 4.19, 4.20).   
 
5.5 PURIFICATION OF RECOMBINANT HIS-TAGGED B23  
As seen in Figure 4.11, the purified protein in elution fractions A13 and A14 used in 
the C1s cleavage assay contained low levels of low molecular weight fragments. 
Mutant His-tagged B23 proteins purified using the same protocol also has some lower 
bands co-purified with the 35 kDa band. The presence of several proteins with 
different sizes prior to C1s cleavage add on to the difficulties in elucidating C1s 
cleavage sites. 
 
Efforts were made to obtain samples containing only the 35 kDa intact His-tagged 
B23 but was unsuccessful. For example, protease inhibitor cocktail was included in 
the buffer used to sonicate the bacteria; the induction of protein expression was also 
slowed down by reducing the amount of IPTG added by 10 fold or 100 fold; a lower 
induction temperature (25oC) was used instead of 37oC; sonication amplitude was also 
weaken to avoid shearing of protein structure due to mechanical force. Western blot 
analysis using anti-His antibody showed these attempt had no significant 
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improvement on reducing the expression of low molecular weight His-tagged B23 
(data not shown). This could be because of two reasons: 1) extensive degradation of 
His-tagged B23 inside the bacteria, and/or 2) His-tagged B23 was expressed as 
truncated proteins.  
 
B23 consists of four functional domains (Fig 4.6 B). N-terminus oligomerization 
domain, also known as core domain, folds into nine β-strands connected by linkers. 
N-terminal domain of B23 crystalizes as a pentermer, and is highly thermostable 
(withstanding temperatures of up to 105˚C) and and resistant to protease in buffer 
containing 150 mM NaCl (Scognamiglio et al., 2014). The central acidic and basic 
domains are higly disordered. Till now, no crystal structure of this region has been 
solved. The C-terminus DNA/RNA binding domain, also called aromatic domain, 
folds into three helix bundle, and is responsible for the nucleolar localization of the 
protein (Gallo et al., 2012; Wang et al., 1994). Due to the apparent reason that N-
terminus is higly stable and resistant to protease degradation, degredation is unlikely 
to occur at this domain. Acidic domain, basic domain and aromatic domain are all 
potentially susceptable to protease degradation due to their flexible structure.  
 
It is more likely that His-tagged B23 was expressed as incomplete or truncated 
proteins in the bacteria due to the conformation of the plasmid. Secondary structure of 
the plasmid may cause certain gene sequences to be skipped from being properly 
transcribed. Since the polyhistidine tag was expressed as an N-terminal tag, any form 
of expressed proteins, including truncated protein, would be expressed with His tag 
and captured by Ni-NTA beads. Separation of the full-length protein from the 
truncated protein was futile, though different salt concentrations and buffers were 
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tested (data not shown). One possible explanation is that proteins forms pentamers 
through the N-terminus oligomerization domain regardless of their length. This is 
confirmed by the separation profile from Superose 6 column by the position where the 
protein is eluted out coresponding to the molecular weight of a pentamer (Fig 4.11 D). 
Point mutations of N-terminus domain residues were performed in order to break the 
pentamer formation (Enomoto et al., 2006; Mitrea et al., 2014). It would be more 
feasible to achieve homogeneity in purified protein if they were to exist in the form of 
monomers. But the mutations on Lys102, Gly105 and Gly107, which are the critical 
residues for ARF binding near GSGP loop, did not generate mutants that are defective 
for oligomerization (Enomoto et al., 2006).  
 
One of the solutions to the problem may be putting the His-tag at C-terminal of B23, 
instead of N-terminal. In this way, only protein with C-terminal His-tag expressed can 
be selected by Ni-NTA beads. A linker sequence would be necessary to avoid 
disruption of the C-terminus structure. The structural integrity of the C-terminus 
domain is critical for the nucleolar localization of B23, and depends heavily on the 
aromatic tryptophan residues, W288 and W290, located at C-terminal end of B23 
(Grummitt et al., 2008). Consideration must be made in regards to the possible 
disruption of B23 C-terminal folding prior to the use of recombinant B23 for cleavage 
studies. 
 
5.6 SIGNIFICANCE OF THE STUDY 
C1q binding to apopototic cell nucleolus lead to two potential outcomes: 1) to 
increase exposure of self-antigen to developing B-cells and maintain self-tolerance; 2) 
to recruit C1 complex to the site of apoptosis and degrade potentially immunogenic 
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autoantigens and DAMPs. The two ways go hand in hand with each other in 
complementing the “tolerance hypothesis” and “waste disposal hypothesis” (Carroll, 
2004b). The discovery of a number of new C1s substrates outside the complement 
system broadens the understanding of C1s substrate specificity, and also adds a new 
layer to our current knowledge so as to how C1r/s has a protective role towards 
autoimmunity.  
 
5.7 FUTURE WORK 
 
5.7.1. Delineation of C1s cleavage sites on B23 
Site directed mutagenesis on three Arg residues that score highest in PoPS C1s model 
did not block the cleavage of B23 by C1s. This could mean that a single mutation of 
Arg to Ala may not have enough impact on changing the substrate conformation, or 
C1s cleavage sites were not predicted accurately. A definitive proof of the sites can be 
achieved by incubating activated C1s or C1 complex with purified B23. Subsequently 
sample can be separated on a SDS-PAGE and transferred to PVDF membrane. 
Distinct band can be cut out and N-terminal sequencing can be performed to 
determine the actual C1s cleavage sites on B23.  
 
5.7.2. Identification of other cellular ligands of C1q  
We hope to identify other novel intracellular C1q ligands, and examine by literature 
review whether these C1q ligands have any pro-inflammatory property and whether 
they are associated with SLE. If so, the disruption of potential DAMPs and 
autoreactive epitopes by C1s cleavage of these proteins will be examined using 
patient serum. The potential C1q ligands can be identified using pull-down assay. C1q 
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can be coated onto beads to generate a C1q column. Viable cell lysate, apoptotic cell 
lysate and apoptotic cell supernatant can be passed through the column to capture the 
potential ligands. The identities of bound proteins can be determined by mass 
spectrometry. Isolated nucleolus can be utilized in this study to identify nucleolar 
autoantigens. This will contribute to our knowledge on SLE pathogenesis.    
 
5.7.3. C1s deficiency and serum autoantigen level  
We have shown that C1s is able to cleave cellular proteins that could become 
autoantigen when apoptotic cells are not cleared efficiently. In healthy people with no 
C1s deficiency, serum autoantigen level is expected to be low. In C1s deficient 
individuals, it would be interesting to examine if there is any correlation between 
serum C1s level and autoantigen level. If excessive amount of autoantigens are 
present in the serum, and it inversely correlates with low serum C1s level, it would 
help to prove our hypothesis from another angle in a more physiological setting.  
 
5.7.4. What is the effect of C1s cleavage on autoantigens? 
We have proven in so far that C1s is able to cleave autoantigens but the impact of the 
cleavage requires further investigation. We would like to evaluate whether the C1s 
cleavage could affect the binding of autoantigens to their autoantibodies. ACs 
supernatant can be collected and probed using different patient sera to examine the 
recognition of serum autoantibodies and autoantigens present in ACs supernatant. C1 
complex can then be added in the ACs supernatant to allow cleavage to occur. By 
probing the C1 complex treated sample with patient sera, a loss of bands indicates the 
binding of autoantibodies with autoantigens is disrupted. The cleavage sites and 
recognition epitope can then be evaluated.  
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5.7.5. Is C1r involved in the proteolysis of nucleolar proteins? 
Physiologically, C1s circulates in the context of C1 complex and its activation 
requires the activation of C1r as prerequisite. Although the known C1r substrates are 
still limited to complement system (C1r, C1s), we cannot rule out the possibility that 
C1r may play a role in the proteolysis of nucleolar proteins observed in this study. 
This is due to 1) the structural similarities shared by C1r and C1s; 2) the fact that C1s 
cleavage of B23 was not rendered by mutations of all predicted cleavage sites. To test 
this hypothesis, recombinant or serum purified C1r can be used to incubate with 
purified B23 or isolated Hela cell nucleolus. If no degradation of protein is observed, 
C1r is unlikely to cleave the proteins directly. If lost of bands or reduction of protein 
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Observation of nuclear dent during cell apoptosis  
 
 
Staining of uric acid (UA), calnexin, laveling of protein (CFSE) and RNA (aridine 
orange) were performed. Urid acid lights up the boundary of the nuclear bleb, while 
the rest showed no association with the bleb.  Scale bar represents 10 μm. 
